Page last updated: 2024-08-03 06:31:47

ro5126766

Description

RO5126766: a dual MEK/RAF kinase inhibitor [MeSH]

CH5126766 : A member of the class of coumarins that is 4-methyl-7-[(pyrimidin-2-yl)oxy]coumarin carrying an additional [2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl substituent at position 3. [CHeBI]

Cross-References

ID SourceID
PubMed CID16719221
CHEMBL ID3264002
SCHEMBL ID960093
CHEBI ID78825
MeSH IDM0580968

Synonyms (56)

Synonym
ro5126766
ch5126766
S7170
ro 5126766 ,
ch-5126766
ro-5126766
CHEMBL3264002 ,
avutometinib
rg-7304
r-7304
cki-27
vs-6766
n-(3-fluoro-4-{[4-methyl-2-oxo-7-(pyrimidin-2-yloxy)-2h-chromen-3-yl]methyl}pyridin-2-yl)-n'-methylsulfuric diamide
CHU ,
3-[[2-[(methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2h-1-benzopyran-2-one
CHEBI:78825 ,
HY-18652
CS-5254
SCHEMBL960093
946128-88-7
bdbm50010462
ro5126766(ch5126766)
sulfamide, n-(3-fluoro-4-((4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2h-1-benzopyran-3-yl)methyl)-2-pyridinyl)-n'-methyl-
unii-d0d4252v97
3WIG
ch 5126766
AKOS030527032
sulfamide, n-[3-fluoro-4-[[4-methyl-2-oxo-7-(2-pyrimidinyloxy)-2h-1-benzopyran-3-yl]methyl]-2-pyridinyl]-n'-methyl-
avutometinib [who-dd]
ro-5126766 free base
D0D4252V97 ,
n-[3-fluoro-4-({4-methyl-2-oxo-7-[(pyrimidin-2-yl)oxy]-2h-1-benzopyran-3-yl}methyl)pyridin-2-yl]-n'-methylsulfuric diamide
avutometinib [usan]
avutometinib [inn]
Q27147976
ro5126766 (ch5126766)
FT-0737411
EX-A2151
ro5126766; ch5126766
DB15254
SB16628
3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one
CCG-269457
nsc758248
nsc-758248
ro 5126766 - bio-x
BCP21067
ro 5126766; ro5126766; ch5126766; ch5126766; ch 5126766
A916428
3-[(2-((n-methylsulfamoyl)amino)-3-fluoropyridin-4-yl)methyl]-4-methyl-7-(pyrimidin-2-yloxy)-chromen-2-one
MS-28717
AC-35949
nsc800871
nsc-800871
compound 1 [pmid: 24900832]
gtpl11867

Roles (2)

RoleDescription
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitorAn EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of mitogen-activated protein kinase (EC 2.7.11.24).
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.

Drug Classes (5)

ClassDescription
aryloxypyrimidine
coumarins
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
sulfamidesCompounds where two amino groups are bound to an SO2 unit.

Protein Targets (287)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)IC500.0560AID1137633; AID1851094
Cytochrome P450 3A4Homo sapiens (human)IC500.1600AID1137634
Cytochrome P450 2C9 Homo sapiens (human)IC500.1600AID1137634
Serine/threonine-protein kinase B-rafHomo sapiens (human)IC500.0136AID1851095; AID1851096
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)IC500.1600AID1137634

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Bone morphogenetic protein receptor type-1BHomo sapiens (human)Kd30.0000AID1424922
Membrane-associated progesterone receptor component 1Homo sapiens (human)Kd30.0000AID1425109
Cell division cycle 7-related protein kinaseHomo sapiens (human)Kd30.0000AID1424936
Serine/threonine-protein kinase PLK4Homo sapiens (human)Kd30.0000AID1425121
ATP-dependent RNA helicase DDX3XHomo sapiens (human)Kd30.0000AID1424975
Pyridoxal kinaseHomo sapiens (human)Kd30.0000AID1425106
Citron Rho-interacting kinaseHomo sapiens (human)Kd30.0000AID1424954
Serine/threonine-protein kinase Chk1Homo sapiens (human)Kd30.0000AID1424953
Aurora kinase AHomo sapiens (human)Kd30.0000AID1424917
Cyclin-G-associated kinaseHomo sapiens (human)Kd30.0000AID1425009
Ephrin type-B receptor 6Homo sapiens (human)Kd30.0000AID1424995
Peroxisomal acyl-coenzyme A oxidase 3Homo sapiens (human)Kd30.0000AID1424896
Receptor-interacting serine/threonine-protein kinase 2Homo sapiens (human)Kd30.0000AID1425155
Mitotic checkpoint serine/threonine-protein kinase BUB1Homo sapiens (human)Kd30.0000AID1424926
Dynamin-like 120 kDa protein, mitochondrialHomo sapiens (human)Kd30.0000AID1425097
Tyrosine-protein kinase JAK2Homo sapiens (human)Kd30.0000AID1425031
Eukaryotic translation initiation factor 5BHomo sapiens (human)Kd30.0000AID1424986
Rho-associated protein kinase 2Homo sapiens (human)Kd30.0000AID1425158
Serine/threonine-protein kinase ULK1Homo sapiens (human)Kd30.0000AID1425208
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)Kd30.0000AID1424997
Ribosomal protein S6 kinase alpha-5Homo sapiens (human)Kd30.0000AID1425162
U5 small nuclear ribonucleoprotein 200 kDa helicaseHomo sapiens (human)Kd30.0000AID1425174
Ribosomal protein S6 kinase alpha-4Homo sapiens (human)Kd30.0000AID1425161
Serine/threonine-protein kinase 16Homo sapiens (human)Kd30.0000AID1425179
Serine/threonine-protein kinase 10Homo sapiens (human)Kd30.0000AID1425177
Serine/threonine-protein kinase D3Homo sapiens (human)Kd30.0000AID1425137
Structural maintenance of chromosomes protein 2Homo sapiens (human)Kd30.0000AID1425173
Mitogen-activated protein kinase kinase kinase 6Homo sapiens (human)Kd30.0000AID1425050
Mitogen-activated protein kinase kinase kinase kinase 4Homo sapiens (human)Kd30.0000AID1425054
Serine/threonine-protein kinase LATS1Homo sapiens (human)Kd30.0000AID1425033
Serine/threonine-protein kinase PAK 4Homo sapiens (human)Kd30.0000AID1425100
Tyrosine-protein kinase ABL1Homo sapiens (human)Kd30.0000AID1424890
Epidermal growth factor receptorHomo sapiens (human)Kd30.0000AID1424983
Guanine nucleotide-binding protein G(i) subunit alpha-2Homo sapiens (human)Kd30.0000AID1425011
ADP/ATP translocase 2Homo sapiens (human)Kd30.0000AID1425169
Protein kinase C beta typeHomo sapiens (human)Kd30.0000AID1425130
Insulin receptorHomo sapiens (human)Kd30.0000AID1425026
Tyrosine-protein kinase LckHomo sapiens (human)Kd30.0000AID1425034
Tyrosine-protein kinase FynHomo sapiens (human)Kd30.0000AID1425008
Cyclin-dependent kinase 1Homo sapiens (human)Kd30.0000AID1424937
Glycogen phosphorylase, liver formHomo sapiens (human)Kd30.0000AID1425146
Tyrosine-protein kinase Fes/FpsHomo sapiens (human)Kd30.0000AID1425003
Adenine phosphoribosyltransferaseHomo sapiens (human)Kd30.0000AID1424914
Tyrosine-protein kinase YesHomo sapiens (human)Kd30.0000AID1425212
Tyrosine-protein kinase LynHomo sapiens (human)Kd30.0000AID1425037
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)Kd30.0000AID1425154
Insulin-like growth factor 1 receptorHomo sapiens (human)Kd30.0000AID1425022
Signal recognition particle receptor subunit alphaHomo sapiens (human)Kd30.0000AID1425176
Cytochrome c1, heme protein, mitochondrialHomo sapiens (human)Kd30.0000AID1424969
Hepatocyte growth factor receptorHomo sapiens (human)Kd30.0000AID1425076
Tyrosine-protein kinase HCKHomo sapiens (human)Kd30.0000AID1425017
Platelet-derived growth factor receptor betaHomo sapiens (human)Kd30.0000AID1425104
Serine/threonine-protein kinase A-RafHomo sapiens (human)Kd30.0000AID1424915
Glycogen phosphorylase, brain formHomo sapiens (human)Kd30.0000AID1425145
Breakpoint cluster region proteinHomo sapiens (human)Kd30.0000AID1424919
Serine/threonine-protein kinase pim-1Homo sapiens (human)Kd30.0000AID1425111
Fibroblast growth factor receptor 1Homo sapiens (human)Kd30.0000AID1425004
DNA topoisomerase 2-alphaHomo sapiens (human)Kd30.0000AID1425202
Cyclin-dependent kinase 4Homo sapiens (human)Kd30.0000AID1424946
ADP/ATP translocase 3Homo sapiens (human)Kd30.0000AID1425170
Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)Kd30.0000AID1425025
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)Kd30.0000AID1425175
cAMP-dependent protein kinase type II-alpha regulatory subunitHomo sapiens (human)Kd30.0000AID1425128
Serine/threonine-protein kinase B-rafHomo sapiens (human)Kd0.0070AID1424924
Phosphorylase b kinase gamma catalytic chain, liver/testis isoformHomo sapiens (human)Kd30.0000AID1425110
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)Kd30.0000AID1425093
Tyrosine-protein kinase FerHomo sapiens (human)Kd30.0000AID1425002
Protein kinase C alpha typeHomo sapiens (human)Kd30.0000AID1425129
cAMP-dependent protein kinase catalytic subunit alphaHomo sapiens (human)Kd30.0000AID1425123
General transcription and DNA repair factor IIH helicase subunit XPDHomo sapiens (human)Kd30.0000AID1424996
Casein kinase II subunit alpha'Homo sapiens (human)Kd30.0000AID1424968
Ras-related protein Rab-6AHomo sapiens (human)Kd30.0000AID1425150
Multifunctional protein ADE2Homo sapiens (human)Kd30.0000AID1425098
cAMP-dependent protein kinase catalytic subunit betaHomo sapiens (human)Kd30.0000AID1425124
Ferrochelatase, mitochondrialHomo sapiens (human)Kd30.0000AID1425001
Ribosomal protein S6 kinase beta-1Homo sapiens (human)Kd30.0000AID1425164
Tyrosine-protein kinase JAK1Homo sapiens (human)Kd30.0000AID1425030
Cyclin-dependent kinase 2Homo sapiens (human)Kd30.0000AID1424944
Beta-adrenergic receptor kinase 1Homo sapiens (human)Kd30.0000AID1424908
Probable ATP-dependent RNA helicase DDX6Homo sapiens (human)Kd30.0000AID1424977
Mitogen-activated protein kinase 3 Homo sapiens (human)Kd30.0000AID1425061
MAP/microtubule affinity-regulating kinase 3Homo sapiens (human)Kd30.0000AID1425069
Deoxycytidine kinaseHomo sapiens (human)Kd30.0000AID1424970
Mitogen-activated protein kinase 1Homo sapiens (human)Kd30.0000AID1425056
Ephrin type-A receptor 2Homo sapiens (human)Kd30.0000AID1424988
Ephrin type-B receptor 2Homo sapiens (human)Kd30.0000AID1424992
Non-receptor tyrosine-protein kinase TYK2Homo sapiens (human)Kd30.0000AID1425207
Phosphatidylethanolamine-binding protein 1Homo sapiens (human)Kd30.0000AID1425107
Wee1-like protein kinaseHomo sapiens (human)Kd30.0000AID1425210
Heme oxygenase 2Homo sapiens (human)Kd30.0000AID1425018
S-adenosylmethionine synthase isoform type-2Homo sapiens (human)Kd30.0000AID1425071
DnaJ homolog subfamily A member 1Homo sapiens (human)Kd30.0000AID1424980
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1424910
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1424911
Dual specificity protein kinase TTKHomo sapiens (human)Kd30.0000AID1425205
DNA replication licensing factor MCM4Homo sapiens (human)Kd30.0000AID1425072
Myosin-10Homo sapiens (human)Kd30.0000AID1425079
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)Kd0.0370AID1425039
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)Kd30.0000AID1425006
Bone morphogenetic protein receptor type-1AHomo sapiens (human)Kd30.0000AID1424921
Activin receptor type-1BHomo sapiens (human)Kd30.0000AID1424901
TGF-beta receptor type-1Homo sapiens (human)Kd30.0000AID1425196
TGF-beta receptor type-2Homo sapiens (human)Kd30.0000AID1425197
Electron transfer flavoprotein subunit betaHomo sapiens (human)Kd30.0000AID1424999
Tyrosine-protein kinase CSKHomo sapiens (human)Kd30.0000AID1424960
Glycine--tRNA ligaseHomo sapiens (human)Kd30.0000AID1425010
Protein kinase C iota typeHomo sapiens (human)Kd30.0000AID1425133
Exosome RNA helicase MTR4Homo sapiens (human)Kd30.0000AID1425168
Tyrosine-protein kinase TecHomo sapiens (human)Kd30.0000AID1425193
Tyrosine-protein kinase ABL2Homo sapiens (human)Kd30.0000AID1424891
Tyrosine-protein kinase FRKHomo sapiens (human)Kd30.0000AID1425007
Tyrosine-protein kinase SYKHomo sapiens (human)Kd30.0000AID1425188
26S proteasome regulatory subunit 6BHomo sapiens (human)Kd30.0000AID1425141
Mitogen-activated protein kinase 8Homo sapiens (human)Kd30.0000AID1425063
Mitogen-activated protein kinase 9Homo sapiens (human)Kd30.0000AID1425064
Dual specificity mitogen-activated protein kinase kinase 4Homo sapiens (human)Kd30.0000AID1425041
Dual specificity mitogen-activated protein kinase kinase 3Homo sapiens (human)Kd30.0000AID1425040
Phosphatidylinositol 5-phosphate 4-kinase type-2 alphaHomo sapiens (human)Kd30.0000AID1425113
Casein kinase I isoform alphaHomo sapiens (human)Kd30.0000AID1424961
Casein kinase I isoform deltaHomo sapiens (human)Kd30.0000AID1424962
MAP kinase-activated protein kinase 2Homo sapiens (human)Kd30.0000AID1425065
Elongation factor Tu, mitochondrialHomo sapiens (human)Kd30.0000AID1425206
Cysteine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.0000AID1424932
Casein kinase I isoform epsilonHomo sapiens (human)Kd30.0000AID1424963
Very long-chain specific acyl-CoA dehydrogenase, mitochondrialHomo sapiens (human)Kd30.0000AID1424894
Dual specificity protein kinase CLK1Homo sapiens (human)Kd30.0000AID1424955
Dual specificity protein kinase CLK2Homo sapiens (human)Kd30.0000AID1424956
Dual specificity protein kinase CLK3Homo sapiens (human)Kd30.0000AID1424957
Glycogen synthase kinase-3 alphaHomo sapiens (human)Kd30.0000AID1425013
Glycogen synthase kinase-3 betaHomo sapiens (human)Kd30.0000AID1425014
Cyclin-dependent kinase 7Homo sapiens (human)Kd30.0000AID1424949
Cyclin-dependent kinase 9Homo sapiens (human)Kd30.0000AID1424950
Ras-related protein Rab-27AHomo sapiens (human)Kd30.0000AID1425149
Interleukin-1 receptor-associated kinase 1Homo sapiens (human)Kd30.0000AID1425027
Ribosomal protein S6 kinase alpha-3Homo sapiens (human)Kd30.0000AID1425160
Serine/threonine-protein kinase Nek2Homo sapiens (human)Kd30.0000AID1425086
Serine/threonine-protein kinase Nek3Homo sapiens (human)Kd30.0000AID1425087
Dual specificity mitogen-activated protein kinase kinase 6Homo sapiens (human)Kd30.0000AID1425043
LIM domain kinase 1Homo sapiens (human)Kd30.0000AID1425035
LIM domain kinase 2Homo sapiens (human)Kd30.0000AID1425036
Mitogen-activated protein kinase 10Homo sapiens (human)Kd30.0000AID1425057
Tyrosine--tRNA ligase, cytoplasmicHomo sapiens (human)Kd30.0000AID1425211
5'-AMP-activated protein kinase subunit gamma-1Homo sapiens (human)Kd30.0000AID1425126
Ephrin type-B receptor 3Homo sapiens (human)Kd30.0000AID1424993
Ephrin type-A receptor 5Homo sapiens (human)Kd30.0000AID1424990
Ephrin type-B receptor 4Homo sapiens (human)Kd30.0000AID1424994
Ephrin type-A receptor 4Homo sapiens (human)Kd30.0000AID1424989
Adenylate kinase 2, mitochondrialHomo sapiens (human)Kd30.0000AID1424909
Adenosine kinaseHomo sapiens (human)Kd30.0000AID1424907
Ras-related protein Rab-10Homo sapiens (human)Kd30.0000AID1425148
Actin-related protein 3Homo sapiens (human)Kd30.0000AID1424899
Actin-related protein 2Homo sapiens (human)Kd30.0000AID1424898
GTP-binding nuclear protein RanHomo sapiens (human)Kd30.0000AID1425153
Cyclin-dependent kinase 3Homo sapiens (human)Kd30.0000AID1424945
Cyclin-dependent kinase 6Homo sapiens (human)Kd30.0000AID1424948
Cyclin-dependent-like kinase 5 Homo sapiens (human)Kd30.0000AID1424947
Cyclin-dependent kinase 16Homo sapiens (human)Kd30.0000AID1424941
Cyclin-dependent kinase 17Homo sapiens (human)Kd30.0000AID1424942
ATP-dependent 6-phosphofructokinase, platelet typeHomo sapiens (human)Kd30.0000AID1425108
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)Kd0.0300AID1425038
DNA topoisomerase 2-betaHomo sapiens (human)Kd30.0000AID1425203
Protein kinase C theta typeHomo sapiens (human)Kd30.0000AID1425134
Activin receptor type-1Homo sapiens (human)Kd30.0000AID1424900
Macrophage-stimulating protein receptorHomo sapiens (human)Kd30.0000AID1425078
Focal adhesion kinase 1Homo sapiens (human)Kd30.0000AID1425142
Protein kinase C delta typeHomo sapiens (human)Kd30.0000AID1425131
Tyrosine-protein kinase BTKHomo sapiens (human)Kd30.0000AID1424925
Activated CDC42 kinase 1Homo sapiens (human)Kd30.0000AID1425201
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)Kd30.0000AID1424972
Mitogen-activated protein kinase kinase kinase kinase 2Homo sapiens (human)Kd30.0000AID1425052
Serine/threonine-protein kinase 4Homo sapiens (human)Kd30.0000AID1425185
5'-AMP-activated protein kinase catalytic subunit alpha-1Homo sapiens (human)Kd30.0000AID1425122
Dual specificity mitogen-activated protein kinase kinase 5Homo sapiens (human)Kd1.9960AID1425042
Mitogen-activated protein kinase 7Homo sapiens (human)Kd30.0000AID1425062
Serine/threonine-protein kinase PAK 2Homo sapiens (human)Kd30.0000AID1425099
Serine/threonine-protein kinase 3Homo sapiens (human)Kd30.0000AID1425182
Mitogen-activated protein kinase kinase kinase 1Homo sapiens (human)Kd30.0000AID1425044
Integrin-linked protein kinaseHomo sapiens (human)Kd30.0000AID1425024
Rho-associated protein kinase 1Homo sapiens (human)Kd30.0000AID1425157
Non-receptor tyrosine-protein kinase TNK1Homo sapiens (human)Kd30.0000AID1425200
Calcium/calmodulin-dependent protein kinase type II subunit gammaHomo sapiens (human)Kd30.0000AID1424929
Calcium/calmodulin-dependent protein kinase type II subunit deltaHomo sapiens (human)Kd30.0000AID1424928
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)Kd30.0000AID1424981
Activin receptor type-2BHomo sapiens (human)Kd30.0000AID1424902
Bone morphogenetic protein receptor type-2Homo sapiens (human)Kd30.0000AID1424923
Protein-tyrosine kinase 6Homo sapiens (human)Kd30.0000AID1425144
cGMP-dependent protein kinase 1 Homo sapiens (human)Kd30.0000AID1425138
Cyclin-dependent kinase 13Homo sapiens (human)Kd30.0000AID1424940
Inhibitor of nuclear factor kappa-B kinase subunit epsilonHomo sapiens (human)Kd30.0000AID1425023
Protein-tyrosine kinase 2-betaHomo sapiens (human)Kd30.0000AID1425143
Maternal embryonic leucine zipper kinaseHomo sapiens (human)Kd30.0000AID1425074
Structural maintenance of chromosomes protein 1AHomo sapiens (human)Kd30.0000AID1425172
Chromodomain-helicase-DNA-binding protein 4Homo sapiens (human)Kd30.0000AID1424952
Peroxisomal acyl-coenzyme A oxidase 1Homo sapiens (human)Kd30.0000AID1424895
Ephrin type-A receptor 7Homo sapiens (human)Kd30.0000AID1424991
Delta(24)-sterol reductaseHomo sapiens (human)Kd30.0000AID1424978
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)Kd30.0000AID1425159
Myosin light chain kinase, smooth muscleHomo sapiens (human)Kd30.0000AID1425081
Mitogen-activated protein kinase 11Homo sapiens (human)Kd30.0000AID1425058
Serine/threonine-protein kinase STK11Homo sapiens (human)Kd30.0000AID1425178
Serine/threonine-protein kinase N1Homo sapiens (human)Kd30.0000AID1425117
Serine/threonine-protein kinase N2Homo sapiens (human)Kd30.0000AID1425118
Mitogen-activated protein kinase 14Homo sapiens (human)Kd30.0000AID1425059
Calcium/calmodulin-dependent protein kinase type IVHomo sapiens (human)Kd30.0000AID1424930
Mitogen-activated protein kinase kinase kinase 11Homo sapiens (human)Kd30.0000AID1425045
MAP kinase-activated protein kinase 3Homo sapiens (human)Kd30.0000AID1425066
Discoidin domain-containing receptor 2Homo sapiens (human)Kd30.0000AID1424973
AP2-associated protein kinase 1Homo sapiens (human)Kd30.0000AID1424889
Myosin light chain kinase 3Homo sapiens (human)Kd30.0000AID1425082
Uncharacterized aarF domain-containing protein kinase 5Homo sapiens (human)Kd30.0000AID1424906
Putative heat shock protein HSP 90-beta 2Homo sapiens (human)Kd30.0000AID1425019
Rab-like protein 3Homo sapiens (human)Kd30.0000AID1425151
Serine/threonine-protein kinase MRCK alphaHomo sapiens (human)Kd30.0000AID1424933
Serine/threonine-protein kinase MRCK gammaHomo sapiens (human)Kd30.0000AID1424935
Acyl-CoA dehydrogenase family member 10Homo sapiens (human)Kd30.0000AID1424892
Serine/threonine-protein kinase N3Homo sapiens (human)Kd30.0000AID1425119
Serine/threonine-protein kinase ULK3Homo sapiens (human)Kd30.0000AID1425209
Uncharacterized protein FLJ45252Homo sapiens (human)Kd30.0000AID1425147
Acyl-CoA dehydrogenase family member 11Homo sapiens (human)Kd30.0000AID1424893
Serine/threonine-protein kinase/endoribonuclease IRE2Homo sapiens (human)Kd30.0000AID1424998
Serine/threonine-protein kinase MARK2Homo sapiens (human)Kd30.0000AID1425068
ATP-dependent RNA helicase DHX30Homo sapiens (human)Kd30.0000AID1424979
Serine/threonine-protein kinase TAO1Homo sapiens (human)Kd30.0000AID1425189
STE20-related kinase adapter protein alphaHomo sapiens (human)Kd30.0000AID1425186
Myosin-14Homo sapiens (human)Kd30.0000AID1425080
AarF domain-containing protein kinase 1Homo sapiens (human)Kd30.0000AID1424904
ATP-dependent RNA helicase DDX42Homo sapiens (human)Kd30.0000AID1424976
Mitogen-activated protein kinase kinase kinase kinase 3Homo sapiens (human)Kd30.0000AID1425053
MAP kinase-activated protein kinase 5Homo sapiens (human)Kd30.0000AID1425067
Atypical kinase COQ8A, mitochondrialHomo sapiens (human)Kd30.0000AID1424905
Phosphatidylinositol 5-phosphate 4-kinase type-2 gammaHomo sapiens (human)Kd30.0000AID1425115
Mitogen-activated protein kinase 15Homo sapiens (human)Kd30.0000AID1425060
Serine/threonine-protein kinase Nek9Homo sapiens (human)Kd30.0000AID1425089
Serine/threonine-protein kinase Nek7Homo sapiens (human)Kd30.0000AID1425088
ATP-dependent RNA helicase DDX1Homo sapiens (human)Kd30.0000AID1424974
Aurora kinase BHomo sapiens (human)Kd30.0000AID1424918
MAP/microtubule affinity-regulating kinase 4Homo sapiens (human)Kd30.0000AID1425070
Serine/threonine-protein kinase Nek1Homo sapiens (human)Kd30.0000AID1425085
PAS domain-containing serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1425102
Calcium/calmodulin-dependent protein kinase kinase 2Homo sapiens (human)Kd30.0000AID1424931
EKC/KEOPS complex subunit TP53RKHomo sapiens (human)Kd30.0000AID1425204
Dual specificity testis-specific protein kinase 2Homo sapiens (human)Kd30.0000AID1425195
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinaseHomo sapiens (human)Kd30.0000AID1425116
Mitogen-activated protein kinase kinase kinase 5Homo sapiens (human)Kd30.0000AID1425049
Mitogen-activated protein kinase kinase kinase 3Homo sapiens (human)Kd30.0000AID1425047
Eukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)Kd30.0000AID1424984
Nucleolar GTP-binding protein 1Homo sapiens (human)Kd30.0000AID1425016
Serine/threonine-protein kinase D2Homo sapiens (human)Kd30.0000AID1425136
NUAK family SNF1-like kinase 2Homo sapiens (human)Kd30.0000AID1425095
RNA cytidine acetyltransferaseHomo sapiens (human)Kd30.0000AID1425083
Serine/threonine-protein kinase SIK2Homo sapiens (human)Kd30.0000AID1425166
STE20-like serine/threonine-protein kinase Homo sapiens (human)Kd30.0000AID1425171
Serine/threonine-protein kinase TAO3Homo sapiens (human)Kd30.0000AID1425191
dCTP pyrophosphatase 1Homo sapiens (human)Kd30.0000AID1424971
Dual specificity protein kinase CLK4Homo sapiens (human)Kd30.0000AID1424958
Casein kinase I isoform gamma-1Homo sapiens (human)Kd30.0000AID1424964
Phenylalanine--tRNA ligase beta subunitHomo sapiens (human)Kd30.0000AID1425000
BMP-2-inducible protein kinaseHomo sapiens (human)Kd30.0000AID1424920
Obg-like ATPase 1Homo sapiens (human)Kd30.0000AID1425096
MidasinHomo sapiens (human)Kd30.0000AID1425073
Interleukin-1 receptor-associated kinase 4Homo sapiens (human)Kd30.0000AID1425029
Mitogen-activated protein kinase kinase kinase 20Homo sapiens (human)Kd30.0000AID1425213
Cyclin-dependent kinase 12Homo sapiens (human)Kd30.0000AID1424939
Serine/threonine-protein kinase pim-2Homo sapiens (human)Kd30.0000AID1425112
Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrialHomo sapiens (human)Kd30.0000AID1425187
Serine/threonine-protein kinase NLKHomo sapiens (human)Kd30.0000AID1425090
5'-AMP-activated protein kinase subunit gamma-2Homo sapiens (human)Kd30.0000AID1425127
Serine/threonine-protein kinase TBK1Homo sapiens (human)Kd30.0000AID1425192
Septin-9Homo sapiens (human)Kd30.0000AID1425165
Ribosomal protein S6 kinase alpha-6Homo sapiens (human)Kd30.0000AID1425163
TRAF2 and NCK-interacting protein kinaseHomo sapiens (human)Kd30.0000AID1425199
Serine/threonine-protein kinase TAO2Homo sapiens (human)Kd30.0000AID1425190
Serine/threonine-protein kinase ICKHomo sapiens (human)Kd30.0000AID1425021
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)Kd30.0000AID1424912
Serine/threonine-protein kinase SIK3Homo sapiens (human)Kd30.0000AID1425167
Mitogen-activated protein kinase kinase kinase 2Homo sapiens (human)Kd30.0000AID1425046
Thyroid hormone receptor-associated protein 3Homo sapiens (human)Kd30.0000AID1425198
Mitogen-activated protein kinase kinase kinase kinase 5Homo sapiens (human)Kd30.0000AID1425055
Receptor-interacting serine/threonine-protein kinase 3Homo sapiens (human)Kd30.0000AID1425156
Serine/threonine-protein kinase MRCK betaHomo sapiens (human)Kd30.0000AID1424934
Interleukin-1 receptor-associated kinase 3Homo sapiens (human)Kd30.0000AID1425028
Serine/threonine-protein kinase 24Homo sapiens (human)Kd30.0000AID1425180
Casein kinase I isoform gamma-3Homo sapiens (human)Kd30.0000AID1424966
Mitogen-activated protein kinase kinase kinase 4Homo sapiens (human)Kd30.0000AID1425048

Bioassays (351)

Assay IDTitleYearJournalArticle
AID1425165Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425162Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425121Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425210Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851095Inhibition of wild type human BRAF using 5-Fl-SGQLIDSMANSFV-NH2 peptide as substrate by FRET assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1425198Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425066Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425177Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137647Bioavailability in Crlj:CD rat at 2.5 mg/kg, iv and 5 mg/kg, po by LC-MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425090Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424994Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425138Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425079Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424935Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137643Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425145Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425140Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137651Growth inhibition of human C32 cells harboring R-Raf V600E mutant2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1424922Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424960Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425132Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424971Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425063Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424986Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425036Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424892Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425211Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425046Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425042Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425048Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425021Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424933Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424967Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137646Clearance in BALB-nu/nu mouse at 2.5 mg/kg, iv and 5 mg/kg, po by LC-MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425212Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851093Inhibition of human MEK using 5-Fl-SGQLIDSMANSFV-NH2 peptide as substrate by FRET assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1425009Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424932Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425096Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425106Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425187Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425159Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425133Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691971Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1851094Inhibition of human CRAF using 5-Fl-SGQLIDSMANSFV-NH2 peptide as substrate by FRET assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1425038Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425163Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425127Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425119Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424953Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691969Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1691977Inhibition of MEK in human MDA-MB-231 cells assessed as reduction in ERK phosphorylation at 1 to 10 uM incubated for 2 hrs by Western blot analysis2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425206Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137650Clearance in cynomolgus monkey at 2.5 mg/kg, iv and 5 mg/kg, po by LC-MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1424924Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424985Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851098Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant assessed as cell growth inhibition measured after 72 hrs by WST-8 assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1425136Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424964Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425203Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425100Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424945Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424954Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424941Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425118Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425010Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425123Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425050Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425045Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425002Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425196Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691980Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425112Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1193964Inhibition of PI3K in human PANC1 cells assessed as reduction in pAkt level at 10 uM after 1 hr by Western blotting analysis2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3391
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1424990Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425158Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425188Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425081Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425006Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425095Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137652Antitumor activity against human C32 cells xenografted in po dosed BALB-nu/nu mouse assessed as tumor growth inhibition administered qd for 11 days2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1424989Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424991Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425134Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425069Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424905Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424984Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425170Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691986Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 10 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 4.4%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425117Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425153Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424968Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425111Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425190Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424896Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425193Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425141Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425083Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1193965Inhibition of MEK1 in human PANC1 cells assessed as reduction in pErk1/2 level at 10 uM after 1 hr by Western blotting analysis2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3391
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1137653Toxicity in po dosed BALB-nu/nu mouse xenografted with human C32 cells assessed as body weight administered qd for 11 days2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1424914Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851100Antiproliferative activity against human SW480 cells harboring NRAS G12V mutant assessed as cell growth inhibition measured after 72 hrs by WST-8 assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1137657Dissociation constant, pKa of the compound at 10 mM by spectroscopic titration analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425035Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424918Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424900Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425197Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425073Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425043Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425202Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137642Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1691987Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 10 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 1.084%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424999Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691988Prodrug release in human HCT-116 cells assessed as increase in intracellular NO level at 100 uM measured after 2 hr by DAF-FM DA reagent based scanning electron microscopy2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424974Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425108Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425040Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424995Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691968Antiproliferative activity against human A375 cells harboring BRAF V600E mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425093Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425208Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425154Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425052Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425089Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425070Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425049Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424901Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137634Inhibition of constitutively active MEK1 S218E,S222E mutant (unknown origin) assessed as MAP kinase 2/Erk2-mediated FAM-Erktide phosphorylation using MAP kinase 2/Erk2 as substrate preincubated for 30 mins by IMAP fluorescence polarization assay2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425023Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424934Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691982Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 1 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 4.4%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425213Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424942Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691973Inhibition of MEK in human A549 cells assessed as reduction in MEK phosphorylation at 10 uM incubated for 2 hrs by Western blot analysis2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1691967Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 10 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 3.54%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424975Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424917Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691985Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 10 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 90.962%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1137644Inhibition of human ERG expressed in CHO cells assessed as decrease in channel current at 10 uM by whole cell voltage clamp technique2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1193976Inhibition of PI3K in mouse lung fibroblast assessed as reduction in pAkt level at 10 uM after 1 hr by Western blotting analysis2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3391
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1425173Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424955Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691984Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 1 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 1.084%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425191Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425014Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424940Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425072Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425186Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851101Antiproliferative activity against human HCT-116 cells harboring NRAS G13D mutant assessed as cell growth inhibition measured after 72 hrs by WST-8 assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1425192Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425151Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425207Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1193971Inhibition of MEK1 in human A549 cells assessed as reduction in pErk1/2 level at 10 uM after 1 hr by Western blotting analysis2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3391
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1425126Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424915Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691979Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424962Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425061Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425189Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425025Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424919Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424947Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425166Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425199Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137633Inhibition of truncated active C-Raf (unknown origin) assessed as MEK1 phosphorylation using inactive MEK1 K97R as substrate after 45 mins2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1424978Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425037Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425143Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424949Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425124Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851096Inhibition of human BRAF V600E mutant using 5-Fl-SGQLIDSMANSFV-NH2 peptide as substrate by FRET assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1424997Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137654Toxicity in po dosed BALB-nu/nu mouse xenografted with human C32 cells assessed as adverse clinical signs administered qd for 11 days2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1424911Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425105Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424944Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424904Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425017Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137639AUC in BALB-nu/nu mouse at 100 mg/kg, po measured after 24 hrs by LC-MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1137632Inhibition of human HCT116 cell growth after 96 hrs by counting kit-8 analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425016Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425056Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424907Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425001Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424979Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425059Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424906Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425022Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424910Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425071Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425029Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424969Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425011Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424921Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425030Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425180Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425057Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425130Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137649Bioavailability in cynomolgus monkey at 2.5 mg/kg, iv and 5 mg/kg, po by LC-MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425168Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425086Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424909Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425080Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425155Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424902Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425104Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425102Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425149Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425122Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424920Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425110Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424899Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425201Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425167Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425176Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424976Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425171Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425195Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424948Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425065Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425116Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425172Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425041Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424980Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424898Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1193977Inhibition of MEK1 in mouse lung fibroblast assessed as reduction in pErk1/2 level at 10 uM after 1 hr by Western blotting analysis2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3391
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1425000Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425131Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425088Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425160Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137645Bioavailability in BALB-nu/nu mouse at 2.5 mg/kg, iv and 5 mg/kg, po by LC-MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1424993Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691981Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 1 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 90.962%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1137640Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in absence of NADPH2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425018Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424966Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691983Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 1 uM incubated for 24 hrs by AnnexinV-FITC and propidium iodide staining based flow cytometry (Rvb = 3.54%)2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425109Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425074Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851102Antiproliferative activity against human CT-TC cells harboring HRAS Q61K mutant assessed as cell growth inhibition measured after 72 hrs by WST-8 assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1424950Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425164Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425098Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424912Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425058Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851099Antiproliferative activity against human MIA PaCa-2 cells harboring NRAS G12C mutant assessed as cell growth inhibition measured after 72 hrs by WST-8 assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1425115Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424970Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424992Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137641Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate measured after 30 mins preincubation by LC-MS/MS analysis in presence of NADPH2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425156Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424988Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425205Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424946Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425128Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425068Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137648Clearance in Crlj:CD rat at 2.5 mg/kg, iv and 5 mg/kg, po by LC-MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425144Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425007Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425085Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424972Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425039Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425097Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137637Intrinsic clearance in human liver microsomes at 5 uM by LC/MS/MS analysis2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425178Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425157Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425129Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425033Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425044Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424939Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425076Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424983Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425064Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425204Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425055Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424996Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425142Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424929Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425028Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425209Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425019Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424973Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424998Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425087Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425003Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425026Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424923Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425185Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425161Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424908Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425067Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425013Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424895Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425150Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425182Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424925Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424931Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137636Solubility of the compound in fasted state simulated intestinal fluid by LYSA method2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1425008Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424890Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425147Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425146Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424957Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425027Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425078Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424952Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424893Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425034Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424894Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424926Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425082Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424928Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425148Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425179Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425031Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424889Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424961Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425062Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1137656Saturated solubility of the compound in fasted state simulated intestinal fluid after 24 hrs by shaking flask method2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
ISSN: 1948-5875
Optimizing the Physicochemical Properties of Raf/MEK Inhibitors by Nitrogen Scanning.
AID1691978Inhibition of MEK in human MDA-MB-231 cells assessed as reduction in MEK phosphorylation at 1 to 10 uM incubated for 2 hrs by Western blot analysis2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425024Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691974Inhibition of MEK in human A549 cells assessed as reduction in ERK phosphorylation at 1 uM incubated for 2 hrs by Western blot analysis2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1425053Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425200Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424930Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424891Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425004Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1851097Antiproliferative activity against human SK-MEL-2 cells harboring NRAS Q61R mutant assessed as cell growth inhibition measured after 72 hrs by WST-8 assay2022Bioorganic & medicinal chemistry, 09-15, Volume: 70ISSN: 1464-3391The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
AID1425169Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425175Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424958Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425137Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425107Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1193970Inhibition of PI3K in human A549 cells assessed as reduction in pAkt level at 10 uM after 1 hr by Western blotting analysis2015Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3391
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
AID1425099Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424956Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424937Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425174Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1876328Antiviral activity against SARS-CoV-2 inoculated in african green monkey Vero E6 cells expressing ACE2 assessed as reduction of cytopathic effect measured after 72 hrs by CellTitre-Glo based plate reader method2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
AID1424936Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425054Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425060Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691972Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424981Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425047Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1425113Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1424963Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID1691970Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay2020European journal of medicinal chemistry, Jun-15, Volume: 196ISSN: 1768-3254Hybrids of MEK inhibitor and NO donor as multitarget antitumor drugs.
AID1424977Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry2017Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203
The target landscape of clinical kinase drugs.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Cancer cell, May-12, Volume: 25, Issue:5
ISSN: 1878-3686
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's14 (60.87)24.3611
2020's9 (39.13)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (8.70%)5.53%
Reviews2 (8.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (82.61%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
azoxystrobinaryloxypyrimidine;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
methyl ester;
nitrile
antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
quinone outside inhibitor;
xenobiotic
00low000000
coumarincoumarinsfluorescent dye;
human metabolite;
plant metabolite
00low000000
4-methylumbelliferyl acetateacetate ester;
coumarins
plant metabolite00low000000
5,7-dimethoxycoumarincoumarins00low000000
6-methylcoumarincoumarinsallergen;
fragrance
00low000000
scoparonearomatic ether;
coumarins
anti-allergic agent;
anti-inflammatory agent;
antihypertensive agent;
antilipemic drug;
immunosuppressive agent;
plant metabolite
00low000000
ostholbotanical anti-fungal agent;
coumarins
metabolite00low000000
cyclocumarolcoumarins00low000000
herniarincoumarinsfluorochrome00low000000
coumarin-3-carboxylic acidcoumarins00low000000
chromonarcoumarins00low000000
7-methylcoumarincoumarins00low000000
7-ethoxycoumarinaromatic ether;
coumarins
00low000000
xanthyletinecoumarins00low000000
xanthoxyletincoumarinsmetabolite00low000000
4-methyl-7-ethoxycoumarincoumarins00low000000
seselincoumarinsmetabolite00low000000
suberosinaromatic ether;
coumarins
anticoagulant;
plant metabolite
00low000000
cloricromencoumarins00low000000
3-acetylcoumarincoumarins00low000000
4-methylumbelliferyl sulfatearyl sulfate;
coumarins
human xenobiotic metabolite00low000000
4-methylumbelliferyl butyratebutyrate ester;
coumarins
chromogenic compound00low000000
7-(diethylamino)-1-benzopyran-2-onecoumarins00low000000
4-methylumbelliferyl glucuronidebeta-D-glucosiduronic acid;
coumarins;
monosaccharide derivative
antineoplastic agent;
chromogenic compound;
hyaluronan synthesis inhibitor
00low000000
4-methylumbelliferyl-galactopyranosidebeta-D-galactoside;
coumarins;
monosaccharide derivative
chromogenic compound00low000000
skimmincoumarins;
glycoside
00low000000
n-(4-(7-diethylamino-4-methylcoumarin-3-yl)phenyl)maleimidebenzenes;
coumarins;
maleimides;
tertiary amino compound
fluorescent dye00low000000
4-methylumbelliferylcellobiosidecoumarins;
glycoside
00low000000
N-(2-oxo-1-benzopyran-3-yl)acetamidecoumarins00low000000
bucumololcoumarins00low000000
3-chloro-7-methoxy-4-methyl-1-benzopyran-2-onecoumarins00low000000
khellactonecoumarins00low000000
dentatincoumarinsmetabolite00low000000
rosiglitazoneacetate ester;
coumarins;
diester
pro-angiogenic agent;
radical scavenger
00low000000
5,7-dimethoxy-4-methyl-1-benzopyran-2-onecoumarins00low000000
7-methoxy-4-methyl-1-benzopyran-2-onecoumarins00low000000
scopolinbeta-D-glucoside;
coumarins;
monosaccharide derivative
plant metabolite00low000000
decursincoumarins00low000000
visnadincoumarins00low000000
glycyrinaromatic ether;
coumarins;
hydroxyisoflavans
antibacterial agent;
metabolite;
plant metabolite
00low000000
6-methyl-4-(morpholinomethyl)-2H-chromen-2-onecoumarins00low000000
lomatincoumarins00low000000
2-[(6-chloro-2-oxo-4-propyl-1-benzopyran-7-yl)oxy]-N,N-dimethylacetamidecoumarins00low000000
2-oxo-N-(2-pyridinylmethyl)-1-benzopyran-3-carboxamidecoumarins00low000000
N-[3-(4-morpholinyl)propyl]-2-oxo-1-benzopyran-3-carboxamidecoumarins00low000000
8-methoxy-N-(6-methyl-2-pyridinyl)-2-oxo-1-benzopyran-3-carboxamidecoumarins00low000000
2-[(6-chloro-4-ethyl-2-oxo-1-benzopyran-7-yl)oxy]propanoic acidcoumarins00low000000
4,8-dimethyl-3-(phenylmethyl)-7-(2H-tetrazol-5-ylmethoxy)-1-benzopyran-2-onecoumarins00low000000
1-[1-oxo-2-[(4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl)oxy]ethyl]-4-piperidinecarboxylic acidcoumarins00low000000
3-[4,8-dimethyl-2-oxo-7-(2H-tetrazol-5-ylmethoxy)-1-benzopyran-3-yl]propanoic acid ethyl estercoumarins00low000000
3,4,7-trimethyl-5-(3-oxobutan-2-yloxy)-1-benzopyran-2-onecoumarins00low000000
4,9-dimethyl-3-(2H-tetrazol-5-ylmethoxy)-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-6-onecoumarins00low000000
4-[(4-ethyl-1-piperazinyl)methyl]-5,7-dimethyl-1-benzopyran-2-onecoumarins00low000000
7-[(3,5-dimethyl-4-isoxazolyl)methoxy]-1-benzopyran-2-onecoumarins00low000000
7-(diethylamino)-2-oxo-1-benzopyran-3-carbonitrilecoumarins00low000000
2-oxo-N-(3-pyridinylmethyl)-1-benzopyran-3-carboxamidecoumarins00low000000
2-[(3-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-1-yl)oxy]acetic acid propan-2-yl estercoumarins;
isopropyl ester
00low000000
5-methyl-4-[(2-oxo-1-benzopyran-7-yl)oxymethyl]-2-furancarboxylic acid methyl estercoumarins00low000000
6-methoxy-2-oxo-N-(3-pyridinylmethyl)-1-benzopyran-3-carboxamidecoumarins00low000000
(4-Methyl-2-oxochromen-7-yl) furan-2-carboxylatecoumarinsanticoronaviral agent00low000000
2-furancarboxylic acid (7-methyl-4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-9-yl) estercoumarins00low000000
N-(4-amino-2-oxo-1-benzopyran-3-yl)acetamidecoumarins00low000000
3-(8-methyl-2-imidazo[1,2-a]pyridinyl)-1-benzopyran-2-onecoumarins00low000000
(4-Ethyl-2-oxochromen-7-yl) furan-2-carboxylatecoumarinsanticoronaviral agent00low000000
5-(3,3-dimethyl-2-oxobutoxy)-4-ethyl-7-methyl-1-benzopyran-2-onecoumarins00low000000
7-methoxy-4,8-dimethyl-1-benzopyran-2-onecoumarins00low000000
8-chloro-7-propan-2-yloxy-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-4-onecoumarins00low000000
2-[(3-ethyl-4-methyl-2-oxo-1-benzopyran-7-yl)oxy]acetic acid methyl estercoumarins00low000000
7-methoxy-2-oxo-1-benzopyran-3-carboxylic acid ethyl estercoumarins00low000000
2-(2,3-dimethylphenoxy)-N-(2-oxo-1-benzopyran-6-yl)acetamidecoumarins00low000000
1-(4-methyl-2-oxo-1-benzopyran-7-yl)-3-(2-pyridinylmethyl)thioureacoumarins00low000000
8-methoxy-N-methyl-2-oxo-1-benzopyran-3-carboxamidecoumarins00low000000
4-methyl-6-[2-(4-methyl-1-piperidinyl)-2-oxoethoxy]-1-benzopyran-2-onecoumarins00low000000
3-[(4-benzoyl-1-piperazinyl)-oxomethyl]-8-methoxy-1-benzopyran-2-onecoumarins00low000000
3-[(4-nitrophenyl)methoxy]-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-6-onecoumarins00low000000
3-[2-(4-aminoanilino)-4-thiazolyl]-1-benzopyran-2-onecoumarins00low000000
2-[(4-methyl-2-oxo-1-benzopyran-7-yl)oxy]-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)acetamidecoumarins00low000000
3-[oxo-[4-(2-phenylethyl)-1-piperazinyl]methyl]-1-benzopyran-2-onecoumarins00low000000
6-bromo-N-[2-(dimethylamino)ethyl]-2-oxo-1-benzopyran-3-carboxamidecoumarins00low000000
8-methoxy-6-nitro-3-[oxo-(2-phenyl-4,5-dihydroimidazol-1-yl)methyl]-1-benzopyran-2-onecoumarins00low000000
N-cyclohexyl-2-[(8-methoxy-6-oxo-3-benzo[c][1]benzopyranyl)oxy]acetamidecoumarins00low000000
5-methyl-4-[(3-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-1-yl)oxymethyl]-2-furancarboxylic acidcoumarins00low000000
5-[(3-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-1-yl)oxymethyl]-2-furancarboxylic acid methyl estercoumarins00low000000
4-methyl-3-(phenylmethyl)-7-[(3,4,5-trimethoxyphenyl)methoxy]-1-benzopyran-2-onecoumarins00low000000
5-(3,3-dimethyl-2-oxobutoxy)-3,4,7-trimethyl-1-benzopyran-2-onecoumarins00low000000
Methyl 7-methoxycoumarin-4-acetatecoumarins00low000000
auraptencoumarins;
monoterpenoid
antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
dopaminergic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
gamma-secretase modulator;
gastrointestinal drug;
hepatoprotective agent;
matrix metalloproteinase inhibitor;
neuroprotective agent;
plant metabolite;
PPARalpha agonist;
vulnerary
00low000000
2-[(7-methyl-4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-9-yl)oxy]acetic acid butyl estercoumarins00low000000
4-(4-methylphenyl)-2-[[oxo-(2-oxo-1-benzopyran-3-yl)methyl]amino]-3-thiophenecarboxylic acid ethyl estercoumarins00low000000
5-[(4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl)oxymethyl]-2-furancarboxylic acidcoumarins00low000000
6-methyl-7-[2-nitro-4-(trifluoromethyl)phenoxy]-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-4-onecoumarins00low000000
3-methoxy-N-[[(2-oxo-1-benzopyran-6-yl)amino]-sulfanylidenemethyl]benzamidecoumarins00low000000
3-acetyl-7-methoxycoumarincoumarins00low000000
acetic acid 2-[[oxo-(2-oxo-1-benzopyran-3-yl)methyl]amino]ethyl estercoumarins00low000000
4-(2,3-dihydroindol-1-ylmethyl)-7-ethyl-1-benzopyran-2-onecoumarins00low000000
3-[4-[(4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-ylidene)methyl]-3-(2-oxo-1-benzopyran-3-yl)-1-pyrazolyl]propanoic acidcoumarins00low000000
2-[(3-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-2-yl)oxy]acetic acid ethyl estercoumarins00low000000
1-[oxo-(2-oxo-1-benzopyran-3-yl)methyl]-4-piperidinecarboxylic acid methyl estercoumarins00low000000
2-[(3,4-dimethyl-2-oxo-1-benzopyran-7-yl)oxy]acetic acid prop-2-enyl estercoumarins00low000000
2-[(3,4,8-trimethyl-2-oxo-1-benzopyran-7-yl)oxy]acetic acid prop-2-enyl estercoumarins00low000000
1-(2-hydroxyethyl)-4-[1]benzopyrano[3,4-d]triazolonecoumarins00low000000
2-[(4-methyl-2-oxo-1-benzopyran-7-yl)oxy]-N-(2-pyridinylmethyl)acetamidecoumarins00low000000
4-[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)methyl]-7-ethyl-1-benzopyran-2-onecoumarins00low000000
N-cyclohexyl-2-[(4-oxo-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-7-yl)oxy]acetamidecoumarins00low000000
3-bromo-N-(4-methyl-2-oxo-1-benzopyran-7-yl)benzamidecoumarins00low000000
3-[ethyl(phenyl)sulfamoyl]-4-methylbenzoic acid (4-methyl-2-oxo-1-benzopyran-7-yl) estercoumarins00low000000
aflatoxin g2coumarins00low000000
4-methylumbelliferyl glucosidebeta-D-glucoside;
coumarins;
monosaccharide derivative
chromogenic compound00low000000
6,8-difluoro-4-methylumbelliferyl phosphatecoumarins00low000000
2,3-dihydro-2,3-dihydroxyaflatoxin b(1)coumarins00low000000
6,7,8-trimethoxycoumarincoumarins00low000000
3-O-Acetylepisamarcandincoumarins00low000000
conferonecoumarins00low000000
2-[(2-ethyl-6-oxo-7,8,9,10-tetrahydrobenzo[c][1]benzopyran-3-yl)oxy]acetic acid methyl estercoumarins00low000000
N-[2-(1-cyclohexenyl)ethyl]-2-(4-oxo-1-[1]benzopyrano[4,3-c]pyrazolyl)acetamidecoumarins00low000000
3-pyridinecarboxylic acid 2-[[oxo-(2-oxo-1-benzopyran-3-yl)methyl]amino]ethyl estercoumarins00low000000
N-(3-methoxypropyl)-2-(4-oxo-1-[1]benzopyrano[4,3-c]pyrazolyl)acetamidecoumarins00low000000
7-[[5-(4-methoxyphenyl)-4-thieno[2,3-d]pyrimidinyl]oxy]-4-methyl-1-benzopyran-2-onecoumarins;
thienopyrimidine
00low000000
N-(2-oxo-1-benzopyran-3-yl)cyclohexanecarboxamidecoumarins00low000000
4-[(4-chlorophenyl)methylamino]-3-nitro-1-benzopyran-2-onecoumarins00low000000
2-(3-oxo-4H-1,4-benzothiazin-2-yl)acetic acid (7-methoxy-2-oxo-1-benzopyran-4-yl)methyl estercoumarins00low000000
2-(3-oxo-4H-1,4-benzothiazin-2-yl)acetic acid (7-acetamido-2-oxo-1-benzopyran-4-yl)methyl estercoumarins00low000000
Meranzin hydratecoumarins00low000000
N-(1,1-dioxo-3-thiolanyl)-N-[(4-ethoxyphenyl)methyl]-2-oxo-1-benzopyran-3-carboxamidecoumarins00low000000
capillarisincoumarins00low000000
pteryxincoumarins00low000000
4-[1-[(4-methyl-2-oxo-1-benzopyran-7-yl)amino]-3-oxo-1H-isoindol-2-yl]-1-piperidinecarboxylic acid ethyl estercoumarins00low000000
glycycoumarinaromatic ether;
coumarins;
resorcinols
antispasmodic drug;
plant metabolite
00low000000
phebalosincoumarins00low000000
urolithin bcoumarins00low000000
7-hydroxy-6-(4-morpholinylmethyl)-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-4-onecoumarins00low000000
3,8-dihydroxy-6h-dibenzo(b,d)pyran-6-onecoumarinsgeroprotector00low000000
N-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-8-methyl-4-oxo-2-thieno[3,2-c][1]benzopyrancarboxamidecoumarins00low000000
N-ethyl-8-methyl-4-oxo-N-(phenylmethyl)-2-thieno[3,2-c][1]benzopyrancarboxamidecoumarins00low000000
trichodermamide acoumarins00low000000
3-hydroxy-3-methyl-5-oxo-5-[[3,4,5-trihydroxy-6-[[6-methoxy-2-oxo-3-[(2-oxo-1-benzopyran-7-yl)oxy]-1-benzopyran-7-yl]oxy]-2-oxanyl]methoxy]pentanoic acidcoumarins;
glycoside
00low000000
auraptenolcoumarins00low000000
foetidincoumarins00low000000
8-[1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)propyl]-5,7-dimethoxy-4-pentyl-1-benzopyran-2-onecoumarins00low000000
5,7-dimethoxy-4-methyl-8-[3-(4-morpholinyl)-1-(3,4,5-trimethoxyphenyl)propyl]-1-benzopyran-2-onecoumarins00low000000
8-{1-[4-(dimethylamino)phenyl]-3-(pyrrolidin-1-yl)propyl}-5,7-dimethoxy-4-pentyl-2H-chromen-2-onearomatic ether;
coumarins;
pyrrolidines;
tertiary amino compound
00low000000
8-[3-(diethylamino)-1-(4-methoxyphenyl)propyl]-5,7-dimethoxy-4-pentyl-1-benzopyran-2-onecoumarins00low000000
coumermycinaromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor
00low000000
urolithin ccoumarins00low000000
3-cyanopyridinenitrile;
pyridines
00low000000
2-(3-pyridine)acetic acidmonocarboxylic acid;
pyridines
human xenobiotic metabolite00low000000
nicotine 1-n-oxidepyridines;
pyrrolidine N-oxides
00low000000
norcotininepyridines;
pyrrolidines
00low000000
4-oxo-4-(3-pyridyl)butanoic acidaromatic ketone;
monocarboxylic acid;
pyridines
00low000000
pyridineazaarene;
mancude organic heteromonocyclic parent;
monocyclic heteroarene;
pyridines
environmental contaminant;
NMR chemical shift reference compound
00low000000
carbinoxaminemonochlorobenzenes;
pyridines;
tertiary amino compound
anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist
00low000000
chlorpheniraminemonochlorobenzenes;
pyridines;
tertiary amino compound
anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
00low000000
disopyramidemonocarboxylic acid amide;
pyridines;
tertiary amino compound
anti-arrhythmia drug00low000000
doxylaminepyridines;
tertiary amine
anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative
00low000000
fusaric acidaromatic carboxylic acid;
pyridines
00low000000
iproniazidcarbohydrazide;
pyridines
00low000000
lansoprazolebenzimidazoles;
pyridines;
sulfoxide
anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
00low000000
entinostatbenzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
niflumic acidaromatic carboxylic acid;
pyridines
00low000000
omeprazolearomatic ether;
benzimidazoles;
pyridines;
sulfoxide
00low000000
pantoprazolearomatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide
anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic
00low000000
pheniraminepyridines;
tertiary amino compound
00low000000
pinacidilpyridines00low000000
pioglitazonearomatic ether;
pyridines;
thiazolidinediones
antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
00low000000
pirbuterolpyridines00low000000
pyridinolcarbamatepyridines00low000000
quipazinepiperazines;
pyridines
00low000000
rabeprazolebenzimidazoles;
pyridines;
sulfoxide
anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
00low000000
sb 202190imidazoles;
organofluorine compound;
phenols;
pyridines
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
risedronic acidpyridines00low000000
imatinibaromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
00low000000
streptonigrinpyridines;
quinolone
antimicrobial agent;
antineoplastic agent
00low000000
sulfapyridinepyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide
antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic
00low000000
tazaroteneacetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane
keratolytic drug;
prodrug;
teratogenic agent
00low000000
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamineN-substituted diamine;
pyridines;
tertiary amino compound
apoptosis inducer;
chelator;
copper chelator
00low000000
thurfyl nicotinatearomatic carboxylic acid;
pyridines
00low000000
brompheniramineorganobromine compound;
pyridines
anti-allergic agent;
H1-receptor antagonist
00low000000
methyl nicotinatearomatic carboxylic acid;
pyridines
00low000000
citrazinic acidaromatic carboxylic acid;
pyridines
00low000000
nicotinyl alcoholaromatic primary alcohol;
pyridines
antilipemic drug;
vasodilator agent
00low000000
beta-nicotyrinepyridines00low000000
3-ethylpyridinepyridines00low000000
2-Pyridinylmethanolpyridines00low000000
nicoboxilaromatic carboxylic acid;
pyridines
00low000000
clopyralidorganochlorine pesticide;
pyridines
herbicide00low000000
oxiniacic acidaromatic carboxylic acid;
pyridines
00low000000
2-(aminomethyl)pyridinepyridines00low000000
propirampyridines00low000000
n'-nitrosonornicotinepyridines;
pyrrolidines
00low000000
[4-(2-pyridinyl)-1-piperazinyl]-(3,4,5-trimethoxyphenyl)methanonepiperazines;
pyridines
00low000000
5-hydroxynicotinic acidaromatic carboxylic acid;
pyridines
00low000000
n-cyano-n'-(1,1-dimethylpropyl)-n''-(3-pyridinyl)guanidinepyridines00low000000
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanonenitrosamine;
pyridines
00low000000
haloxyfoparomatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
pyridines
00low000000
fluazifop-butylaromatic ether;
carboxylic ester;
organofluorine compound;
pyridines
00low000000
imazapyr, (+-)-isomerimidazolines;
imidazolone;
pyridinemonocarboxylic acid;
pyridines
00low000000
imazethapyraromatic carboxylic acid;
pyridines
00low000000
2,2'-dipyridyl disulfideorganic disulfide;
pyridines
oxidising agent00low000000
droxicamorganic heterotricyclic compound;
pyridines
cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug
00low000000
methyridinepyridines00low000000
picosulfate sodiumaryl sulfate;
pyridines
00low000000
2-hydroxynicotinic acidaromatic carboxylic acid;
pyridines
00low000000
ethylnicotinatearomatic carboxylic acid;
pyridines
00low000000
nicametatearomatic carboxylic acid;
pyridines
00low000000
nicotinamide n-oxidepyridines00low000000
nicosulfuronN-sulfonylurea;
pyridines;
pyrimidines
environmental contaminant;
herbicide;
xenobiotic
00low000000
4,4'-dipyridyl disulfideorganic disulfide;
pyridines
00low000000
2-Chloronicotinic acidaromatic carboxylic acid;
pyridines
00low000000
4-methoxymethylpyridoxinepyridines00low000000
6-chloronicotinic acidaromatic carboxylic acid;
pyridines
00low000000
2-pyridylacetic acidpyridines00low000000
fluazifoparomatic ether;
monocarboxylic acid;
organofluorine compound;
pyridines
00low000000
pyriproxyfenaromatic ether;
pyridines
juvenile hormone mimic00low000000
dithiopyrorganofluorine compound;
pyridines;
thioester
00low000000
thiazopyraromatic carboxylic acid;
pyridines
00low000000
dpx e9636aromatic ether;
N-sulfonylurea;
pyridines;
pyrimidines;
sulfone
environmental contaminant;
herbicide;
xenobiotic
00low000000
clodinafop-propargylaromatic ether;
carboxylic ester;
organochlorine compound;
organofluorine compound;
propyzamide;
pyridines
agrochemical;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
herbicide
00low000000
flazasulfuronpyridines;
sulfonamide
00low000000
2,6-dichloroisonicotinic acidmonocarboxylic acid;
organochlorine compound;
pyridines
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor00low000000
difenpiramidebiphenyls;
monocarboxylic acid amide;
pyridines
antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
4-(methylnitrosamino)-1-(3-pyridyl)-1-butan-1-olnitrosamine;
pyridines;
secondary alcohol
biomarker;
carcinogenic agent;
human urinary metabolite
00low000000
hydroxycotinineN-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
00low000000
5-hydroxymethylomeprazolearomatic ether;
benzimidazoles;
pyridines;
sulfoxide
drug metabolite00low000000
forasartanbenzenes;
pyridines;
tetrazoles;
triazoles
angiotensin receptor antagonist;
antihypertensive agent
00low000000
abiraterone3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines
antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
00low000000
agn 190299monocarboxylic acid;
pyridines;
retinoid;
thiochromane
keratolytic drug;
teratogenic agent
00low000000
vatalanibmonochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
metyrapolpyridines00low000000
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
00low000000
aminopyralidaromatic amine;
organochlorine pesticide;
pyridines
herbicide00low000000
dabigatran etexilatearomatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
carboxylic ester;
pyridines
anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug
00low000000
dabigatranaromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines
anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor
00low000000
alpha-(trichloromethyl)-4-pyridineethanolpyridines00low000000
6-methyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrilenitrile;
pyridines
00low000000
gant58pyridines00low000000
3-(3-pyridinyl)propanoic acidpyridines00low000000
rosoxacinpyridines;
quinolinemonocarboxylic acid;
quinolone antibiotic
antibacterial drug;
antiinfective agent
00low000000
gant 61aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor
00low000000
e 3040benzothiazoles;
organic hydroxy compound;
pyridines;
secondary amino compound
anti-inflammatory drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
uricosuric drug
00low000000
E3040 glucuronidebenzothiazoles;
beta-D-glucosiduronic acid;
pyridines;
secondary amino compound
xenobiotic metabolite00low000000
cerivastatindihydroxy monocarboxylic acid;
pyridines;
statin (synthetic)
00low000000
hts 466284pyrazoles;
pyridines;
quinolines
TGFbeta receptor antagonist00low000000
prinomastataromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor
00low000000
6-methyl-2-oxo-5-[oxo-(1-phenylethylamino)methyl]-1H-pyridine-3-carboxylic acid ethyl esteraromatic carboxylic acid;
pyridines
00low000000
5-(2-furanyl)-3-(3-pyridinyl)-1,2,4-oxadiazolepyridines00low000000
1-(2-pyridin-4-yl-1-oxa-3,4-diazaspiro[4.6]undec-2-en-4-yl)ethanonepyridines00low000000
s 1033(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
2-pyridinecarboxylic acid [2-(2,3-dichloroanilino)-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
N-methyl-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)-3-oxolanecarboxamidepyridines00low000000
5-(4-propylcyclohexyl)-3-(3-pyridinyl)-1,2,4-oxadiazolepyridines00low000000
N-methyl-N-[5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl]-3-oxolanecarboxamidepyridines00low000000
2-methoxy-N-methyl-N-[5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl]acetamidepyridines00low000000
6-methyl-2-[4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-3-quinolinecarbonitrilepiperazines;
pyridines
00low000000
[5-(2-furanyl)-7-(trifluoromethyl)-2-pyrazolo[1,5-a]pyrimidinyl]-[4-(2-pyridinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
6-hydroxy-1-(3-hydroxypropyl)-4-methyl-2-oxo-5-(1-piperidinylmethyl)-3-pyridinecarbonitrilenitrile;
pyridines
00low000000
5,8-dimethoxy-4-(4-methyl-1-piperazinyl)-2-(trifluoromethyl)quinolinepiperazines;
pyridines
00low000000
5-ethyl-4,6-dimethyl-2-sulfanylidene-1H-pyridine-3-carbonitrilenitrile;
pyridines
00low000000
8-(2-furanyl)-6-[4-[2-furanyl(oxo)methyl]-1-piperazinyl]-3,3-dimethyl-1,4-dihydrothiopyrano[3,4-c]pyridine-5-carbonitrilepiperazines;
pyridines
00low000000
N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamideacetamides;
piperidines;
pyridines;
sulfonamide
00low000000
2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazolinepyridines;
pyrrolidines;
quinazolines
00low000000
2-methyl-3-phenyl-5-propyl-7-[4-(2-pyridinyl)-1-piperazinyl]pyrazolo[1,5-a]pyrimidinepiperazines;
pyridines
00low000000
prothionamidepyridines00low000000
N2-(4-fluorophenyl)-6-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-1,3,5-triazine-2,4-diaminepiperazines;
pyridines
00low000000
1-(4-methyl-1,2,5-oxadiazol-3-yl)-3-(3-pyridinyl)ureapyridines00low000000
N-(3-fluorophenyl)-2-(pyridin-4-yl)quinazolin-4-aminearomatic amine;
monofluorobenzenes;
pyridines;
quinazolines;
secondary amino compound;
substituted aniline
00low000000
5-cyano-2-methyl-6-sulfanylidene-1H-pyridine-3-carboxylic acid ethyl esteraromatic carboxylic acid;
pyridines
00low000000
2-(1H-imidazol-1-yl)-5-(trifluoromethyl)pyridinepyridines00low000000
5-(3-pyridinylmethyl)-1,3,5-triazinane-2-thionepyridines00low000000
2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrilenitrile;
pyridines
00low000000
4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrilenitrile;
pyridines
00low000000
GS4012 free basearyl sulfide;
monomethoxybenzene;
pyridines
VEGF activator00low000000
5-(phenylmethyl)-3-(2-pyridinyl)-1,2,4-oxadiazolepyridines00low000000
4-(methoxymethyl)-6-methyl-2-(4-phenyl-1-piperazinyl)-3-pyridinecarbonitrilepiperazines;
pyridines
00low000000
1-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-2-benzo[cd]indolonepiperazines;
pyridines
00low000000
cotinineN-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid
antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite
00low000000
1-propylsulfonyl-4-(2-pyridinyl)piperazinepiperazines;
pyridines
00low000000
2-(2-phenylethylthio)-3-pyridinecarboxylic acidaromatic carboxylic acid;
pyridines
00low000000
1,3-benzothiazol-2-yl-[4-(2-pyridinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
2-(2,6-dichloroanilino)-3-pyridinesulfonamidepyridines;
sulfonamide
00low000000
4-(4-chloroanilino)-3-pyridinesulfonamidepyridines;
sulfonamide
00low000000
6-(2-oxopropylthio)-3-pyridinecarboxylic acidaromatic carboxylic acid;
pyridines
00low000000
6-chloro-N-(2-hydroxyphenyl)-3-pyridinesulfonamidepyridines;
sulfonamide
00low000000
3-(phenylmethyl)-6-pyridin-4-yl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazolepyridines;
triazolothiadiazole
00low000000
6-(4-benzoyl-1-piperazinyl)-3,3-dimethyl-8-propan-2-yl-1,4-dihydropyrano[3,4-c]pyridine-5-carbonitrilepiperazines;
pyridines
00low000000
5-bromo-6-chloro-N-(4-methyl-2-pyridinyl)-3-pyridinesulfonamidepyridines;
sulfonamide
00low000000
pyrabactinnaphthalenes;
organobromine compound;
pyridines;
sulfonamide
abscisic acid receptor agonist;
hormone;
plant growth regulator
00low000000
4-[4-(benzenesulfonyl)-1-piperazinyl]-2-methylquinolinepiperazines;
pyridines
00low000000
2-(4-bromophenyl)-1-[4-(2-pyridinyl)-1-piperazinyl]ethanonepiperazines;
pyridines
00low000000
(4-chlorophenyl)-[4-(7-chloro-4-quinolinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
7-chloro-4-[4-(3,4-dimethylphenyl)sulfonyl-1-piperazinyl]quinolinepiperazines;
pyridines
00low000000
1-ethyl-3-sulfanylidene-5,6,7,8-tetrahydro-2H-isoquinoline-4-carbonitrilepyridines00low000000
7-methoxy-2-[4-[(2-methylphenyl)-oxomethyl]-1-piperazinyl]-3-quinolinecarbonitrilepiperazines;
pyridines
00low000000
6-tert-butyl-2-oxo-4-(trifluoromethyl)-1H-pyridine-3-carbonitrilenitrile;
pyridines
00low000000
5-cyano-2-phenyl-6-[4-(2-pyridinyl)-1-piperazinyl]-3-pyridinecarboxylic acid ethyl esterpiperazines;
pyridines
00low000000
N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-aminepyridines;
quinazolines;
tertiary amino compound
00low000000
4,6-dimethyl-2-[3-(4-morpholinyl)propylamino]-3-pyridinecarbonitrilenitrile;
pyridines
00low000000
2-ethoxy-3-pyridinecarboxylic acid [2-[1-(2-furanylmethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
mcb-613cyclic ketone;
enone;
pyridines
antineoplastic agent;
steroid receptor coactivator stimulator
00low000000
5,6-dichloro-3-pyridinecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
4-pyridinecarboxylic acid [2-[1-(2-furanylmethyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
2-oxo-1H-pyridine-3-carboxylic acid [2-(2,5-dimethyl-1-propyl-3-pyrrolyl)-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
2-thiopyridinearyl thiol;
pyridines
allergen;
fluorescence quencher
00low000000
2-(methylamino)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrilenitrile;
pyridines
00low000000
2-(1-piperidinyl)-6-thiophen-2-yl-4-(trifluoromethyl)-3-pyridinecarbonitrilenitrile;
pyridines
00low000000
N-benzyl-N'-methyl-N-(pyridin-3-ylmethyl)thioureapyridines00low000000
3-Chloro-5-(trifluoromethyl)pyridine-2-carbothioamidepyridines00low000000
2,6-dimethyl-4-(3-thienyl)pyridine-3,5-dicarboxylic acidaromatic carboxylic acid;
pyridines
00low000000
N-tert-butyl-4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamidepiperazines;
pyridines
00low000000
5-cyano-2-(methoxymethyl)-6-sulfanylidene-1H-pyridine-3-carboxylic acid methyl esteraromatic carboxylic acid;
pyridines
00low000000
ethionamidepyridines;
thiocarboxamide
antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
00low000000
2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrilepiperazines;
pyridines
00low000000
2-(propylthio)nicotinic acidaromatic carboxylic acid;
pyridines
00low000000
5-Chloro-2-hydroxy-4,6-dimethylnicotinonitrilenitrile;
pyridines
00low000000
3-[1-(2,4-dichlorophenyl)sulfonyl-2-pyrrolidinyl]pyridinepyridines;
pyrrolidines
00low000000
(3,5-dichlorophenyl)-[4-[2-(trifluoromethyl)-4-quinolinyl]-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
3-[5-[[4-(2-pyridinyl)-1-piperazinyl]sulfonyl]-2-thiophenyl]isoxazolepiperazines;
pyridines
00low000000
2-oxo-4,6-dithiophen-2-yl-1H-pyridine-3-carbonitrilenitrile;
pyridines
00low000000
4-[4-(3-bromophenyl)sulfonyl-1-piperazinyl]-7-chloroquinolinepiperazines;
pyridines
00low000000
3,7-dimethyl-2-[4-(2-pyridinyl)-1-piperazinyl]quinolinepiperazines;
pyridines
00low000000
3-phenyl-1-[4-(2-pyridinyl)-1-piperazinyl]-1-propanonepiperazines;
pyridines
00low000000
4-phenoxy-1-[4-(2-pyridinyl)-1-piperazinyl]-1-butanonepiperazines;
pyridines
00low000000
2-[4-(2-methyl-4-quinolinyl)-1-piperazinyl]-4-phenylthiazolepiperazines;
pyridines
00low000000
6-(2,3-dihydro-1,4-benzodioxin-3-ylmethylamino)-N-ethyl-N-phenyl-3-pyridinesulfonamidepyridines;
sulfonamide
00low000000
alpha-nicotyrinepyridines00low000000
dapiprazoleN-alkylpiperazine;
N-arylpiperazine;
pyridines
alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug
00low000000
glucitol hexanicotinatearomatic carboxylic acid;
pyridines
00low000000
6,8-difluoro-4-(pyridin-3-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolineorganic heterotricyclic compound;
organofluorine compound;
pyridines;
secondary amino compound
00low000000
N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamidebenzodioxoles;
pyridines;
secondary carboxamide;
tertiary carboxamide;
trifluoroacetamide
00low000000
1-methyl-4-[[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]thio]-2-quinolinonepiperazines;
pyridines
00low000000
1-(4-amino-1,2,5-oxadiazol-3-yl)-5-[(2-pyridinylthio)methyl]-4-triazolecarboxylic acid propan-2-yl esteraryl sulfide;
azole;
isopropyl ester;
oxadiazole;
pyridines
00low000000
6-bromo-3-[4-oxo-4-[4-(2-pyridinyl)-1-piperazinyl]butyl]-2-sulfanylidene-1H-quinazolin-4-onepiperazines;
pyridines
00low000000
N-[4-methyl-2-(4-methyl-1-piperazinyl)-6-quinolinyl]-1,3-benzodioxole-5-carboxamidepiperazines;
pyridines
00low000000
4-[2-(1-cyclohexenyl)ethyl]-1-cyclohexyl-3-pyridin-4-ylpiperazine-2,5-dionepiperazines;
pyridines
00low000000
ml012piperazines;
pyridines
00low000000
[4-(2-pyrimidinyl)-1-piperazinyl]-[1-[4-(2-pyrimidinyl)-1-piperazinyl]-4-isoquinolinyl]methanonepiperazines;
pyridines
00low000000
N-(2-furanylmethyl)-N'-[4-methyl-2-(4-methyl-1-piperazinyl)-6-quinolinyl]butanediamidepiperazines;
pyridines
00low000000
[3-(4-methylphenyl)-1-phenyl-4-pyrazolyl]-[4-(2-pyridinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
2-pyridinecarboxylic acid [2-(5-chloro-2-thiophenyl)-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
2-[[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]thio]-3-pyridinecarboxylic acid [2-[(2-methoxyphenyl)methylamino]-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
2-[(5-formyl-2-methoxyphenyl)methylthio]-3-pyridinecarboxylic acidaromatic carboxylic acid;
pyridines
00low000000
[3-(2,3-dihydroindol-1-ylsulfonyl)phenyl]-[4-(2-pyridinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
3-(4-benzoyl-1-piperazinyl)-1-(2-methylpropyl)-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrilepiperazines;
pyridines
00low000000
5-cyano-6-[4-(4-methoxyphenyl)-1-piperazinyl]-2-oxo-1H-pyridine-3-carboxylic acid ethyl esterpiperazines;
pyridines
00low000000
2-[4-(3-chlorophenyl)-1-piperazinyl]-3-pyridinecarboxylic acid propan-2-yl esterisopropyl ester;
piperazines;
pyridines
00low000000
3-(1-hydroxy-5,5-dimethyl-4-phenyl-2H-imidazol-2-yl)pyridinepyridines00low000000
[4-[(2-chlorophenyl)methylsulfonyl]-3-nitrophenyl]-[4-(2-pyridinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
2-pyridinecarboxylic acid [2-[2-(difluoromethoxy)anilino]-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
hydroxypioglitazonearomatic ether;
pyridines;
thiazolidinediones
human xenobiotic metabolite00low000000
2-(2-fluoroanilino)-3-pyridinecarboxylic acid [2-[(1,1-dioxo-3-thiolanyl)-methylamino]-2-oxoethyl] esteraromatic carboxylic acid;
pyridines
00low000000
3-(4-ethylphenyl)-4-hydroxy-4-[oxo-[4-(2-pyridinyl)-1-piperazinyl]methyl]-1H-quinazolin-2-onepiperazines;
pyridines
00low000000
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamidebenzamides;
benzodioxoles;
imidazoles;
pyridines
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor00low000000
N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-aminearomatic amine;
piperidines;
pyridines;
quinazolines;
secondary amino compound;
tertiary amino compound
00low000000
abt724piperazines;
pyridines
00low000000
2-(4-acetyl-1-piperazinyl)-6-amino-4-(cyanomethyl)pyridine-3,5-dicarbonitrilepiperazines;
pyridines
00low000000
triprolidineN-alkylpyrrolidine;
olefinic compound;
pyridines
H1-receptor antagonist00low000000
pibutidinearomatic ether;
cyclobutenones;
olefinic compound;
piperidines;
primary amino compound;
pyridines;
secondary amino compound
anti-ulcer drug;
H2-receptor antagonist
00low000000
acrivastinealpha,beta-unsaturated monocarboxylic acid;
N-alkylpyrrolidine;
olefinic compound;
pyridines
H1-receptor antagonist00low000000
2-[3-(diethylamino)propylamino]-4-(methoxymethyl)-6-methyl-3-pyridinecarbonitrilenitrile;
pyridines
00low000000
[2-(1-piperidinyl)-1,3-benzothiazol-6-yl]-[4-(2-pyridinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
N-[2-(4-ethyl-1-piperazinyl)-4-methyl-6-quinolinyl]-2-pyrazinecarboxamidepiperazines;
pyridines
00low000000
clodinafoparomatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
pyridines
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
phenoxy herbicide
00low000000
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-oneenone;
pyridines
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor
00low000000
[4-(3-chlorophenyl)sulfonyl-3-nitrophenyl]-[4-(2-pyridinyl)-1-piperazinyl]methanonepiperazines;
pyridines
00low000000
axitinibaryl sulfide;
benzamides;
indazoles;
pyridines
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
2-[4-(2-pyrimidinyl)-1-piperazinyl]quinolinepiperazines;
pyridines
00low000000
(2-Chloro-4-pyridinyl)methanolorganohalogen compound;
pyridines
00low000000
pymetrozine1,2,4-triazines;
pyridines
antifeedant;
environmental contaminant;
TRPV channel modulator;
xenobiotic
00low000000
abiraterone acetatepyridines;
sterol ester
antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug
00low000000
mocetinostataminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
00low000000
n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamidepiperazines;
pyridines
00low000000
4-(1H-imidazol-5-ylmethyl)pyridinepyridines00low000000
680c91fluoroindole;
olefinic compound;
pyridines
EC 1.13.11.11 (tryptophan 2,3-dioxygenase) inhibitor00low000000
masitinib1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines
antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
00low000000
vorapaxarcarbamate ester;
lactone;
naphthofuran;
organofluorine compound;
pyridines
cardiovascular drug;
platelet aggregation inhibitor;
protease-activated receptor-1 antagonist
00low000000
azd2858aromatic amine;
N-methylpiperazine;
pyrazines;
pyridines;
secondary carboxamide;
sulfonamide
antineoplastic agent;
bone density conservation agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
00low000000
ciclonicatearomatic carboxylic acid;
pyridines
00low000000
tedizolidcarbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles
antimicrobial agent;
drug metabolite;
protein synthesis inhibitor
00low000000
chlorantranilipolemonochlorobenzenes;
organobromine compound;
pyrazole insecticide;
pyrazoles;
pyridines;
secondary carboxamide
ryanodine receptor agonist00low000000
picoxystrobinaromatic ether;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
organofluorine compound;
pyridines
antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor
00low000000
tedizolid phosphatecarbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles
antimicrobial agent;
prodrug;
protein synthesis inhibitor
00low000000
dorsomorphinaromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines
bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
00low000000
cyantraniliprolenitrile;
organobromine compound;
organochlorine compound;
pyrazole insecticide;
pyridines;
secondary carboxamide
ryanodine receptor agonist00low000000
GDC-0879indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines
antineoplastic agent;
B-Raf inhibitor
00low000000
bgt226aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
00low000000
[4-(3-chlorophenyl)-1-piperazinyl]-[1-[4-(2-pyridinyl)-1-piperazinyl]-4-isoquinolinyl]methanonepiperazines;
pyridines
00low000000
dafadine Caromatic amide;
aromatic ether;
difluorobenzene;
isoxazoles;
N-acylpiperidine;
pyridines
P450 inhibitor00low000000
dafadine Baromatic amide;
aromatic ether;
isoxazoles;
monochlorobenzenes;
monofluorobenzenes;
N-acylpiperidine;
pyridines
P450 inhibitor00low000000
1-butyl-3-[2-(4-ethyl-1-piperazinyl)-4-methyl-6-quinolinyl]-1-methylthioureapiperazines;
pyridines
00low000000
lumacaftoraromatic amide;
benzodioxoles;
benzoic acids;
cyclopropanes;
organofluorine compound;
pyridines
CFTR potentiator;
orphan drug
00low000000
sulfoxaflornitrile;
organofluorine compound;
pyridines;
sulfoximide
00low000000
cnf 20242-aminopurines;
aromatic ether;
organochlorine compound;
pyridines
antineoplastic agent;
Hsp90 inhibitor
00low000000
gdc 0449benzamides;
monochlorobenzenes;
pyridines;
sulfone
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
00low000000
bms 754807pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridinearomatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines
geroprotector;
P450 inhibitor
00low000000
dafadine Daromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
organofluorine compound;
pyridines
P450 inhibitor00low000000
dafadine Oaromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines;
ring assembly
P450 inhibitor00low000000
florbetapir f 18(18)F radiopharmaceutical;
aromatic ether;
organofluorine compound;
pyridines;
substituted aniline
radioactive imaging agent00low000000
sch772984biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide
analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
gsk 2126458aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
00low000000
1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-(2-pyridinylsulfonyl)piperazinepyridines;
sulfonamide
00low000000
ml228 probe1,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound
hypoxia-inducible factor pathway activator00low000000
lgk974bipyridines;
pyrazines;
pyridines;
secondary carboxamide
Wnt signalling inhibitor00low000000
N-(4,6-dimethyl-2-pyridinyl)-4-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarbothioamidepiperazines;
pyridines
00low000000
afidopyropencyclopropanecarboxylate ester;
organic heterotetracyclic compound;
pyridines;
secondary alcohol
agrochemical;
insecticide;
TRPV channel modulator
00low000000
piroxicambenzothiazine;
monocarboxylic acid amide;
pyridines
analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
00low000000
mobiflexheteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine
antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
lornoxicamheteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine
antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
MK-8353aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
gsk-2816126piperazines;
pyridines
00low000000
acp-196aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
GSK1059615pyridines;
quinolines;
thiazolidinone
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
pf-06687252azabicycloalkane;
enone;
phenols;
pyridines
00low000000
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrilehydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor
00low000000
sb-590885aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound
00low000000
dabigatran etexilatearomatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
carboxylic ester;
pyridines
anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug
00low000000
benefinC-nitro compound;
organofluorine compound;
substituted aniline;
tertiary amino compound
agrochemical;
herbicide
00low000000
celecoxiborganofluorine compound;
pyrazoles;
sulfonamide;
toluenes
cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
cgs 12066N-arylpiperazine;
organofluorine compound;
pyrroloquinoxaline
serotonergic agonist00low000000
citalopram2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound
00low000000
diflunisalmonohydroxybenzoic acid;
organofluorine compound
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
droperidolaromatic ketone;
benzimidazoles;
organofluorine compound
anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
00low000000
enfluraneether;
organochlorine compound;
organofluorine compound
anaesthetic00low000000
carbonyl cyanide p-trifluoromethoxyphenylhydrazonearomatic ether;
hydrazone;
nitrile;
organofluorine compound
ATP synthase inhibitor;
geroprotector;
ionophore
00low000000
flecainidearomatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines
anti-arrhythmia drug00low000000
flucytosineaminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone
prodrug00low000000
fludiazepam1,4-benzodiazepinone;
organochlorine compound;
organofluorine compound
anxiolytic drug00low000000
flufenamic acidaromatic amino acid;
organofluorine compound
antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
fluphenazineN-alkylpiperazine;
organofluorine compound;
phenothiazines
anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug
00low000000
flumazenilethyl ester;
imidazobenzodiazepine;
organofluorine compound
antidote to benzodiazepine poisoning;
GABA antagonist
00low000000
flumequine3-oxo monocarboxylic acid;
organofluorine compound;
pyridoquinoline;
quinolone antibiotic
00low000000
fluorouracilnucleobase analogue;
organofluorine compound
antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
00low000000
fluphenazine depotdecanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines
dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug
00low000000
vanoxerineether;
N-alkylpiperazine;
organofluorine compound;
tertiary amino compound
dopamine uptake inhibitor00low000000
haloperidolaromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol
antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
00low000000
halothanehaloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound
inhalation anaesthetic00low000000
isofluraneorganofluorine compoundinhalation anaesthetic00low000000
ketanserinaromatic ketone;
organofluorine compound;
piperidines;
quinazolines
alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
00low000000
mefloquine hydrochlorideorganofluorine compound;
piperidines;
quinolines;
secondary alcohol
00low000000
methoxyfluraneether;
organochlorine compound;
organofluorine compound
hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic
00low000000
ofloxacin3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline
00low000000
pipamperonearomatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
00low000000
risperidone1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine
alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist
00low000000
ritanserinorganofluorine compound;
piperidines;
thiazolopyrimidine
antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
00low000000
sb 220025aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines
angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
sevofluraneether;
organofluorine compound
central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
00low000000
fluoroacetic acidhaloacetic acid;
organofluorine compound
EC 4.2.1.3 (aconitate hydratase) inhibitor00low000000
spiperonearomatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound
alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
00low000000
gatifloxacinN-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone
antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
00low000000
tosufloxacin1,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound
00low000000
trifluoperazineN-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines
antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
00low000000
triflupromazineorganofluorine compound;
phenothiazines;
tertiary amine
anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic
00low000000
zardaverineorganofluorine compound;
pyridazinone
anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug
00low000000
floxuridinenucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
00low000000
trifluridinenucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
00low000000
dinitrofluorobenzeneC-nitro compound;
organofluorine compound
agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent
00low000000
1,1-difluoroethyleneolefinic compound;
organofluorine compound
00low000000
1,1,1-trifluoro-2-chloroethaneorganofluorine compound00low000000
chloropentafluoroethaneorganochlorine compound;
organofluorine compound
00low000000
2-fluoroadenosineadenosines;
organofluorine compound
00low000000
perfluorotributylamineorganofluorine compoundblood substitute;
greenhouse gas;
solvent
00low000000
5-fluorouridineorganofluorine compound;
uridines
mutagen00low000000
5-fluorotryptophannon-proteinogenic alpha-amino acid;
organofluorine compound;
tryptophan derivative
00low000000
bromochlorodifluoromethaneone-carbon compound;
organobromine compound;
organochlorine compound;
organofluorine compound
00low000000
difluoroacetic acidmonocarboxylic acid;
organofluorine compound
00low000000
fluroxeneorganofluorine compound00low000000
2,3,4,5,6-pentafluorobenzyl alcoholbenzyl alcohols;
organofluorine compound
00low000000
2-fluoroadenineorganofluorine compound;
purines
antineoplastic agent00low000000
n-dichlorofluoromethylthio-n',n'-dimethyl-n-p-tolylsulfamideorganochlorine compound;
organofluorine compound;
phenylsulfamide fungicide;
sulfamides
antifungal agrochemical;
genotoxin
00low000000
hexafluoroisopropanolorganofluorine compound;
secondary alcohol
drug metabolite00low000000
dichlofluanidorganochlorine compound;
organofluorine compound;
phenylsulfamide fungicide;
sulfamides
acaricide;
antifungal agrochemical
00low000000
pimozidebenzimidazoles;
heteroarylpiperidine;
organofluorine compound
antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist
00low000000
5-fluorocytidinecytidines;
organofluorine compound
00low000000
doxifluridineorganofluorine compound;
pyrimidine 5'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
prodrug
00low000000
fludarabine phosphatenucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate
antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
00low000000
flubendazolearomatic ketone;
benzimidazoles;
carbamate ester;
organofluorine compound
antinematodal drug;
teratogenic agent
00low000000
flunixinaminopyridine;
organofluorine compound;
pyridinemonocarboxylic acid
antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
desfluraneorganofluorine compoundinhalation anaesthetic00low000000
paroxetinearomatic ether;
benzodioxoles;
organofluorine compound;
piperidines
antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
00low000000
acifluorfenaromatic ether;
benzoic acids;
C-nitro compound;
monocarboxylic acid;
organochlorine compound;
organofluorine compound
agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
00low000000
triflumuronaromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound
00low000000
4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acidaminopyridine;
aromatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound
environmental contaminant;
herbicide;
xenobiotic
00low000000
fomesafenaromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols
agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
00low000000
temafloxacinamino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound
00low000000
sertindoleheteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole
alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist
00low000000
gemcitabine hydrochloridehydrochloride;
organofluorine compound
anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
00low000000
gemcitabineorganofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
00low000000
emtricitabinemonothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone
antiviral drug;
HIV-1 reverse transcriptase inhibitor
00low000000
capecitabinecarbamate ester;
cytidines;
organofluorine compound
antimetabolite;
antineoplastic agent;
prodrug
00low000000
4-fluorofentanylmonocarboxylic acid amide;
organofluorine compound;
piperidines
00low000000
efavirenzacetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound
antiviral drug;
HIV-1 reverse transcriptase inhibitor
00low000000
heptafluorobutyric anhydrideacyclic carboxylic anhydride;
organofluorine compound
chromatographic reagent00low000000
perfluorotripropylamineorganofluorine compoundblood substitute00low000000
3-fluoropyruvate2-oxo monocarboxylic acid;
organofluorine compound
00low000000
spiramidearomatic ether;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound
dopaminergic antagonist;
serotonergic antagonist
00low000000
flunoxaprofen1,3-benzoxazoles;
monocarboxylic acid;
organofluorine compound
antirheumatic drug;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
00low000000
halopropaneorganofluorine compound00low000000
enrofloxacincyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone
antibacterial agent;
antimicrobial agent;
antineoplastic agent
00low000000
flurithromycincyclic ketone;
erythromycin derivative;
organofluorine compound;
semisynthetic derivative
antibacterial drug00low000000
nebivololchromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound
00low000000
hp 8731,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist
00low000000
fluphenacuraromatic ether;
benzoylurea insecticide;
dichlorobenzene;
N-acylurea;
organofluorine compound
00low000000
nucleocidin6-aminopurines;
adenosines;
diol;
organofluorine compound;
sulfamate ester
antibacterial agent;
bacterial metabolite;
nucleoside antibiotic;
protein synthesis inhibitor;
trypanocidal drug
00low000000
fluoroacetaldehydealdehyde;
organofluorine compound
cardiotoxic agent00low000000
fc 75alkyltetrahydrofuran;
organofluorine compound
00low000000
tetraconazoledichlorobenzene;
ether;
organofluorine compound;
triazoles
00low000000
hei 712organofluorine compound;
quinolone
00low000000
n-(2,4-dichloro-5-(4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1h-1,2,4-triazol-1-yl)phenyl)methanesulfonamidedichlorobenzene;
organofluorine compound;
sulfonamide;
triazoles
agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
00low000000
thifluzamide1,3-thiazoles;
anilide fungicide;
aromatic amide;
aromatic ether;
dibromobenzene;
organofluorine compound
antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor
00low000000
fludioxonilbenzodioxoles;
nitrile;
organofluorine compound;
pyrroles
androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist
00low000000
fluquinconazoleconazole fungicide;
dichlorobenzene;
organofluorine compound;
quinazolines;
triazole fungicide;
triazoles
antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor
00low000000
cloransulam-methylmethyl ester;
monochlorobenzenes;
organofluorine compound;
sulfonamide;
triazolopyrimidines
agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide
00low000000
s 53482benzoxazine;
dicarboximide;
organofluorine compound;
terminal acetylenic compound
agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide;
teratogenic agent
00low000000
triflusulfuron-methyl1,3,5-triazines;
aromatic ether;
benzoate ester;
methyl ester;
N-sulfonylurea;
organofluorine compound;
tertiary amino compound
agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
proherbicide
00low000000
novaluronaromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound
00low000000
fulvestrant17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide
antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
00low000000
cyfluthrinaromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound
agrochemical;
pyrethroid ester insecticide
00low000000
fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl etherorganofluorine compound00low000000
florfenicolorganochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone
antimicrobial agent00low000000
paliperidone1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol
00low000000
sc 58125organofluorine compound;
pyrazoles;
sulfone
antineoplastic agent;
cyclooxygenase 2 inhibitor
00low000000
clofarabineadenosines;
organofluorine compound
antimetabolite;
antineoplastic agent
00low000000
5-fluoromethylornithineorganofluorine compound;
ornithine derivative
EC 2.6.1.13 (ornithine aminotransferase) inhibitor00low000000
nitroflurbiprofenbiphenyls;
carboxylic ester;
nitrate ester;
organofluorine compound
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector;
non-steroidal anti-inflammatory drug;
vasodilator agent
00low000000
ezogabinecarbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline
anticonvulsant;
potassium channel modulator
00low000000
garenoxacinaromatic ether;
cyclopropanes;
isoindoles;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic
antibacterial drug;
non-steroidal anti-inflammatory drug
00low000000
5-fluorowillardiineL-alanine derivative;
non-proteinogenic L-alpha-amino acid;
organofluorine compound
AMPA receptor agonist00low000000
perfluoro-n-methyldecahydroisoquinolineorganofluorine compoundblood substitute00low000000
fc 80alkyltetrahydrofuran;
organofluorine compound
00low000000
ezetimibeazetidines;
beta-lactam;
organofluorine compound
anticholesteremic drug;
antilipemic drug;
antimetabolite
00low000000
5-fluorouridine 5'-phosphateorganofluorine compound;
pyrimidine ribonucleoside 5'-monophosphate
drug metabolite00low000000
cox 189amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
00low000000
canertinibmonochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
jte 5221,3-oxazoles;
organofluorine compound;
sulfonamide
cyclooxygenase 2 inhibitor00low000000
trifluoromethionineL-methionine derivative;
non-proteinogenic L-alpha-amino acid;
organofluorine compound
00low000000
lapatinibfurans;
organochlorine compound;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
cimicoxibaromatic ether;
imidazoles;
organochlorine compound;
organofluorine compound;
sulfonamide
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug
00low000000
diflomotecanepsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
00low000000
5',5',5'-trifluoroleucineleucine derivative;
non-proteinogenic alpha-amino acid;
organofluorine compound
00low000000
sorbinilazaspiro compound;
chromanes;
imidazolidinone;
organofluorine compound;
oxaspiro compound
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor
00low000000
linezolidacetamides;
morpholines;
organofluorine compound;
oxazolidinone
antibacterial drug;
protein synthesis inhibitor
00low000000
2'-deoxy-2-fluoroadenosineadenosines;
organofluorine compound
00low000000
8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine6-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound
antineoplastic agent;
Hsp90 inhibitor
00low000000
roflumilastaromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound
anti-asthmatic drug;
phosphodiesterase IV inhibitor
00low000000
posaconazolearomatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles
trypanocidal drug00low000000
efinaconazoleconazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor00low000000
favipiravirhydroxypyrazine;
organofluorine compound;
primary carboxamide
anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
00low000000
ck-0944666benzamides;
indoles;
organofluorine compound
actin polymerisation inhibitor00low000000
2-(3-Chloro-2-fluorophenyl)-2,3-dihydroisothiazol-3-oneorganofluorine compound00low000000
4-[(3-fluorophenyl)methyl-(3-pyridinylmethyl)amino]-4-oxobutanoic acidorganofluorine compound00low000000
transfluthrincarboxylic ester;
cyclopropanes;
organochlorine compound;
organofluorine compound
pyrethroid ester insecticide00low000000
4-(4-fluorophenyl)-3H-thiazole-2-thioneorganofluorine compound00low000000
2-(4-chlorophenyl)-5-(4-fluorophenyl)-1,3,4-oxadiazoleorganofluorine compound00low000000
N-[(4-fluorophenyl)methyl]-2-thiophen-2-ylacetamideorganofluorine compound00low000000
1-(cycloheptylideneamino)-3-(4-fluorophenyl)thioureaorganofluorine compound00low000000
2-(2-fluorophenyl)-5-phenyl-4-thieno[2,3-d][1,3]oxazinoneorganofluorine compound00low000000
sulindacmonocarboxylic acid;
organofluorine compound;
sulfoxide
analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
00low000000
N-cyano-N'-(2-fluorophenyl)carbamimidothioic acid [2-(tert-butylamino)-2-oxoethyl] esterorganofluorine compound00low000000
N-(4-fluorobenzyl)ureaorganofluorine compound00low000000
N1-(3-chloro-4-fluorophenyl)-2-(methylthio)acetamideorganofluorine compound00low000000
ethyl 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylateethyl ester;
monochlorobenzenes;
organofluorine compound;
pyrazoles;
sulfonamide
00low000000
S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioateacetylenic compound;
furans;
organofluorine compound;
thioester;
triazoles
00low000000
4-[1-(4-fluorophenyl)ethyl]-3-thiophen-2-yl-1H-1,2,4-triazole-5-thioneorganofluorine compound00low000000
1-(4-fluorophenyl)-1-cyclopentanecarboxylic acid [2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl] esterorganofluorine compound00low000000
deracoxiborganofluorine compound;
pyrazoles;
sulfonamide
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
zd 6474aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
1-(4-fluorophenyl)-N-methyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carbothioamideorganofluorine compound00low000000
2-[[2-[3-(4-fluorophenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-2-oxoethyl]thio]acetic acid butyl esterorganofluorine compound00low000000
sc 560aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles
angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
00low000000
1-[(2-fluorophenyl)methyl]-4-pyrazolamineorganofluorine compound00low000000
3-[2,2-dichloro-1-(3-fluoro-4-methylphenyl)ethyl]-1,1-bis(phenylmethyl)ureaorganofluorine compound00low000000
ro 60-0175indoles;
organochlorine compound;
organofluorine compound;
primary amino compound
00low000000
jtk-303aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone
HIV-1 integrase inhibitor00low000000
arachidonyltrifluoromethanefatty acid derivative;
ketone;
olefinic compound;
organofluorine compound
EC 3.1.1.4 (phospholipase A2) inhibitor00low000000
cyhalothrinaromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound
agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide
00low000000
sulindac sulfidearyl sulfide;
monocarboxylic acid;
organofluorine compound
antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug
00low000000
bw b70caromatic ether;
hydroxamic acid;
organofluorine compound;
ureas
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor00low000000
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic aciddihydroxy monocarboxylic acid;
indoles;
organofluorine compound
00low000000
sulindac sulfonemonocarboxylic acid;
organofluorine compound;
sulfone
apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor
00low000000
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-oneorganic heterotetracyclic compound;
organofluorine compound
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor00low000000
z-val-ala-asp(ome)-fluoromethylketonecarbamate ester;
organofluorine compound;
tripeptide
apoptosis inhibitor;
protease inhibitor
00low000000
robenacoxibaromatic amino acid;
monocarboxylic acid;
organofluorine compound;
phenylacetic acids;
secondary amino compound
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
acrinathrincyclopropanecarboxylate ester;
organofluorine compound
pyrethroid ester acaricide;
pyrethroid ester insecticide
00low000000
bifenthrincarboxylic ester;
cyclopropanecarboxylate ester;
cyclopropanes;
organochlorine compound;
organofluorine compound
pyrethroid ester acaricide;
pyrethroid ester insecticide
00low000000
netupitantaminopyridine;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
toluenes
antiemetic;
neurokinin-1 receptor antagonist
00low000000
flibanserinbenzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound
antidepressant;
serotonergic agonist;
serotonergic antagonist
00low000000
ru 5866817beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone
anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
00low000000
nepicastat1,3-dihydroimidazole-2-thiones;
organofluorine compound;
primary amino compound;
tetralins
EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor00low000000
gw 5015161,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound
carcinogenic agent;
PPARbeta/delta agonist
00low000000
noviflumuronaromatic ether;
benzoylurea insecticide;
dichlorobenzene;
organofluorine compound
00low000000
flonicamidnitrile;
organofluorine compound;
pyridinecarboxamide
environmental contaminant;
insecticide;
xenobiotic
00low000000
4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamideorganofluorine compound;
pyrazoles;
sulfonamide
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
paliperidone palmitate1,2-benzoxazoles;
fatty acid ester;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine
00low000000
cangreloradenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound
P2Y12 receptor antagonist;
platelet aggregation inhibitor
00low000000
tafluprostisopropyl ester;
organofluorine compound;
prostaglandins Falpha
prostaglandin receptor agonist00low000000
ticagreloraryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines
P2Y12 receptor antagonist;
platelet aggregation inhibitor
00low000000
am 694aromatic ketone;
indoles;
organofluorine compound;
organoiodine compound;
synthetic cannabinoid
cannabinoid receptor agonist00low000000
rucaparibazepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
00low000000
NNC 55-0396 (free base)benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker
00low000000
osu 03012antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
azd 6244benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
bibw 2992aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
rolapitantazaspiro compound;
ether;
organofluorine compound;
piperidines;
pyrrolidin-2-ones
antiemetic;
neurokinin-1 receptor antagonist
00low000000
r-138727organofluorine compound00low000000
fluoxastrobinaromatic ether;
dioxazine;
monochlorobenzenes;
organofluorine compound;
oxime O-ether;
pyrimidines;
strobilurin antifungal agent
antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor
00low000000
flumorpharomatic ether;
enamide;
morpholines;
organofluorine compound;
tertiary carboxamide
00low000000
fluopicolidebenzamide fungicide;
benzamides;
dichlorobenzene;
monochloropyridine;
organofluorine compound
antifungal agrochemical00low000000
gamendazolealpha,beta-unsaturated monocarboxylic acid;
dichlorobenzene;
indazoles;
olefinic compound;
organofluorine compound
antispermatogenic agent;
eukaryotic translation elongation factor 1alpha 1 inhibitor;
Hsp90 inhibitor;
synthetic oral contraceptive
00low000000
rx-3117organofluorine compound;
primary allylic alcohol;
triol
antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug
00low000000
bay 63-2521aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine
antihypertensive agent;
soluble guanylate cyclase activator
00low000000
penthiopyradaromatic amide;
organofluorine compound;
pyrazoles;
thiophenes
00low000000
tavaborolebenzoxaborole;
organofluorine compound
antifungal agent;
EC 6.1.1.4 (leucine--tRNA ligase) inhibitor;
protein synthesis inhibitor
00low000000
tembotrionearomatic ketone;
beta-triketone;
cyclic ketone;
ether;
monochlorobenzenes;
organofluorine compound;
sulfone
agrochemical;
carotenoid biosynthesis inhibitor;
EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor;
herbicide
00low000000
finafloxacincyclopropanes;
monocarboxylic acid;
nitrile;
organofluorine compound;
quinolone;
secondary amino compound;
tertiary amino compound
antibacterial drug;
antimicrobial agent
00low000000
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineaminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate
antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
idelalisibaromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
zstk474benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
trifloxystrobinmethoxyiminoacetate strobilurin antifungal agent;
methyl ester;
organofluorine compound;
oxime O-ether
antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor
00low000000
5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]pyrazole-4-carboxamidearomatic amide;
organofluorine compound;
pyrazoles
00low000000
n-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxamidearomatic amide;
cyclopropanes;
organofluorine compound;
pyrazoles;
ring assembly
00low000000
trametinibacetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
00low000000
butafenacilbenzoate ester;
diester;
monochlorobenzenes;
olefinic compound;
organofluorine compound
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide
00low000000
buparlisibaminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
azd 7545benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide
EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent
00low000000
ph 797804aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
lde225aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
00low000000
canagliflozinC-glycosyl compound;
organofluorine compound;
thiophenes
hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor
00low000000
navitoclaxaryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
00low000000
dcc-2036organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines
tyrosine kinase inhibitor00low000000
cabozantinibaromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
pexidartinibaminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
TAK-5801,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
00low000000
dabrafenib1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
00low000000
sofosbuvirisopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester
antiviral drug;
hepatitis C protease inhibitor;
prodrug
00low000000
[5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acidorganofluorine compoundnon-steroidal anti-inflammatory drug00low000000
torin 1N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines
antineoplastic agent;
mTOR inhibitor
00low000000
ro 4929097dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound
EC 3.4.23.46 (memapsin 2) inhibitor00low000000
torin 2aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline
antineoplastic agent;
mTOR inhibitor
00low000000
gsk2656157biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
00low000000
N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamidearomatic amide;
bridged compound;
olefinic compound;
organochlorine compound;
organofluorine compound;
pyrazoles
00low000000
vericiguataminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine
antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent
00low000000
pacific blue succinimidyl esterhydroxycoumarin;
N-hydroxysuccinimide ester;
organofluorine compound
fluorochrome00low000000
3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]pyrazole-4-carboxamidearomatic amide;
monocarboxylic acid amide;
organofluorine compound;
pyrazoles;
trichlorobenzene
00low000000
oxathiapiprolin1,3-thiazoles;
isoxazoline;
N-acylpiperidine;
organofluorine compound;
pyrazoles;
tertiary carboxamide
00low000000
5-[[5-(4-fluoro-2-hydroxyphenyl)-2-furanyl]methylidene]thiazolidine-2,4-dionehalophenol;
organofluorine compound
00low000000
LimKi 31,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide
LIM kinase inhibitor00low000000
ledipasvirazaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound
antiviral drug;
hepatitis C protease inhibitor
00low000000
ivosidenibcyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
00low000000
as 1842856organofluorine compound;
primary amino compound;
quinolinemonocarboxylic acid;
quinolone;
secondary amino compound;
tertiary amino compound
anti-obesity agent;
antineoplastic agent;
apoptosis inducer;
autophagy inhibitor;
forkhead box protein O1 inhibitor;
hypoglycemic agent
00low000000
praliciguataminopyrimidine;
isoxazoles;
monofluorobenzenes;
organofluorine compound;
pyrazoles;
secondary amino compound;
tertiary alcohol
anti-inflammatory agent;
antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent
00low000000
enasidenib1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
00low000000
MMP-9-IN-1aromatic compound;
organic sulfide;
organofluorine compound;
pyrimidone;
secondary carboxamide
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor
00low000000
5-(2,5-difluorophenyl)-N-(2-oxolanylmethyl)-6H-1,3,4-thiadiazin-2-amineorganofluorine compound00low000000
nirmatrelvirazabicyclohexane;
nitrile;
organofluorine compound;
pyrrolidin-2-ones;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide
anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
00low000000
mesulergineergot alkaloid;
sulfamides
antiparkinson drug;
dopamine agonist;
serotonergic antagonist
00low000000
sulfamidesulfamides00low000000
N,N-dimethyl-N'-p-tolylsulfamidesulfamidesmarine xenobiotic metabolite00low000000
cyazofamidimidazole fungicide;
imidazoles;
nitrile;
organochlorine compound;
sulfamides;
sulfonamide fungicide
antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor
00low000000
macitentanaromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides
antihypertensive agent;
endothelin receptor antagonist;
orphan drug
00low000000
act-132577aromatic ether;
organobromine compound;
pyrimidines;
sulfamides
antihypertensive agent;
drug metabolite;
endothelin receptor antagonist;
xenobiotic metabolite
00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pd 98059aromatic amine;
monomethoxyflavone
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
00low000000
sb 220025aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines
angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
sb 202190imidazoles;
organofluorine compound;
phenols;
pyridines
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
cercosporamidedibenzofurans;
methyl ketone;
monocarboxylic acid amide;
polyphenol
antifungal agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite;
phytotoxin
00low000000
birb 796aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
00low000000
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
00low000000
1-(3-tert-butyl-1-methylpyrazol-5-yl)-3-(4-chlorophenyl)ureamonochlorobenzenes;
phenylureas;
pyrazoles
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor00low000000
auraptencoumarins;
monoterpenoid
antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
dopaminergic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
gamma-secretase modulator;
gastrointestinal drug;
hepatoprotective agent;
matrix metalloproteinase inhibitor;
neuroprotective agent;
plant metabolite;
PPARalpha agonist;
vulnerary
00low000000
u 0126aryl sulfide;
dinitrile;
enamine;
substituted aniline
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
00low000000
vx-745aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine
anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
scio-469aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
hypothemycinaromatic ether;
diol;
enone;
epoxide;
macrolide;
phenols;
polyketide;
secondary alpha-hydroxy ketone
antifungal agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite
00low000000
azd 6244benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide1,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor00low000000
binimetinibbenzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
trametinibacetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
00low000000
pamapimodaromatic amine;
aromatic ether;
difluorobenzene;
diol;
primary alcohol;
pyridopyrimidine;
secondary amino compound
antirheumatic drug;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
gdc-0973aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
ph 797804aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamidebenzamides;
biphenyls;
cyclopropanes;
dicarboxylic acid diamide
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor00low000000
sch772984biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide
analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
MK-8353aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
protocatechuic acidcatechols;
dihydroxybenzoic acid
antineoplastic agent;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
human xenobiotic metabolite;
plant metabolite
00low000000
aminolevulinic acid4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid
antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
00low000000
gallic acidtrihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
00low000000
perillic acidalpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid
antineoplastic agent;
human metabolite;
mouse metabolite
00low000000
pk 11195aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes
antineoplastic agent00low000000
pd 173074aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
00low000000
aminopropionitrileaminopropionitrileantineoplastic agent;
antirheumatic drug;
collagen cross-linking inhibitor;
plant metabolite
00low000000
5-(n,n-hexamethylene)amiloridearomatic amine;
azepanes;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines
antineoplastic agent;
apoptosis inducer;
odorant receptor antagonist;
sodium channel blocker
00low000000
7,8-dihydroxyflavonedihydroxyflavoneantidepressant;
antineoplastic agent;
antioxidant;
plant metabolite;
tropomyosin-related kinase B receptor agonist
00low000000
ro 48-8071aromatic ether;
aromatic ketone;
bromobenzenes;
monofluorobenzenes;
olefinic compound;
tertiary amino compound
antineoplastic agent;
EC 5.4.99.7 (lanosterol synthase) inhibitor
00low000000
rtki cpdaromatic ether;
monochlorobenzenes;
quinazolines
antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
00low000000
alfuzosinmonocarboxylic acid amide;
quinazolines;
tetrahydrofuranol
alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
00low000000
am 251amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles
antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist
00low000000
am 580amidobenzoic acid;
tetralins
antineoplastic agent;
retinoic acid receptor alpha/beta agonist
00low000000
aminoglutethimidedicarboximide;
piperidones;
substituted aniline
adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
00low000000
amsacrineacridines;
aromatic ether;
sulfonamide
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
00low000000
anastrozolenitrile;
triazoles
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
00low000000
azathioprinearyl sulfide;
C-nitro compound;
imidazoles;
thiopurine
antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug
00low000000
azelaic acidalpha,omega-dicarboxylic acid;
dicarboxylic fatty acid
antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite
00low000000
berberinealkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound
antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
00low000000
buforminbiguanidesantineoplastic agent;
antiviral agent;
geroprotector;
hypoglycemic agent;
radiosensitizing agent
00low000000
busulfanmethanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent
00low000000
camostatbenzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide
anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
00low000000
carmustineN-nitrosoureas;
organochlorine compound
alkylating agent;
antineoplastic agent
00low000000
cgs 15943aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline
adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant
00low000000
chelerythrinebenzophenanthridine alkaloid;
organic cation
antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
00low000000
chlorambucilaromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound
alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
00low000000
ci 994acetamides;
benzamides;
substituted aniline
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
ciglitazonearomatic ether;
thiazolidinone
antineoplastic agent;
insulin-sensitizing drug
00low000000
cl 387785bromobenzenes;
quinazolines;
secondary carboxamide;
ynamide
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
00low000000
clioquinolmonohydroxyquinoline;
organochlorine compound;
organoiodine compound
antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator
00low000000
clofibric acidaromatic ether;
monocarboxylic acid;
monochlorobenzenes
anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist
00low000000
dacarbazineimidazoles;
monocarboxylic acid amide;
triazene derivative
alkylating agent;
antineoplastic agent;
carcinogenic agent;
prodrug
00low000000
dequaliniumquinolinium ionantifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor
00low000000
3,3'-diindolylmethaneindolesantineoplastic agent;
P450 inhibitor
00low000000
disulfiramorganic disulfide;
organosulfur acaricide
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor
00low000000
doxazosinaromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines
alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent
00low000000
ebselenbenzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
00low000000
ellipticineindole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene
antineoplastic agent;
plant metabolite
00low000000
embelindihydroxy-1,4-benzoquinonesantimicrobial agent;
antineoplastic agent;
hepatitis C protease inhibitor;
plant metabolite
00low000000
emodintrihydroxyanthraquinoneantineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor
00low000000
etanidazoleC-nitro compound;
imidazoles;
monocarboxylic acid amide
alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent
00low000000
etidronate1,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
00low000000
fluorouracilnucleobase analogue;
organofluorine compound
antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
00low000000
flutamide(trifluoromethyl)benzenes;
monocarboxylic acid amide
androgen antagonist;
antineoplastic agent
00low000000
miltefosinephosphocholines;
phospholipid
anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
00low000000
beta-thujaplicincyclic ketone;
enol;
monoterpenoid
antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite
00low000000
hydroxyureaone-carbon compound;
ureas
antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
00low000000
ifosfamideifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
00low000000
indole-3-carbinolindolyl alcoholantineoplastic agent;
plant metabolite
00low000000
beta-lapachonebenzochromenone;
orthoquinones
anti-inflammatory agent;
antineoplastic agent;
plant metabolite
00low000000
leflunomide(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide
antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
00low000000
letrozolenitrile;
triazoles
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
00low000000
lomustineN-nitrosoureas;
organochlorine compound
alkylating agent;
antineoplastic agent
00low000000
6-anilino-5,8-quinolinedioneaminoquinoline;
aromatic amine;
p-quinones;
quinolone
antineoplastic agent;
EC 4.6.1.2 (guanylate cyclase) inhibitor
00low000000
4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamidebenzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
meclofenamic acidaminobenzoic acid;
organochlorine compound;
secondary amino compound
analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
00low000000
vitamin k 31,4-naphthoquinones;
vitamin K
angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
00low000000
methoxsalenaromatic ether;
psoralens
antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite
00low000000
nocodazolearomatic ketone;
benzimidazoles;
carbamate ester;
thiophenes
antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
00low000000
midazolamimidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound
anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
00low000000
mitoxantronedihydroxyanthraquinoneanalgesic;
antineoplastic agent
00low000000
entinostatbenzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
n(1), n(12)-diethylsperminepolyazaalkane;
secondary amino compound;
substituted spermine;
tetramine
antineoplastic agent00low000000
nilutamide(trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone
androgen antagonist;
antineoplastic agent
00low000000
nortriptylineorganic tricyclic compound;
secondary amine
adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite
00low000000
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamidearomatic ether;
C-nitro compound;
sulfonamide
antineoplastic agent;
cyclooxygenase 2 inhibitor
00low000000
oxyphenbutazonephenols;
pyrazolidines
antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite
00low000000
pd 158780aromatic amine;
bromobenzenes;
diamine;
pyridopyrimidine;
secondary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
4-phenylbutyric acidmonocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
00low000000
oxophenylarsinearsine oxidesantineoplastic agent;
apoptosis inducer;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
00low000000
phloretindihydrochalconesantineoplastic agent;
plant metabolite
00low000000
pipobromanN-acylpiperazine;
organobromine compound;
tertiary carboxamide
alkylating agent;
antineoplastic agent
00low000000
pj-34phenanthridines;
secondary carboxamide;
tertiary amino compound
angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
00low000000
procarbazinebenzamides;
hydrazines
antineoplastic agent00low000000
salicylsalicylic acidbenzoate ester;
benzoic acids;
phenols;
salicylates
antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug
00low000000
semustineN-nitrosoureas;
organochlorine compound
alkylating agent;
antineoplastic agent;
carcinogenic agent
00low000000
imatinibaromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
00low000000
streptonigrinpyridines;
quinolone
antimicrobial agent;
antineoplastic agent
00low000000
SU6656oxindoles;
sulfonamide
antineoplastic agent;
Aurora kinase inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
vorinostatdicarboxylic acid diamide;
hydroxamic acid
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
sulforaphaneisothiocyanate;
sulfoxide
antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
00low000000
suraminnaphthalenesulfonic acid;
phenylureas;
secondary carboxamide
angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
00low000000
temozolomideimidazotetrazine;
monocarboxylic acid amide;
triazene derivative
alkylating agent;
antineoplastic agent;
prodrug
00low000000
terazosinfurans;
piperazines;
primary amino compound;
quinazolines
alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent
00low000000
2,2'-thiodiethanolaliphatic sulfide;
diol
antineoplastic agent;
antioxidant;
metabolite;
solvent
00low000000
tiloronearomatic ether;
diether;
fluoren-9-ones;
tertiary amino compound
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
00low000000
troglitazonechromanes;
thiazolidinone
anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent
00low000000
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazolearomatic primary alcohol;
furans;
indazoles
antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent
00low000000
mitomycinmitomycinalkylating agent;
antineoplastic agent
00low000000
prednisolone11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
00low000000
floxuridinenucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
00low000000
prednisone11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug
00low000000
estrone17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols
antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
00low000000
azauridineN-glycosyl-1,2,4-triazineantimetabolite;
antineoplastic agent;
drug metabolite
00low000000
mechlorethamine hydrochloridehydrochlorideantineoplastic agent00low000000
allyl isothiocyanatealkenyl isothiocyanate;
isothiocyanate
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lachrymator;
metabolite
00low000000
vincristineacetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid
antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
00low000000
methyltestosterone17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone
anabolic agent;
androgen;
antineoplastic agent
00low000000
dromostanolone17beta-hydroxy steroid;
3-oxo-5alpha-steroid;
anabolic androgenic steroid
anabolic agent;
antineoplastic agent
00low000000
bromodeoxyuridinepyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
00low000000
tributyrinbutyrate ester;
triglyceride
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug;
protective agent
00low000000
ethyl methanesulfonatemethanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
genotoxin;
mutagen;
teratogenic agent
00low000000
triaziquone1,4-benzoquinones;
aziridines
alkylating agent;
antineoplastic agent
00low000000
tubercidinantibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside
antimetabolite;
antineoplastic agent;
bacterial metabolite
00low000000
cytarabinebeta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside
antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
00low000000
trifluridinenucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
00low000000
medroxyprogesterone acetate20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester
adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
00low000000
fluoxymesterone11beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid
anabolic agent;
antineoplastic agent
00low000000
rotenoneorganic heteropentacyclic compound;
rotenones
antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
00low000000
acetopyrrothineacetamides;
dithiolopyrrolone antibiotic
angiogenesis inhibitor;
antibacterial agent;
antifungal agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite;
protein synthesis inhibitor;
toxin
00low000000
phenforminbiguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
00low000000
dibenzoylmethanearomatic ketone;
beta-diketone
antimutagen;
antineoplastic agent;
metabolite
00low000000
suramin sodiumorganic sodium saltangiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
00low000000
pyrazolanthroneanthrapyrazole;
aromatic ketone;
cyclic ketone
antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector
00low000000
diazooxonorleucineamino acid zwitterion;
diazo compound;
ketone;
non-proteinogenic L-alpha-amino acid
analgesic;
antibacterial agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
bacterial metabolite;
EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor;
EC 3.5.1.2 (glutaminase) inhibitor;
EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor;
EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor;
EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor;
glutamine antagonist
00low000000
azacitidineN-glycosyl-1,3,5-triazine;
nucleoside analogue
antineoplastic agent00low000000
diazomethanediazo compoundalkylating agent;
antineoplastic agent;
carcinogenic agent;
poison
00low000000
procarbazine hydrochloridehydrochlorideantineoplastic agent00low000000
naphthazarinhydroxy-1,4-naphthoquinoneacaricide;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
geroprotector;
plant metabolite
00low000000
liriodeninealkaloid antibiotic;
cyclic ketone;
organic heteropentacyclic compound;
oxacycle;
oxoaporphine alkaloid
antifungal agent;
antimicrobial agent;
antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
metabolite
00low000000
lucanthonethioxanthenesadjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug
00low000000
plumbaginhydroxy-1,4-naphthoquinone;
phenols
anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite
00low000000
aloe emodinaromatic primary alcohol;
dihydroxyanthraquinone
antineoplastic agent;
plant metabolite
00low000000
emetineisoquinoline alkaloid;
pyridoisoquinoline
antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor
00low000000
thymoquinone1,4-benzoquinonesadjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite
00low000000
podophyllotoxinfuronaphthodioxole;
lignan;
organic heterotetracyclic compound
antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
00low000000
physcionedihydroxyanthraquinoneanti-inflammatory agent;
antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
hepatoprotective agent;
metabolite
00low000000
dequalinium chlorideorganic chloride saltantifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor
00low000000
4-methyl-1-(1-methylethyl)-3-cyclohexen-1-olterpineol;
tertiary alcohol
anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiparasitic agent;
apoptosis inducer;
plant metabolite;
volatile oil component
00low000000
formestane17-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
00low000000
chlorotrianisenechloroalkeneantineoplastic agent;
estrogen receptor modulator;
xenoestrogen
00low000000
megestrol acetate20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester
antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
00low000000
toyocamycinantibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside
antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
00low000000
2-hydroxyacetanilideacetamides;
phenols
anti-inflammatory agent;
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
platelet aggregation inhibitor;
xenobiotic metabolite
00low000000
methoxyacetic acidether;
monocarboxylic acid
antineoplastic agent;
apoptosis inducer;
human xenobiotic metabolite;
mutagen
00low000000
hadacidinaldehyde;
monocarboxylic acid;
N-hydroxy-alpha-amino-acid
antimicrobial agent;
antineoplastic agent;
Penicillium metabolite;
teratogenic agent
00low000000
2-fluoroadenineorganofluorine compound;
purines
antineoplastic agent00low000000
tetramethylpyrazinealkaloid;
pyrazines
antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent
00low000000
guanazolearomatic amine;
triazoles
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor
00low000000
diallyl trisulfideorganic trisulfideanti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
antioxidant;
antiprotozoal drug;
apoptosis inducer;
estrogen receptor antagonist;
insecticide;
platelet aggregation inhibitor;
vasodilator agent
00low000000
diallyl disulfideorganic disulfideantifungal agent;
antineoplastic agent;
plant metabolite
00low000000
phenethyl isothiocyanateisothiocyanateantineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite
00low000000
glaucineaporphine alkaloid;
organic heterotetracyclic compound;
polyether;
tertiary amino compound
antibacterial agent;
antineoplastic agent;
antitussive;
muscle relaxant;
NF-kappaB inhibitor;
plant metabolite;
platelet aggregation inhibitor;
rat metabolite
00low000000
acadesine1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue
antineoplastic agent;
platelet aggregation inhibitor
00low000000
doxifluridineorganofluorine compound;
pyrimidine 5'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
prodrug
00low000000
megestrol17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone
antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive
00low000000
mitomycin aether;
mitomycin
alkylating agent;
antimicrobial agent;
antineoplastic agent;
toxin
00low000000
cladribineorganochlorine compound;
purine 2'-deoxyribonucleoside
antineoplastic agent;
immunosuppressive agent
00low000000
tabersoninealkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound
antineoplastic agent;
metabolite
00low000000
vidarabinebeta-D-arabinoside;
purine nucleoside
antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
00low000000
cyclophosphamidehydratealkylating agent;
antineoplastic agent;
carcinogenic agent;
immunosuppressive agent
00low000000
helenalincyclic ketone;
gamma-lactone;
organic heterotricyclic compound;
secondary alcohol;
sesquiterpene lactone
anti-inflammatory agent;
antineoplastic agent;
metabolite;
plant metabolite
00low000000
etidronate disodiumorganic sodium saltantineoplastic agent;
bone density conservation agent;
chelator
00low000000
camptothecindelta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
00low000000
isopentenyladenosineN-ribosyl-N(6)-isopentenyladenine;
nucleoside analogue
antineoplastic agent;
plant growth regulator;
plant metabolite
00low000000
nsc-145,668hydrochlorideantimetabolite;
antineoplastic agent
00low000000
ancitabinediol;
organic heterotricyclic compound
antimetabolite;
antineoplastic agent;
prodrug
00low000000
clodronic acid1,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound
antineoplastic agent;
bone density conservation agent
00low000000
tetradecanoylphorbol acetateacetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester
antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
00low000000
streptozocinN-acylglucosamine;
N-nitrosoureas
antimicrobial agent;
antineoplastic agent;
DNA synthesis inhibitor;
metabolite
00low000000
daunorubicinaminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones
antineoplastic agent;
bacterial metabolite
00low000000
fludarabine phosphatenucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate
antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
00low000000
2,6-diaminopurine2,6-diaminopurines;
primary amino compound
antineoplastic agent00low000000
silybinaromatic ether;
benzodioxine;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone
antineoplastic agent;
antioxidant;
hepatoprotective agent;
plant metabolite
00low000000
glucaric acidglucaric acidantineoplastic agent00low000000
paclitaxeltaxane diterpenoid;
tetracyclic diterpenoid
antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
00low000000
etoposidebeta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound
antineoplastic agent;
DNA synthesis inhibitor
00low000000
promegestone20-oxo steroid;
3-oxo-Delta(4) steroid
antineoplastic agent;
progesterone receptor agonist;
progestin
00low000000
perfosfamidenitrogen mustard;
organochlorine compound;
peroxol;
phosphorodiamide
alkylating agent;
antineoplastic agent;
drug allergen;
immunosuppressive agent;
metabolite
00low000000
nimustineaminopyrimidine;
N-nitrosoureas;
organochlorine compound
alkylating agent;
antineoplastic agent
00low000000
lonidaminedichlorobenzene;
indazoles;
monocarboxylic acid
antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector
00low000000
vindesinemethyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
primary carboxamide;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid
antineoplastic agent00low000000
epirubicinaminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
00low000000
diaziquone1,4-benzoquinones;
aziridines;
carbamate ester;
enamine
alkylating agent;
antineoplastic agent
00low000000
midazolam hydrochloridehydrochloride;
imidazobenzodiazepine
anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
00low000000
oltipraz1,2-dithiole;
pyrazines
angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug
00low000000
fazarabineN-glycosyl-1,3,5-triazine;
nucleoside analogue
antineoplastic agent00low000000
mitoxantrone hydrochloridehydrochlorideantineoplastic agent00low000000
bisantreneanthracenes;
hydrazone;
imidazolidines
antineoplastic agent00low000000
swainsonineindolizidine alkaloidantineoplastic agent;
EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor;
immunological adjuvant;
plant metabolite
00low000000
lovastatindelta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)
anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
00low000000
cabergolineN-acylureaantineoplastic agent;
antiparkinson drug;
dopamine agonist
00low000000
nitrogenase stabilizing-protective protein, bacteriaN-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamideandrogen antagonist;
antineoplastic agent
00low000000
bmy 25067C-nitro compound;
organic disulfide
antineoplastic agent00low000000
brequinarbiphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid
anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor
00low000000
imiquimodimidazoquinolineantineoplastic agent;
interferon inducer
00low000000
aromasil17-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
00low000000
cidofovir anhydrousphosphonic acids;
pyrimidone
anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent
00low000000
topotecanpyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
00low000000
gemcitabine hydrochloridehydrochloride;
organofluorine compound
anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
00low000000
gemcitabineorganofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
00low000000
irinotecancarbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
00low000000
capecitabinecarbamate ester;
cytidines;
organofluorine compound
antimetabolite;
antineoplastic agent;
prodrug
00low000000
nelfinavir mesylatemethanesulfonate saltantineoplastic agent;
HIV protease inhibitor
00low000000
nelfinaviraryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound
antineoplastic agent;
HIV protease inhibitor
00low000000
betulinic acidhydroxy monocarboxylic acid;
pentacyclic triterpenoid
anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
00low000000
baicalindihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative
antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug
00low000000
ro 5-33351,4-benzodiazepinone;
organochlorine compound;
pyrroles
anti-HIV-1 agent;
antineoplastic agent;
HIV-1 Tat inhibitor;
RUNX1 inhibitor
00low000000
plerixaforazacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound
anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant
00low000000
epigallocatechin gallateflavans;
gallate ester;
polyphenol
antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
00low000000
salvinabietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite
00low000000
1,2,3,4,6-pentakis-O-galloyl-beta-D-glucosegallate ester;
galloyl beta-D-glucose
anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger
00low000000
pyrrolidine dithiocarbamatedithiocarbamic acids;
pyrrolidines
anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
00low000000
triptonidebutenolide;
cyclic ketone;
diterpene triepoxide;
organic heteroheptacyclic compound
anti-inflammatory agent;
antineoplastic agent;
immunosuppressive agent
00low000000
3'-deoxyadenosine 5'-triphosphatepurine ribonucleoside 5'-triphosphateantifungal agent;
antimetabolite;
antineoplastic agent;
antiviral agent
00low000000
2-methoxyestradiol17beta-hydroxy steroid;
3-hydroxy steroid
angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite
00low000000
toxoflavincarbonyl compound;
pyrimidotriazine
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor
00low000000
lupulonbeta-bitter acidangiogenesis inhibitor;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer
00low000000
pinocembrin(2S)-flavan-4-one;
dihydroxyflavanone
antineoplastic agent;
antioxidant;
metabolite;
neuroprotective agent;
vasodilator agent
00low000000
tangeretinpentamethoxyflavoneantineoplastic agent;
plant metabolite
00low000000
ethinylestradiol-3-sulfate17beta-hydroxy steroid;
steroid sulfate
antineoplastic agent;
estrogen
00low000000
lonazolacmonocarboxylic acid;
monochlorobenzenes;
pyrazoles
antineoplastic agent;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
bromopyruvate2-oxo monocarboxylic acid;
organobromine compound;
oxo carboxylic acid
alkylating agent;
antineoplastic agent
00low000000
enrofloxacincyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone
antibacterial agent;
antimicrobial agent;
antineoplastic agent
00low000000
dexrazoxanerazoxaneantineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent
00low000000
masoprocolnordihydroguaiaretic acidantineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite
00low000000
dw a 2114rplatinum coordination entity;
pyrrolidines
antineoplastic agent00low000000
prednisolone phosphate11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
glucocorticoid;
steroid phosphate;
tertiary alpha-hydroxy ketone
anti-inflammatory agent;
antineoplastic agent;
glucocorticoid receptor agonist;
prodrug
00low000000
hesperetin3'-hydroxyflavanones;
4'-methoxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone
antineoplastic agent;
antioxidant;
plant metabolite
00low000000
sesaminbenzodioxoles;
furofuran;
lignan
antineoplastic agent;
neuroprotective agent;
plant metabolite
00low000000
betulindiol;
pentacyclic triterpenoid
analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
00low000000
nobiletinmethoxyflavoneantineoplastic agent;
plant metabolite
00low000000
picropodophyllinfuronaphthodioxole;
lignan;
organic heterotetracyclic compound
antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor
00low000000
alantolactonenaphthofuran;
olefinic compound;
sesquiterpene lactone
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
kaurenoic acident-kaurane diterpenoidanti-HIV-1 agent;
antineoplastic agent;
plant metabolite
00low000000
dehydrocostus lactonegamma-lactone;
guaiane sesquiterpenoid;
organic heterotricyclic compound;
sesquiterpene lactone
antimycobacterial drug;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 2 inhibitor;
metabolite;
trypanocidal drug
00low000000
xanthomicroldihydroxyflavone;
trimethoxyflavone
antineoplastic agent;
plant metabolite
00low000000
voacaminealkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
plant metabolite
00low000000
brazilincatechols;
organic heterotetracyclic compound;
tertiary alcohol
anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
biological pigment;
hepatoprotective agent;
histological dye;
NF-kappaB inhibitor;
plant metabolite
00low000000
uvaretinaromatic ether;
dihydrochalcones;
polyketide;
resorcinol
antineoplastic agent;
plant metabolite
00low000000
fangchinolinearomatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle
anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite
00low000000
maslinic aciddihydroxy monocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
00low000000
tetrazolium violetorganic chloride saltantineoplastic agent;
apoptosis inducer;
dye
00low000000
irinotecan hydrochloridehydrochlorideantineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
00low000000
5-(3-methyl-1-triazeno)imidazole-4-carboxamideimidazoles;
monocarboxylic acid amide;
triazene derivative
alkylating agent;
antineoplastic agent
00low000000
hydroxyguanidineguanidines;
one-carbon compound
antineoplastic agent;
antiviral agent
00low000000
cryptolepineindole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
cysteine protease inhibitor;
plant metabolite
00low000000
bexarotenebenzoic acids;
naphthalenes;
retinoid
antineoplastic agent00low000000
3,4-dihydroxyphenylethanolcatechols;
primary alcohol
antineoplastic agent;
antioxidant;
metabolite
00low000000
terreic acidarene epoxide;
diketone;
monohydroxy-1,4-benzoquinones;
tertiary alpha-hydroxy ketone
antibacterial agent;
antineoplastic agent;
Aspergillus metabolite;
EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
mycotoxin
00low000000
4-methylumbelliferyl glucuronidebeta-D-glucosiduronic acid;
coumarins;
monosaccharide derivative
antineoplastic agent;
chromogenic compound;
hyaluronan synthesis inhibitor
00low000000
9-hydroxyellipticineorganic heterotetracyclic compound;
organonitrogen heterocyclic compound
antineoplastic agent00low000000
nimustinehydrochlorideantineoplastic agent00low000000
beta-peltatinfuronaphthodioxole;
gamma-lactone;
lignan;
organic heterotetracyclic compound;
phenols
antineoplastic agent;
plant metabolite
00low000000
alpha-peltatinfuronaphthodioxole;
gamma-lactone;
lignan;
organic heterotetracyclic compound;
phenols
antineoplastic agent;
metabolite
00low000000
cryptopleurinealkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound
antineoplastic agent;
antiviral agent;
protein synthesis inhibitor
00low000000
sugiolabietane diterpenoid;
carbotricyclic compound;
cyclic terpene ketone;
meroterpenoid;
phenols
antineoplastic agent;
antioxidant;
antiviral agent;
plant metabolite;
radical scavenger
00low000000
eupatorindihydroxyflavone;
polyphenol;
trimethoxyflavone
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
Brassica napus metabolite;
calcium channel blocker;
P450 inhibitor;
vasodilator agent
00low000000
1-methyltryptophannon-proteinogenic alpha-amino acid;
tryptophan derivative
antineoplastic agent;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor
00low000000
atromentindihydroxy-1,4-benzoquinones;
polyphenol
antibacterial agent;
anticoagulant;
antineoplastic agent;
apoptosis inducer;
biological pigment;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
fungal metabolite
00low000000
diosgenin3beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal
antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite
00low000000
alpha-glutamyltryptophandipeptideangiogenesis modulating agent;
antineoplastic agent;
immunomodulator;
metabolite
00low000000
fulvestrant17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide
antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
00low000000
ici 16438417beta-hydroxy steroid;
3-hydroxy steroid;
tertiary carboxamide
anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
00low000000
sn 38delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
00low000000
hc toxinhomodetic cyclic peptide;
tetrapeptide
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
metabolite;
phytotoxin
00low000000
deguelinaromatic ether;
diether;
organic heteropentacyclic compound;
rotenones
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite
00low000000
fingolimodaminodiol;
primary amino compound
antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist
00low000000
cafestolditerpenoid;
furans;
organic heteropentacyclic compound;
primary alcohol;
tertiary alcohol
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
plant metabolite
00low000000
tamibarotenedicarboxylic acid monoamide;
retinoid;
tetralins
antineoplastic agent;
retinoic acid receptor alpha/beta agonist
00low000000
ecteinascidin 743acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound
alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite
00low000000
homoorientinflavone C-glycoside;
tetrahydroxyflavone
antineoplastic agent;
radical scavenger
00low000000
kahweolditerpenoid;
furans;
organic heteropentacyclic compound;
primary alcohol;
tertiary alcohol
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite
00low000000
selenomethylselenocysteinenon-proteinogenic alpha-amino acid;
selenocysteines
antineoplastic agent;
human metabolite
00low000000
tephrosinaromatic ether;
cyclic ketone;
organic heteropentacyclic compound;
rotenones
antineoplastic agent;
metabolite;
pesticide
00low000000
5-(tetradecyloxy)-2-furancarboxylic acidaromatic ether;
furoic acid
antineoplastic agent;
apoptosis inducer;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
PPARalpha agonist
00low000000
sc 58125organofluorine compound;
pyrazoles;
sulfone
antineoplastic agent;
cyclooxygenase 2 inhibitor
00low000000
marimastathydroxamic acid;
secondary carboxamide
antineoplastic agent;
matrix metalloproteinase inhibitor
00low000000
1'-acetoxychavicol acetateacetate ester;
phenylpropanoid
antineoplastic agent;
NF-kappaB inhibitor;
plant metabolite
00low000000
clofarabineadenosines;
organofluorine compound
antimetabolite;
antineoplastic agent
00low000000
dioscinhexacyclic triterpenoid;
spiroketal;
spirostanyl glycoside;
trisaccharide derivative
anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 1.14.18.1 (tyrosinase) inhibitor;
hepatoprotective agent;
metabolite
00low000000
ginsenoside rh212beta-hydroxy steroid;
20-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
hepatoprotective agent;
plant metabolite
00low000000
trapoxin aepoxide;
homodetic cyclic peptide;
ketone
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
fungal metabolite
00low000000
celastrolmonocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
00low000000
4'-demethylepipodophyllotoxinfuronaphthodioxole;
organic heterotetracyclic compound;
phenols
antineoplastic agent00low000000
imatinib mesylatemethanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
00low000000
aminolevulinic acid hydrochloridehydrochlorideantineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug
00low000000
gefitinibaromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
00low000000
cgp 42112abenzyl ester;
oligopeptide;
pyridinecarboxamide
angiotensin receptor agonist;
anti-inflammatory agent;
antineoplastic agent;
neuroprotective agent;
vasodilator agent
00low000000
vadimezanmonocarboxylic acid;
xanthones
antineoplastic agent00low000000
rubimaillinbenzochromene;
methyl ester;
phenols
acyl-CoA:cholesterol acyltransferase 2 inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
NF-kappaB inhibitor;
plant metabolite
00low000000
4-carbamoylimidazolium 5-olatehydroxyimidazole;
monocarboxylic acid amide
antineoplastic agent00low000000
nsc 2240701,4-benzoquinones;
aziridines;
enamine;
primary alcohol;
secondary amino compound
alkylating agent;
antineoplastic agent
00low000000
psorosperminepoxide;
organic heterotetracyclic compound;
xanthones
antineoplastic agent;
plant metabolite
00low000000
ay 25545acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
00low000000
methotrexatedicarboxylic acid;
monocarboxylic acid amide;
pteridines
abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
00low000000
3,7-dihydroxytropolonealpha-hydroxy ketone;
cyclic ketone;
enol;
triol
antineoplastic agent;
bacterial metabolite
00low000000
delphinidin5-hydroxyanthocyanidinantineoplastic agent;
biological pigment;
plant metabolite
00low000000
tamsulosin5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent
00low000000
saintopintetracenequinonesantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
fungal metabolite;
intercalator
00low000000
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octenemonoterpenoid;
organobromine compound;
organochlorine compound
algal metabolite;
antineoplastic agent;
marine metabolite
00low000000
ilomastathydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid
anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent
00low000000
abiraterone3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines
antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
00low000000
yakuchinone-aketone;
monomethoxybenzene;
phenols
antineoplastic agent;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
metabolite
00low000000
pomalidomidearomatic amine;
dicarboximide;
isoindoles;
piperidones
angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
00low000000
tempolaminoxyls;
hydroxypiperidine
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger
00low000000
selenomethylselenocysteineamino acid zwitterion;
L-selenocysteine derivative;
non-proteinogenic L-alpha-amino acid;
Se-methylselenocysteine
antineoplastic agent00low000000
10-propargyl-10-deazaaminopterinN-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound
antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor
00low000000
docetaxelhydrate;
secondary alpha-hydroxy ketone
antineoplastic agent00low000000
docetaxel anhydroussecondary alpha-hydroxy ketone;
tetracyclic diterpenoid
antimalarial;
antineoplastic agent;
photosensitizing agent
00low000000
lonafarnib4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
00low000000
aclacinomycinaminoglycoside;
anthracycline;
deoxy hexoside;
methyl ester;
monosaccharide derivative;
phenols;
polyketide;
tertiary alcohol;
tetracenequinones;
zwitterion
antimicrobial agent;
antineoplastic agent;
metabolite
00low000000
6-azauridine-5'-monophosphateN-glycosyl-1,2,4-triazine;
nucleoside monophosphate analogue
antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor
00low000000
ptk 787succinate saltangiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
vatalanibmonochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
cyc 682nitrile;
nucleoside analogue;
secondary carboxamide
antimetabolite;
antineoplastic agent;
DNA synthesis inhibitor;
prodrug
00low000000
canertinibmonochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
methyl 5-aminolevulinate hydrochloridehydrochlorideantineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug
00low000000
methyl 5-aminolevulinatedelta-amino acid esterantineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug
00low000000
tipifarnibimidazoles;
monochlorobenzenes;
primary amino compound;
quinolone
antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
00low000000
aklavinoneanthracycline;
methyl ester;
tertiary alcohol;
tetracenequinones
antineoplastic agent00low000000
actinodaphineaporphine alkaloid;
aromatic ether;
organic heteropentacyclic compound;
phenols;
secondary amino compound
antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite;
platelet aggregation inhibitor;
topoisomerase inhibitor
00low000000
i-677L-serine derivative;
non-proteinogenic L-alpha-amino acid
antimetabolite;
antimicrobial agent;
antineoplastic agent;
metabolite
00low000000
anonaineaporphine alkaloid;
organic heteropentacyclic compound;
oxacycle
antineoplastic agent;
antiplasmodial drug;
trypanocidal drug
00low000000
4'-demethyldesoxypodophyllotoxinfuronaphthodioxole;
gamma-lactone;
lignan;
methoxybenzenes;
phenols
antineoplastic agent;
antioxidant;
immunosuppressive agent;
plant metabolite
00low000000
salvigeninmonohydroxyflavone;
trimethoxyflavone
antilipemic drug;
antineoplastic agent;
apoptosis inhibitor;
autophagy inducer;
hypoglycemic agent;
immunomodulator;
neuroprotective agent;
plant metabolite
00low000000
deferrioxamine ecyclic desferrioxamine;
cyclic hydroxamic acid;
macrocycle
antineoplastic agent;
bacterial metabolite;
marine metabolite;
siderophore
00low000000
ampelopsindihydromyricetin;
secondary alpha-hydroxy ketone
antineoplastic agent;
antioxidant;
metabolite
00low000000
methylselenic acidone-carbon compound;
organoselenium compound
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
human xenobiotic metabolite
00low000000
acetyl aleuritolic acidacetate ester;
monocarboxylic acid;
pentacyclic triterpenoid
antineoplastic agent;
plant metabolite
00low000000
withanolide d20-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
secondary alcohol;
tertiary alcohol;
withanolide
antineoplastic agent00low000000
myricanonearomatic ether;
cyclic ketone;
diarylheptanoid;
methoxybenzenes;
phenols
antineoplastic agent;
plant metabolite
00low000000
cirsilineoldihydroxyflavone;
trimethoxyflavone
antineoplastic agent;
plant metabolite
00low000000
pannarinaldehyde;
aromatic ether;
depsidones;
organic heterotricyclic compound;
organochlorine compound;
phenols
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lichen metabolite
00low000000
6-methylthiohexyl isothiocyanateisothiocyanate;
methyl sulfide
antineoplastic agent;
Arabidopsis thaliana metabolite;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
neuroprotective agent
00low000000
pectolinarindimethoxyflavone;
disaccharide derivative;
glycosyloxyflavone;
monohydroxyflavanone;
rutinoside
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
plant metabolite
00low000000
albicanolcarbobicyclic compound;
homoallylic alcohol;
primary alcohol;
sesquiterpenoid
antifeedant;
antifungal agent;
antineoplastic agent;
fungal metabolite;
mammalian metabolite;
marine metabolite;
plant metabolite
00low000000
5-o-methylembelinenol ether;
monohydroxy-1,4-benzoquinones
antileishmanial agent;
antineoplastic agent;
hepatitis C protease inhibitor;
metabolite
00low000000
asperphenamatebenzamides;
carboxylic ester;
L-phenylalanine derivative
antineoplastic agent00low000000
erlotinibaromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound
antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
00low000000
erlotinib hydrochloridehydrochloride;
terminal acetylenic compound
antineoplastic agent;
protein kinase inhibitor
00low000000
corynolinebenzophenanthridine alkaloid;
cyclic acetal;
isoquinolines;
organic heterohexacyclic compound;
secondary alcohol
antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hepatoprotective agent;
metabolite
00low000000
helioxanthinbenzodioxoles;
furonaphthodioxole;
lignan
anti-HBV agent;
antineoplastic agent;
plant metabolite
00low000000
top 53furonaphthodioxole;
gamma-lactone;
organic heterotetracyclic compound;
phenols;
tertiary amino compound
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
00low000000
5-heptadecylresorcinol5-alkylresorcinolantineoplastic agent;
plant metabolite
00low000000
minquartynoic acidacetylenic fatty acid;
hydroxy polyunsaturated fatty acid;
long-chain fatty acid;
straight-chain fatty acid;
tetrayne
antimalarial;
antineoplastic agent;
antiviral agent
00low000000
scutellaringlucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone
antineoplastic agent;
proteasome inhibitor
00low000000
ergolideacetate ester;
cyclic ketone;
gamma-lactone;
organic heterotricyclic compound;
sesquiterpene lactone
anti-inflammatory agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor;
plant metabolite
00low000000
2,5-dihydroxybenzyl alcoholaromatic primary alcohol;
phenols
antineoplastic agent;
antioxidant;
apoptosis inhibitor;
fungal metabolite
00low000000
chrysosplenol ctrihydroxyflavone;
trimethoxyflavone
antineoplastic agent;
antiviral agent;
plant metabolite
00low000000
lanperisone2-methyl-3-(pyrrolidin-1-yl)-1-[4-(trifluoromethyl)phenyl]propan-1-oneantineoplastic agent;
calcium channel blocker;
ferroptosis inducer;
muscle relaxant;
voltage-gated sodium channel blocker
00low000000
(-)-gallocatechin gallatecatechin;
gallate ester;
polyphenol
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human xenobiotic metabolite;
plant metabolite
00low000000
orantinibmonocarboxylic acid;
oxindoles;
pyrroles
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
lapatinibfurans;
organochlorine compound;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
firocoxibbutenolide;
cyclopropanes;
enol ether;
sulfone
antineoplastic agent;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
00low000000
2-(4-morpholinoanilino)-6-cyclohexylaminopurinemorpholines;
purines;
secondary amino compound;
tertiary amino compound
adenosine A3 receptor antagonist;
antineoplastic agent;
Aurora kinase inhibitor;
cell dedifferentiation agent
00low000000
sorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide
angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
00low000000
lenalidomidearomatic amine;
dicarboximide;
isoindoles;
piperidones
angiogenesis inhibitor;
antineoplastic agent;
immunomodulator
00low000000
lasofoxifenearomatic ether;
N-alkylpyrrolidine;
naphthols;
tetralins
antineoplastic agent;
bone density conservation agent;
cardioprotective agent;
estrogen receptor agonist;
estrogen receptor antagonist
00low000000
l 778,123hydrochlorideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor;
radiosensitizing agent
00low000000
l 778,123imidazoles;
monochlorobenzenes;
nitrile;
piperazinone;
tertiary amino compound
antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor
00low000000
n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamidechloroindole;
organochlorine compound;
sulfonamide
antineoplastic agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
00low000000
diflomotecanepsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
00low000000
demecolcinealkaloid;
secondary amino compound
antineoplastic agent;
microtubule-destabilising agent
00low000000
dromostanolone propionate3-oxo-5alpha-steroid;
steroid ester
antineoplastic agent00low000000
vincaleukoblastineacetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid
antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite
00low000000
vincristine sulfateorganic sulfate saltantineoplastic agent;
geroprotector
00low000000
anisomycinmonohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic
anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
00low000000
estramustine17beta-hydroxy steroid;
carbamate ester;
organochlorine compound
alkylating agent;
antineoplastic agent;
radiation protective agent
00low000000
withaferin a27-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide
antineoplastic agent;
apoptosis inducer
00low000000
noscapinearomatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound
antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
00low000000
homoharringtoninealkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol
anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
00low000000
acivicinisoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound
antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite
00low000000
elesclomolcarbohydrazide;
thiocarbonyl compound
antineoplastic agent;
apoptosis inducer
00low000000
wortmanninacetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound
anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
00low000000
rocaglamidemonocarboxylic acid amide;
monomethoxybenzene;
organic heterotricyclic compound
antileishmanial agent;
antineoplastic agent;
metabolite
00low000000
anthricinfuronaphthodioxole;
gamma-lactone;
lignan;
methoxybenzenes
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
acronineacridone derivatives;
alkaloid
antineoplastic agent;
metabolite
00low000000
taiwanin cbenzodioxoles;
furonaphthodioxole;
lignan
antineoplastic agent;
plant metabolite;
platelet aggregation inhibitor
00low000000
o-(chloroacetylcarbamoyl)fumagillolcarbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide
angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist
00low000000
bortezomibamino acid amide;
L-phenylalanine derivative;
pyrazines
antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
00low000000
gant 61aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor
00low000000
carnosineamino acid zwitterion;
dipeptide
anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent
00low000000
puromycinpuromycinsantiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor
00low000000
pentostatincoformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
00low000000
canalineamino acid zwitterion;
non-proteinogenic L-alpha-amino acid
antimetabolite;
antineoplastic agent;
phytogenic insecticide;
plant metabolite
00low000000
hippeastrinedelta-lactone;
indole alkaloid;
organic heteropentacyclic compound;
secondary alcohol
antineoplastic agent;
metabolite
00low000000
peonidin5-hydroxyanthocyanidinantineoplastic agent;
antioxidant;
apoptosis inducer;
metabolite
00low000000
glaucarubinonecarboxylic ester;
organic heteropentacyclic compound;
quassinoid;
secondary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone;
tetrol
antimalarial;
antineoplastic agent;
geroprotector;
plant metabolite
00low000000
helveticoside14beta-hydroxy steroid;
5beta-hydroxy steroid;
cardenolide glycoside;
digitoxoside;
monosaccharide derivative;
steroid aldehyde;
steroid lactone
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
ginsenoside re12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
nephroprotective agent;
neuroprotective agent;
plant metabolite
00low000000
ginsenoside rf12beta-hydroxy steroid;
20-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
ferruginolabietane diterpenoid;
carbotricyclic compound;
meroterpenoid;
phenols
antibacterial agent;
antineoplastic agent;
plant metabolite;
protective agent
00low000000
steviosidebeta-D-glucoside;
bridged compound;
diterpene glycoside;
ent-kaurane diterpenoid;
tetracyclic diterpenoid
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
hypoglycemic agent;
plant metabolite;
sweetening agent
00low000000
decursinolcyclic ether;
delta-lactone;
organic heterotricyclic compound;
secondary alcohol
analgesic;
antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite
00low000000
naringin(2S)-flavan-4-one;
4'-hydroxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
neohesperidoside
anti-inflammatory agent;
antineoplastic agent;
metabolite
00low000000
eugeniinbeta-D-glucoside;
ellagitannin;
gallate ester;
lactone
anti-HSV-1 agent;
antifungal agent;
antineoplastic agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
metabolite
00low000000
knipholonearomatic ketone;
dihydroxyanthraquinone;
methoxybenzenes;
methyl ketone;
polyphenol;
resorcinols
antineoplastic agent;
antioxidant;
antiplasmodial drug;
leukotriene antagonist;
metabolite
00low000000
gingerolbeta-hydroxy ketone;
guaiacols
antineoplastic agent;
plant metabolite
00low000000
mucronulatolhydroxyisoflavans;
methoxyisoflavan
antineoplastic agent;
plant metabolite
00low000000
syringaresinolsyringaresinolantineoplastic agent00low000000
enkephalin, methioninepentapeptide;
peptide zwitterion
analgesic;
antineoplastic agent;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist
00low000000
devazepide1,4-benzodiazepinone;
indolecarboxamide
antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug
00low000000
sodium arsenitearsenic molecular entity;
inorganic sodium salt
antibacterial agent;
antifungal agent;
antineoplastic agent;
carcinogenic agent;
herbicide;
insecticide;
rodenticide
00low000000
surfactin ccyclodepsipeptide;
lipopeptide antibiotic;
macrocyclic lactone
antibacterial agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
metabolite;
platelet aggregation inhibitor;
surfactant
00low000000
kerriamycin bangucycline antibioticantineoplastic agent00low000000
carubicinaminoglycoside antibiotic;
anthracycline antibiotic;
p-quinones;
tertiary alpha-hydroxy ketone;
tetracenequinones
antineoplastic agent;
apoptosis inducer
00low000000
tretinoinretinoic acid;
vitamin A
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
00low000000
docosahexaenoatedocosahexaenoic acid;
omega-3 fatty acid
algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical
00low000000
eicosapentaenoic acidicosapentaenoic acid;
omega-3 fatty acid
anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical
00low000000
mycophenolic acid2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols
anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic
00low000000
formycinformycinantineoplastic agent00low000000
neocarzinostatin chromophorecyclopentacyclononaoxirene;
D-galactosaminide;
dioxolane;
monosaccharide derivative;
naphthoate ester
antineoplastic agent00low000000
epothilone bepothilone;
epoxide
antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent
00low000000
adenosine-5'-(n-ethylcarboxamide)adenosines;
monocarboxylic acid amide
adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
00low000000
n(1)-guanyl-1,7-diaminoheptaneguanidines;
primary amino compound
antineoplastic agent;
EC 2.5.1.46 (deoxyhypusine synthase) inhibitor
00low000000
diethylstilbestrololefinic compound;
polyphenol
antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
00low000000
bms 214662benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes
antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
00low000000
epothilone aepothilone;
epoxide
antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
00low000000
8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine6-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound
antineoplastic agent;
Hsp90 inhibitor
00low000000
alitretinoinretinoic acidantineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist
00low000000
afimoxifenephenols;
tertiary amino compound
antineoplastic agent;
estrogen receptor antagonist;
metabolite
00low000000
aclarubicinaminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
00low000000
teniposidearomatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
00low000000
steviolbridged compound;
ent-kaurane diterpenoid;
monocarboxylic acid;
tertiary allylic alcohol;
tetracyclic diterpenoid
antineoplastic agent00low000000
tiazofurin1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
00low000000
aphidicolintetracyclic diterpenoidantimicrobial agent;
antimitotic;
antineoplastic agent;
antiviral drug;
apoptosis inducer;
Aspergillus metabolite;
DNA synthesis inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
fungal metabolite
00low000000
azaserinecarboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid
antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite
00low000000
melphalanL-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound
alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
00low000000
prinomastataromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor
00low000000
rubitecanC-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
00low000000
arsenic trioxidearsenic oxideantineoplastic agent;
insecticide
00low000000
rhapontinrhaponticinangiogenesis inhibitor;
anti-allergic agent;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
hypoglycemic agent;
neuroprotective agent;
plant metabolite
00low000000
isoliquiritigeninchalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
00low000000
antofinealkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound
angiogenesis inhibitor;
anti-inflammatory agent;
antimicrobial agent;
antineoplastic agent;
antiviral agent;
phytotoxin;
plant metabolite
00low000000
xanthohumolaromatic ether;
chalcones;
polyphenol
anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite
00low000000
vedelianincyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid
antineoplastic agent;
plant metabolite
00low000000
s 1033(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
amygdalinamygdalinantineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
trilostane17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile
abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
00low000000
leuprolide acetateacetate saltantineoplastic agent;
gonadotropin releasing hormone agonist
00low000000
leuprolideoligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
00low000000
mercaptopurinearyl thiol;
purines;
thiocarbonyl compound
anticoronaviral agent;
antimetabolite;
antineoplastic agent
00low000000
3,3',4,5'-tetrahydroxystilbenecatechols;
polyphenol;
resorcinols;
stilbenol
antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor
00low000000
iFSP1aromatic amine;
nitrile;
primary amino compound;
pyridobenzimidazole;
toluenes
antineoplastic agent;
ferroptosis inducer;
ferroptosis suppressor protein 1 inhibitor
00low000000
4-iodo-6-phenylpyrimidinebiaryl;
organoiodine compound;
pyrimidines
antineoplastic agent;
apoptosis inducer;
macrophage migration inhibitory factor inhibitor
00low000000
oncrasin-1arenecarbaldehyde;
indoles;
monochlorobenzenes
antineoplastic agent;
apoptosis inducer
00low000000
curcuminaromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol
anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
00low000000
cct018159benzodioxine;
pyrazoles;
resorcinols
antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
00low000000
sulindacmonocarboxylic acid;
organofluorine compound;
sulfoxide
analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
00low000000
xl147aromatic amine;
benzothiadiazole;
quinoxaline derivative;
sulfonamide
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
mcb-613cyclic ketone;
enone;
pyridines
antineoplastic agent;
steroid receptor coactivator stimulator
00low000000
thioguanine anhydrous2-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
00low000000
tamoxifenstilbenoid;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
00low000000
stattic1-benzothiophenes;
C-nitro compound;
sulfone
antineoplastic agent;
radiosensitizing agent;
STAT3 inhibitor
00low000000
krn 7000glycophytoceramide;
N-acyl-beta-D-galactosylphytosphingosine
allergen;
antigen;
antineoplastic agent;
epitope;
immunological adjuvant
00low000000
10058-F4olefinic compound;
thiazolidinone
antineoplastic agent;
apoptosis inducer
00low000000
monastrolenoate ester;
ethyl ester;
phenols;
racemate;
thioureas
antileishmanial agent;
antimitotic;
antineoplastic agent;
EC 3.5.1.5 (urease) inhibitor
00low000000
toremifenearomatic ether;
organochlorine compound;
tertiary amine
antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
00low000000
beauvericincyclodepsipeptideantibiotic insecticide;
antifungal agent;
antineoplastic agent;
apoptosis inhibitor;
fungal metabolite;
ionophore;
mycotoxin;
P450 inhibitor
00low000000
nelarabinebeta-D-arabinoside;
monosaccharide derivative;
purine nucleoside
antineoplastic agent;
DNA synthesis inhibitor;
prodrug
00low000000
bms 3870321,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
manoollabdane diterpenoid;
tertiary alcohol
antibacterial agent;
antineoplastic agent;
plant metabolite
00low000000
amrubicinanthracycline antibiotic;
methyl ketone;
primary amino compound;
quinone;
tetracenes
antineoplastic agent;
prodrug;
topoisomerase II inhibitor
00low000000
ospemifenearomatic ether;
organochlorine compound;
primary alcohol
anti-inflammatory agent;
antineoplastic agent;
estrogen receptor modulator
00low000000
tandutinibaromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
dasatinib1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
emetine dihydrochloridehydrochlorideanticoronaviral agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
protein synthesis inhibitor
00low000000
bigelovinacetate ester;
cyclic ketone;
gamma-lactone;
organic heterotricyclic compound;
sesquiterpene lactone
antineoplastic agent;
apoptosis inducer;
immunomodulator;
plant metabolite
00low000000
zd 6474aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
l 663536aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes
antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
00low000000
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dionebenzenes;
thiadiazolidine
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
00low000000
sc 560aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles
angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
00low000000
alsterpaulloneC-nitro compound;
caprolactams;
organic heterotetracyclic compound
anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
00low000000
ginkgetinbiflavonoid;
hydroxyflavone;
methoxyflavone;
ring assembly
anti-HSV-1 agent;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
metabolite
00low000000
eupatilindihydroxyflavone;
trimethoxyflavone
anti-inflammatory agent;
anti-ulcer drug;
antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
metabolite
00low000000
quercetin7-hydroxyflavonol;
pentahydroxyflavone
antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
00low000000
biochanin a4'-methoxyisoflavones;
7-hydroxyisoflavones
antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
00low000000
vitexinC-glycosyl compound;
trihydroxyflavone
antineoplastic agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
plant metabolite;
platelet aggregation inhibitor
00low000000
apigenintrihydroxyflavoneantineoplastic agent;
metabolite
00low000000
luteolin3'-hydroxyflavonoid;
tetrahydroxyflavone
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
00low000000
calcitriolD3 vitamins;
hydroxycalciol;
triol
antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
00low000000
herbacetin7-hydroxyflavonol;
pentahydroxyflavone
angiogenesis inhibitor;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
plant metabolite
00low000000
hymecromonehydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
00low000000
chrysoeriolmonomethoxyflavone;
trihydroxyflavone
antineoplastic agent;
antioxidant;
metabolite
00low000000
dexmedetomidinetrihydroxyflavone;
trimethoxyflavone
antineoplastic agent;
metabolite
00low000000
bryostatin 1acetate ester;
bryostatins;
cyclic hemiketal;
enoate ester;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol
alpha-secretase activator;
anti-HIV-1 agent;
antineoplastic agent;
marine metabolite;
protein kinase C agonist
00low000000
quercetin 3-o-glucopyranosidebeta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone
antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
00low000000
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2prostaglandins J;
secondary alcohol
antineoplastic agent;
antiviral agent
00low000000
genistein7-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
00low000000
pyrviniumquinolinium ionanthelminthic drug;
antineoplastic agent
00low000000
cyclobenzaprine9,11,13-octadecatrienoic acidantineoplastic agent;
plant metabolite
00low000000
buteinchalcones;
polyphenol
antineoplastic agent;
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
geroprotector;
hypoglycemic agent;
plant metabolite;
radiosensitizing agent;
tyrosine kinase inhibitor
00low000000
cucurbitacin icucurbitacin;
tertiary alpha-hydroxy ketone
antineoplastic agent;
plant metabolite
00low000000
daphnoretinaromatic ether;
hydroxycoumarin
antineoplastic agent;
antiviral agent;
metabolite
00low000000
costunolidegermacranolide;
heterobicyclic compound
anthelminthic drug;
antiinfective agent;
antineoplastic agent;
antiparasitic agent;
antiviral drug;
metabolite
00low000000
eupatolidegamma-lactone;
germacranolide;
homoallylic alcohol;
secondary alcohol
antineoplastic agent;
plant metabolite
00low000000
oleuropeinbeta-D-glucoside;
catechols;
diester;
methyl ester;
pyrans;
secoiridoid glycoside
anti-inflammatory agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
NF-kappaB inhibitor;
nutraceutical;
plant metabolite;
radical scavenger
00low000000
agathisflavonebiaryl;
biflavonoid;
hydroxyflavone
antineoplastic agent;
antiviral agent;
hepatoprotective agent;
metabolite
00low000000
baicaleintrihydroxyflavoneangiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger
00low000000
chrysin7-hydroxyflavonol;
dihydroxyflavone
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite
00low000000
diosmetin3'-hydroxyflavonoid;
monomethoxyflavone;
trihydroxyflavone
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
plant metabolite;
tropomyosin-related kinase B receptor agonist;
vasodilator agent
00low000000
hinokiflavonearomatic ether;
biflavonoid;
hydroxyflavone
antineoplastic agent;
metabolite;
neuroprotective agent
00low000000
hispidulinmonomethoxyflavone;
trihydroxyflavone
anti-inflammatory agent;
anticonvulsant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite
00low000000
gartaninpolyphenol;
xanthones
antineoplastic agent;
plant metabolite
00low000000
mangostinaromatic ether;
phenols;
xanthones
antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite
00low000000
norathyriolpolyphenol;
xanthones
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite
00low000000
morin7-hydroxyflavonol;
pentahydroxyflavone
angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent
00low000000
morusinextended flavonoid;
trihydroxyflavone
antineoplastic agent;
plant metabolite
00low000000
myricetin7-hydroxyflavonol;
hexahydroxyflavone
antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
00low000000
robustaflavonebiflavonoid;
hydroxyflavone;
ring assembly
anti-HBV agent;
antineoplastic agent;
antioxidant;
metabolite
00low000000
tricetinpentahydroxyflavoneantineoplastic agent;
metabolite
00low000000
wogonindihydroxyflavone;
monomethoxyflavone
angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
00low000000
daidzein7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
00low000000
astringinbeta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid
antineoplastic agent;
antioxidant;
metabolite
00low000000
pterostilbenediether;
methoxybenzenes;
stilbenol
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger
00low000000
irilonehydroxyisoflavone;
organic heterotricyclic compound;
oxacycle
antineoplastic agent;
immunomodulator;
metabolite
00low000000
caffeic acid phenethyl esteralkyl caffeate esteranti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent
00low000000
wedelolactonearomatic ether;
coumestans;
delta-lactone;
polyphenol
antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite
00low000000
maytansinealpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound
antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
00low000000
rottlerinaromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone
anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
00low000000
tectochrysinmonohydroxyflavone;
monomethoxyflavone
antidiarrhoeal drug;
antineoplastic agent;
plant metabolite
00low000000
plaunotolditerpenoid;
primary alcohol
anti-ulcer drug;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
nephroprotective agent;
plant metabolite;
vulnerary
00low000000
tranilastamidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide
anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent
00low000000
tocotrienol, betatocotrienol;
vitamin E
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
gamma-tocotrienoltocotrienol;
vitamin E
antineoplastic agent;
antioxidant;
apoptosis inducer;
hepatoprotective agent;
plant metabolite;
radiation protective agent
00low000000
tocotrienol, deltatocotrienol;
vitamin E
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
NF-kappaB inhibitor;
plant metabolite;
radiation protective agent;
Saccharomyces cerevisiae metabolite
00low000000
4'-hydroxychalconechalcones;
phenols
anti-inflammatory agent;
antineoplastic agent
00low000000
isotretinoinretinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
00low000000
9,11-linoleic acidoctadeca-9,11-dienoic acidanti-inflammatory agent;
antiatherogenic agent;
antineoplastic agent;
apoptosis inducer;
bacterial xenobiotic metabolite;
human metabolite
00low000000
camostat mesylatemethanesulfonate saltanti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
00low000000
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
00low000000
3',4',7-trihydroxyisoflavone7-hydroxyisoflavonesantineoplastic agent;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor;
metabolite
00low000000
alvocidibdihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
fenretinidemonocarboxylic acid amide;
retinoid
antineoplastic agent;
antioxidant
00low000000
geldanamycin1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound
antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor
00low000000
4-oxoretinolcyclic ketone;
enone;
primary allylic alcohol;
retinoid
antineoplastic agent00low000000
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acidbenzoic acids;
naphthalenes;
retinoid
antineoplastic agent;
retinoic acid receptor agonist;
teratogenic agent
00low000000
vinorelbineacetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid
antineoplastic agent;
photosensitizing agent
00low000000
centaureidintrihydroxyflavone;
trimethoxyflavone
antineoplastic agent;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
plant metabolite
00low000000
3,3'-di-o-methylquercetin3'-methoxyflavones;
dimethoxyflavone;
trihydroxyflavone
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
ethyl caffeatealkyl caffeate ester;
ethyl ester;
hydroxycinnamic acid
anti-inflammatory agent;
antineoplastic agent;
metabolite
00low000000
andrographolidecarbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol
anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite
00low000000
isoginkgetinaromatic ether;
biflavonoid
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
plant metabolite
00low000000
cudraflavone ctetrahydroxyflavoneantibacterial agent;
antineoplastic agent;
plant metabolite
00low000000
neobavaisoflavone7-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
plant metabolite;
platelet aggregation inhibitor
00low000000
neoglycyrolaromatic ether;
coumestans;
delta-lactone;
polyphenol
antineoplastic agent;
plant metabolite
00low000000
5,7-dihydroxy-6-methoxy-2-phenylchromen-4-onedihydroxyflavone;
monomethoxyflavone
antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor
00low000000
spiraeosidebeta-D-glucoside;
flavonols;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone
antineoplastic agent;
antioxidant;
plant metabolite
00low000000
rhamnazinaromatic ether;
dimethoxyflavone;
phenols;
trihydroxyflavone
antineoplastic agent;
plant metabolite
00low000000
oridonincyclic hemiketal;
enone;
ent-kaurane diterpenoid;
organic heteropentacyclic compound;
secondary alcohol
angiogenesis inhibitor;
anti-asthmatic agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
pd 166866biaryl;
dimethoxybenzene;
primary arylamine;
pyridopyrimidine;
ureas
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
bosutinibaminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
semaxinibolefinic compound;
oxindoles;
pyrroles
angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
00low000000
palbociclibaminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
mitoguazoneguanidines;
hydrazone
antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
00low000000
reumycincarbonyl compound;
pyrimidotriazine
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
00low000000
ergosterol-5,8-peroxide3beta-sterol;
ergostanoid;
organic peroxide;
phytosterols
antimycobacterial drug;
antineoplastic agent;
metabolite;
trypanocidal drug
00low000000
ermanindihydroxyflavone;
dimethoxyflavone
anti-inflammatory agent;
antimycobacterial drug;
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
romidepsincyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
sulindac sulfidearyl sulfide;
monocarboxylic acid;
organofluorine compound
antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug
00low000000
bay 11-7085benzenes;
nitrile;
sulfone
anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor
00low000000
macluraxanthone bphenols;
xanthones
anti-HIV agent;
antineoplastic agent;
metabolite
00low000000
flavokawain bchalcones;
dimethoxybenzene;
phenols
anti-inflammatory agent;
antileishmanial agent;
antineoplastic agent;
apoptosis inducer;
metabolite
00low000000
tamsulosin hydrochloridehydrochloridealpha-adrenergic antagonist;
antineoplastic agent
00low000000
batimastathydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide
angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor
00low000000
glyceryl behenate1-monoglyceride;
fatty acid ester
antineoplastic agent;
plant metabolite
00low000000
jaceosidindimethoxyflavone;
trihydroxyflavone
anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
metabolite
00low000000
5,7,3'-trihydroxy-3,4'-dimethoxyflavonedimethoxyflavone;
trihydroxyflavone
antineoplastic agent;
metabolite
00low000000
pederincyclic ketal;
diol;
oxanes;
polyketide;
secondary alcohol;
secondary carboxamide
antimitotic;
antineoplastic agent;
bacterial metabolite;
vesicant
00low000000
artocarpin lectinmonomethoxyflavone;
trihydroxyflavone
antineoplastic agent;
metabolite
00low000000
cisplatindiamminedichloroplatinumantineoplastic agent;
apoptosis inducer;
cross-linking reagent;
ferroptosis inducer;
genotoxin;
mutagen;
nephrotoxin;
photosensitizing agent
00low000000
bleomycinbleomycinantineoplastic agent;
metabolite
00low000000
beta-aminopropionitrile fumarate (2:1)fumarate saltantineoplastic agent;
antirheumatic drug;
collagen cross-linking inhibitor;
plant metabolite
00low000000
gamma-mangostinphenols;
xanthones
antineoplastic agent;
plant metabolite;
protein kinase inhibitor
00low000000
demethoxycurcuminbeta-diketone;
diarylheptanoid;
enone;
polyphenol
anti-inflammatory agent;
antineoplastic agent;
metabolite
00low000000
cystothiazole a1,3-thiazoles;
biaryl;
enoate ester;
enol ether;
methyl ester;
organonitrogen heterocyclic antibiotic
antifungal agent;
antineoplastic agent;
bacterial metabolite
00low000000
lespenefrilalpha-L-rhamnoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative;
polyphenol
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
hypoglycemic agent;
immunomodulator;
plant metabolite
00low000000
baohuoside iglycosyloxyflavoneanti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
arglabinepoxide;
gamma-lactone;
organic heterotetracyclic compound;
sesquiterpene lactone
antineoplastic agent;
metabolite
00low000000
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-oneenone;
pyridines
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor
00low000000
ma-1carboxamidine;
organochlorine compound;
pyrimidone;
pyrrolidines
antineoplastic agent;
EC 2.4.2.4 (thymidine phosphorylase) inhibitor
00low000000
apratoxin a1,3-thiazoles;
apratoxin
antineoplastic agent;
metabolite
00low000000
coronardinealkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound
antileishmanial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
ascofuranonedihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid;
tetrahydrofuranone
angiogenesis inhibitor;
antilipemic drug;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite
00low000000
columbianadinalpha,beta-unsaturated carboxylic ester;
furanocoumarin
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
hepatoprotective agent;
plant metabolite;
rat metabolite
00low000000
germacronegermacrane sesquiterpenoid;
olefinic compound
androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component
00low000000
rhizoxin1,3-oxazoles;
epoxide;
macrolide antibiotic
antimitotic;
antineoplastic agent;
metabolite
00low000000
sibiromycinaminoglycoside antibiotic;
hemiaminal;
phenols;
pyrrolobenzodiazepine
antineoplastic agent;
bacterial metabolite
00low000000
bryostatin 2bryostatins;
cyclic hemiketal;
enoate ester;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol
antineoplastic agent;
marine metabolite;
protein kinase C agonist
00low000000
manumycinenamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol
antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite
00low000000
thermozymocidinalpha-amino fatty acid;
hydroxy monocarboxylic acid;
non-proteinogenic alpha-amino acid;
sphingoid
antifungal agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor;
fungal metabolite;
immunosuppressive agent
00low000000
asukamycinenamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol
antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
00low000000
everolimuscyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol
anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
00low000000
13(S)-HODEHODEantineoplastic agent;
human xenobiotic metabolite;
mouse metabolite
00low000000
ixabepilone1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle
antineoplastic agent;
microtubule-destabilising agent
00low000000
axitinibaryl sulfide;
benzamides;
indazoles;
pyridines
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
salvianolic acid B1-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite
00low000000
l 744832benzenes;
ether;
isopropyl ester;
secondary carboxamide;
sulfone;
thiol
antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
geroprotector
00low000000
sophoraflavanone a(2S)-flavan-4-one;
4'-hydroxyflavanones;
trihydroxyflavanone
antibacterial agent;
antineoplastic agent;
metabolite
00low000000
tanespimycin1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
00low000000
manzamine aalkaloid;
beta-carbolines;
isoquinolines
animal metabolite;
anti-HSV-1 agent;
antimalarial;
antineoplastic agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
marine metabolite
00low000000
aureothin4-pyranones;
C-nitro compound;
ketene acetal;
olefinic compound;
oxolanes
antibacterial agent;
antifungal agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor
00low000000
fostriecin2-pyranones;
olefinic compound;
phosphate monoester;
polyketide;
primary allylic alcohol;
secondary allylic alcohol;
triol
antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
topoisomerase II inhibitor
00low000000
artesunateartemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid
antimalarial;
antineoplastic agent;
ferroptosis inducer
00low000000
ru 5866817beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone
anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
00low000000
soblidotintetrapeptideantineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
00low000000
beta-elemenebeta-elemeneantineoplastic agent00low000000
laulimalidecarboxylic ester;
epoxide;
macrolide;
secondary alcohol;
secondary allylic alcohol
animal metabolite;
antimitotic;
antineoplastic agent;
marine metabolite;
microtubule-stabilising agent
00low000000
jwh-133benzochromene;
dibenzopyran;
organic heterotricyclic compound
analgesic;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inhibitor;
CB2 receptor agonist;
opioid analgesic;
vasodilator agent
00low000000
belinostathydroxamic acid;
olefinic compound;
sulfonamide
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
on 01910N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycineantineoplastic agent;
apoptosis inducer;
EC 2.7.11.21 (polo kinase) inhibitor;
microtubule-destabilising agent
00low000000
panobinostatcinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound
angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
bml 210dicarboxylic acid diamideantineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
bufalin14beta-hydroxy steroid;
3beta-hydroxy steroid
animal metabolite;
anti-inflammatory agent;
antineoplastic agent;
cardiotonic drug
00low000000
alpha-solanineglycoalkaloid;
organic heterohexacyclic compound;
steroid saponin;
trisaccharide derivative
antineoplastic agent;
apoptosis inducer;
phytotoxin;
plant metabolite
00low000000
rhosinD-tryptophan derivative;
hydrazone;
quinoxaline derivative
antineoplastic agent;
RhoA inhibitor;
RhoC inhibitor
00low000000
s-allylcysteineL-alpha-amino acid zwitterion;
S-hydrocarbyl-L-cysteine
antineoplastic agent;
metabolite
00low000000
2-hydroxy-9-cis-octadecenoic acid2-hydroxy fatty acid;
hydroxy monounsaturated fatty acid;
long-chain fatty acid
antihypertensive agent;
antineoplastic agent;
apoptosis inducer
00low000000
dolastatin 101,3-thiazoles;
tetrapeptide
animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent
00low000000
plitidepsindidemninanticoronaviral agent;
antineoplastic agent;
marine metabolite
00low000000
abiraterone acetatepyridines;
sterol ester
antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug
00low000000
lenvatinibaromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
00low000000
nsc 716970aromatic amine;
aromatic ether;
indolecarboxamide;
organochlorine compound
antineoplastic agent00low000000
pd 0325901difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound
antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
00low000000
midostaurinbenzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
00low000000
jasplakinolidecyclodepsipeptide;
phenols
actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
00low000000
muromonab-cd3alkaloid;
macrocycle;
organic heteropentacyclic compound;
organonitrogen heterocyclic compound;
oxacycle;
tertiary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
IP3 receptor antagonist;
marine metabolite
00low000000
ginsenoside m112beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid
anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
hepatoprotective agent;
plant metabolite
00low000000
cabazitaxeltetracyclic diterpenoidantineoplastic agent;
microtubule-stabilising agent
00low000000
elisidepsincyclodepsipeptideantineoplastic agent00low000000
fr 148083aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone
antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor
00low000000
mocetinostataminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
00low000000
tln 4601dibenzodiazepine;
farnesane sesquiterpenoid;
olefinic compound;
secondary amine;
triol
antineoplastic agent;
antioxidant;
cathepsin L (EC 3.4.22.15) inhibitor
00low000000
tmc-95aindoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
fungal metabolite;
proteasome inhibitor
00low000000
cp 7247142-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamideantineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent
00low000000
9-methoxycanthin-6-onearomatic ether;
indole alkaloid;
organic heterotetracyclic compound
antineoplastic agent;
antiplasmodial drug;
metabolite
00low000000
topopyrone cnaphthochromene;
p-quinones;
phenols
antimicrobial agent;
antineoplastic agent;
antiviral agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
Penicillium metabolite
00low000000
pi103aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
00low000000
5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloridehydrochloride;
iminium salt
antineoplastic agent;
EC 2.4.2.4 (thymidine phosphorylase) inhibitor
00low000000
fty 720pmonoalkyl phosphate;
primary alcohol;
primary amino compound
antineoplastic agent;
immunosuppressive agent;
sphingosine-1-phosphate receptor agonist
00low000000
hmr 1275hydrochlorideantineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
zm 447439aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor
00low000000
hki 272nitrile;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
ginsenoside f212beta-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
ginsenoside rg3ginsenoside;
glycoside;
tetracyclic triterpenoid
angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
es-285amino alcohol;
sphingoid
antineoplastic agent00low000000
nidulalin amethyl ester;
phenols;
xanthones
antimicrobial agent;
antineoplastic agent;
Penicillium metabolite
00low000000
rucaparibazepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
00low000000
jte 607hydrochlorideanti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
CPSF3 inhibitor;
prodrug
00low000000
pasireotidehomodetic cyclic peptide;
peptide hormone
antineoplastic agent00low000000
npi 23582,5-diketopiperazines;
benzenes;
imidazoles;
olefinic compound
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent
00low000000
rubraxanthonearomatic ether;
polyphenol;
xanthones
antibacterial agent;
antineoplastic agent;
metabolite
00low000000
NNC 55-0396 (free base)benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker
00low000000
sr 11302alpha,beta-unsaturated monocarboxylic acid;
retinoid;
toluenes
antineoplastic agent;
AP-1 antagonist
00low000000
sch 51344aromatic amine;
aromatic ether;
primary alcohol;
pyrazoloquinoline;
secondary amino compound
antineoplastic agent00low000000
4alpha-methylergosta-8,24(28)-dien-3,7,11-trione-26-oic acid11-oxo steroid;
3-oxo steroid;
7-oxo steroid;
ergostanoid;
monocarboxylic acid;
steroid acid
anti-inflammatory agent;
antineoplastic agent;
plant metabolite
00low000000
osu 03012antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
ly2090314diazepinoindole;
imidazopyridine;
maleimides;
monofluorobenzenes;
piperidinecarboxamide;
ureas
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
00low000000
cerberinacetate ester;
cardenolide glycoside;
monosaccharide derivative
antineoplastic agent;
metabolite
00low000000
pateamine a1,3-thiazoles;
macrodiolide;
olefinic compound;
primary amino compound;
tertiary amino compound
antineoplastic agent;
antiviral agent;
eukaryotic initiation factor 4F inhibitor;
marine metabolite
00low000000
6-hydroxytaxoltaxane diterpenoid;
tetracyclic diterpenoid
antineoplastic agent00low000000
masitinib1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines
antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
00low000000
avenanthramide bamidobenzoic acid;
cinnamamides;
monohydroxybenzoic acid;
monomethoxybenzene;
phenols;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
phytoalexin
00low000000
ageladine aalkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite
00low000000
ly-2157299aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines
antineoplastic agent;
TGFbeta receptor antagonist
00low000000
pazopanibaminopyrimidine;
indazoles;
sulfonamide
angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
azd2858aromatic amine;
N-methylpiperazine;
pyrazines;
pyridines;
secondary carboxamide;
sulfonamide
antineoplastic agent;
bone density conservation agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
00low000000
bibw 2992aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
bl1521enamide;
hydroxamic acid;
monocarboxylic acid amide
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
jte 013chloropyridine;
pyrazolopyridine
anti-asthmatic agent;
anti-inflammatory agent;
antineoplastic agent;
osteogenesis regulator;
pro-angiogenic agent;
sphingosine-1-phosphate receptor 2 antagonist
00low000000
holomycinacetamides;
dithiolopyrrolone antibiotic
antibacterial agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite
00low000000
aee 7886-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
00low000000
saracatinibaromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
00low000000
crenolanibaminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
trilobacinbutenolide;
polyketide;
triol
antineoplastic agent;
plant metabolite
00low000000
manassantin bbenzodioxoles;
dimethoxybenzene;
lignan;
oxolanes;
secondary alcohol
antineoplastic agent;
metabolite
00low000000
pha 665752dichlorobenzene;
enamide;
indolones;
N-acylpyrrolidine;
pyrrolecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide
antineoplastic agent;
c-Met tyrosine kinase inhibitor
00low000000
PB28aromatic ether;
piperazines;
tetralins
anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist
00low000000
tmc-95bindoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol
antimicrobial agent;
antineoplastic agent;
fungal metabolite;
proteasome inhibitor
00low000000
fr 901464acetate ester;
cyclic hemiketal;
monocarboxylic acid amide;
pyrans;
spiro-epoxide
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
00low000000
vinflunineacetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid
antineoplastic agent00low000000
homocamptothecinepsilon-lactone;
organic heteropentacyclic compound;
organonitrogen heterocyclic compound;
tertiary alcohol
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
00low000000
3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranosidearomatic ether;
benzyl alcohols;
beta-D-glucoside;
monosaccharide derivative;
primary alcohol
antineoplastic agent;
metabolite
00low000000
jaspamide bcyclodepsipeptide;
organobromine compound
animal metabolite;
antineoplastic agent;
marine metabolite
00low000000
ossamycincyclic hemiketal;
macrolide antibiotic;
organic heterotetracyclic compound;
secondary alcohol;
spiroketal;
tertiary alcohol
antineoplastic agent;
bacterial metabolite
00low000000
nigranoic aciddicarboxylic acid;
tetracyclic triterpenoid
antineoplastic agent;
HIV-1 reverse transcriptase inhibitor;
metabolite
00low000000
esculeoside aazaspiro compound;
oxaspiro compound;
saponin;
steroid alkaloid;
steroid saponin
antineoplastic agent;
metabolite
00low000000
azadironeacetate ester;
cyclic terpene ketone;
furans;
limonoid;
tetracyclic triterpenoid
antineoplastic agent;
antiplasmodial drug;
plant metabolite
00low000000
iejimalide bether;
formamides;
macrolide
antineoplastic agent;
marine metabolite
00low000000
migrastatinether;
macrolide antibiotic;
piperidones;
secondary alcohol
antineoplastic agent;
metabolite
00low000000
cembra-2,7,11-triene-4,6-diolcembrane diterpenoidantineoplastic agent00low000000
2,3,6,8-tetrahydroxy-1-(3-methylbut-2-enyl)-5-(2-methylbut-3-en-2-yl)-9h-xanthen-9-onepolyphenol;
xanthones
anti-inflammatory agent;
antineoplastic agent;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite
00low000000
regorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide
antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
00low000000
at 7867monochlorobenzenes;
piperidines;
pyrazoles
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
ym 155organic bromide saltantineoplastic agent;
apoptosis inducer;
survivin suppressant
00low000000
bielschowskysinacetate ester;
cyclic acetal;
diterpenoid;
gamma-lactone;
organic heterohexacyclic compound
antimalarial;
antineoplastic agent;
metabolite
00low000000
erastinaromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide
antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor
00low000000
abt-737aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound
anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
00low000000
brivanibaromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
00low000000
rx-3117organofluorine compound;
primary allylic alcohol;
triol
antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug
00low000000
ascochlorincyclohexanones;
dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid
angiogenesis inhibitor;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite
00low000000
spiculoic acid acarbobicyclic compound;
cyclic ketone;
oxo monocarboxylic acid;
styrenes
antineoplastic agent;
metabolite
00low000000
N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamideD-valine derivative;
hydroxamic acid
antineoplastic agent;
autophagy inducer;
EC 3.4.24.24 (gelatinase A) inhibitor;
melanin synthesis inhibitor
00low000000
at 7519dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
ym 2163911,3-oxazoles;
1,3-thiazoles;
azamacrocycle;
benzenes;
heterodetic cyclic peptide
antineoplastic agent;
bacterial metabolite
00low000000
marizomibbeta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide
antineoplastic agent;
proteasome inhibitor
00low000000
er-086526cyclic ketal;
cyclic ketone;
macrocycle;
polycyclic ether;
polyether;
primary amino compound
antineoplastic agent;
microtubule-destabilising agent
00low000000
obolactone2-pyranones;
4-pyranones
antineoplastic agent;
plant metabolite
00low000000
episilvestroldioxanes;
ether;
methyl ester;
organic heterotricyclic compound
antineoplastic agent;
metabolite
00low000000
abt 869aromatic amine;
indazoles;
phenylureas
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
azd 1152anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor;
prodrug
00low000000
pf 00299804enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
00low000000
ki11502aromatic ether;
benzamides;
quinolines;
thioureas
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
carfilzomibepoxide;
morpholines;
tetrapeptide
antineoplastic agent;
proteasome inhibitor
00low000000
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineaminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate
antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
idelalisibaromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
crizotinib3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
zstk474benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
lyoniresinoldimethoxybenzene;
lignan;
polyphenol;
primary alcohol;
tetralins
antineoplastic agent;
metabolite
00low000000
GDC-0879indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines
antineoplastic agent;
B-Raf inhibitor
00low000000
physalin benone;
lactone;
organic heteroheptacyclic compound;
physalin
antimalarial;
antimicrobial agent;
antineoplastic agent
00low000000
amrubicinoldiastereoisomeric mixture;
quinone;
secondary alcohol;
tetracenes
antineoplastic agent;
apoptosis inducer;
topoisomerase II inhibitor
00low000000
silvestroldioxanes;
ether;
methyl ester;
organic heterotricyclic compound
antineoplastic agent;
metabolite
00low000000
at 13387benzamides;
isoindoles;
N-alkylpiperazine;
resorcinols;
tertiary carboxamide
antineoplastic agent;
Hsp90 inhibitor
00low000000
cytotrienin acyclopropanecarboxylate ester;
ether;
hydroquinones;
lactam;
macrocycle;
secondary alcohol
antibacterial agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
metabolite
00low000000
dactolisibimidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
00low000000
bgt226aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
00low000000
2'-methoxykurarinone4'-hydroxyflavanones;
dihydroxyflavanone;
dimethoxyflavanone
antineoplastic agent;
metabolite
00low000000
geduninacetate ester;
enone;
epoxide;
furans;
lactone;
limonoid;
organic heteropentacyclic compound;
pentacyclic triterpenoid
antimalarial;
antineoplastic agent;
Hsp90 inhibitor;
plant metabolite
00low000000
monascinalpha,beta-unsaturated ketone;
gamma-lactone;
organic heterotricyclic compound;
polyketide
antilipemic drug;
antineoplastic agent;
fungal metabolite;
PPARgamma agonist
00low000000
monascorubrinazaphilone;
enone;
gamma-lactone;
polyketide;
triketone
anti-inflammatory agent;
antineoplastic agent;
biological pigment;
food colouring;
fungal metabolite;
Hsp90 inhibitor
00low000000
5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-onealkaloid;
chromones;
hydroxypiperidine;
resorcinols;
tertiary amino compound
anti-inflammatory agent;
anti-ulcer drug;
anticholesteremic drug;
antileishmanial agent;
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
fungal metabolite;
plant metabolite
00low000000
SYC-435benzenes;
cyclic hydroxamic acid;
pyridone
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
00low000000
ligstrosidebeta-D-glucoside;
diester;
methyl ester;
phenols;
pyrans;
secoiridoid glycoside
antineoplastic agent;
plant metabolite
00low000000
mogrolhydroxy seco-steroid;
tetracyclic triterpenoid
antineoplastic agent00low000000
simalikalactone Dcyclic ether;
delta-lactone;
enone;
organic heteropentacyclic compound;
quassinoid;
secondary alcohol;
secondary alpha-hydroxy ketone;
triol
antimalarial;
antineoplastic agent;
antiviral agent;
metabolite
00low000000
4-methyl-5-pentylbenzene-1,3-diolresorcinolsantineoplastic agent00low000000
mdv 3100(trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound
androgen antagonist;
antineoplastic agent
00low000000
azd 1152-hqpaanilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor
00low000000
adonixanthincarotenone;
cyclic ketone;
secondary alcohol
algal metabolite;
animal metabolite;
antineoplastic agent;
bacterial metabolite;
marine metabolite;
plant metabolite
00low000000
schweinfurthin gcyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid
antineoplastic agent;
metabolite
00low000000
abarelixpolypeptideantineoplastic agent;
hormone antagonist
00low000000
forapinpeptidyl amide;
polypeptide
animal metabolite;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.13 (protein kinase C) inhibitor;
hepatoprotective agent;
neuroprotective agent;
venom
00low000000
gastrin 17gastrinantineoplastic agent00low000000
buparlisibaminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
tubocapsanolide a4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
secondary alcohol;
withanolide
antineoplastic agent;
NF-kappaB inhibitor
00low000000
pevonedistatcyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate
antineoplastic agent;
apoptosis inducer
00low000000
tg101209N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
gsk6906931,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
cnf 20242-aminopurines;
aromatic ether;
organochlorine compound;
pyridines
antineoplastic agent;
Hsp90 inhibitor
00low000000
ku 0063794benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound
antineoplastic agent;
mTOR inhibitor
00low000000
respirantinbenzamides;
cyclodepsipeptide;
formamides;
phenols
antimicrobial agent;
antineoplastic agent;
metabolite
00low000000
sm 164benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles
antineoplastic agent;
apoptosis inducer;
radiosensitizing agent
00low000000
berkeleydionebeta-diketone;
cyclic terpene ketone;
meroterpenoid;
methyl ester;
organic heterotetracyclic compound;
terpene lactone;
tertiary alcohol;
tertiary alpha-hydroxy ketone
antineoplastic agent;
cysteine protease inhibitor;
Penicillium metabolite
00low000000
lucidenic acid ncyclic terpene ketone;
dioxo monocarboxylic acid;
secondary alcohol;
tetracyclic triterpenoid
antineoplastic agent;
EC 3.1.1.8 (cholinesterase) inhibitor;
metabolite
00low000000
bromophycolide aditerpenoid;
macrolide;
organobromine compound;
phenols;
tertiary alcohol
anti-HIV agent;
antibacterial agent;
antifungal agent;
antimalarial;
antineoplastic agent;
metabolite
00low000000
nnc 55-0396hydrochlorideangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker
00low000000
meclofenamate sodium anhydroushydrateanalgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
00low000000
brequinar sodiumorganic sodium saltanticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor
00low000000
borrelidinaliphatic nitrile;
diol;
macrolide;
monocarboxylic acid;
secondary alcohol
antifungal agent;
antimalarial;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite
00low000000
olaparibcyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines
antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
00low000000
plx 4720aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
00low000000
lcl1611,3-thiazoles;
aromatic ketone;
L-alanine derivative;
monofluorobenzenes;
N-acylpyrrolidine
antineoplastic agent;
apoptosis inducer
00low000000
aspergillide bbridged compound;
cyclic ether;
macrolide;
secondary alcohol
antineoplastic agent;
Aspergillus metabolite
00low000000
tenovin-6monocarboxylic acid amide;
tertiary amino compound;
thioureas
antineoplastic agent;
p53 activator;
Sir2 inhibitor
00low000000
lde225aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
00low000000
gdc 0449benzamides;
monochlorobenzenes;
pyridines;
sulfone
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
00low000000
bms 754807pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
marinopyrrole aaromatic ketone;
organochlorine compound;
phenols;
pyrroles
antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite
00low000000
delanzomibC-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative
antineoplastic agent;
apoptosis inducer;
proteasome inhibitor
00low000000
grassypeptolidecyclodepsipeptide;
macrocycle
antineoplastic agent;
metabolite
00low000000
pci 32765acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
ponatinib(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
spiruchostatin bmacrocyclic lactone;
organic disulfide;
organic heterobicyclic compound;
spiruchostatin
antineoplastic agent;
bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
AMG-208aromatic ether;
quinolines;
triazolopyridazine
antineoplastic agent;
c-Met tyrosine kinase inhibitor
00low000000
papuamide bcyclodepsipeptide;
olefinic compound;
secondary alcohol;
tertiary alcohol
anti-HIV-1 agent;
antineoplastic agent;
marine metabolite
00low000000
antroquinonol denol ether;
enone;
secondary alcohol
antineoplastic agent;
fungal metabolite
00low000000
quizartinibbenzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
00low000000
6-methoxyspirotryprostatin baromatic ether;
azaspiro compound;
indole alkaloid;
indolones
antineoplastic agent;
Aspergillus metabolite
00low000000
PP121aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor
00low000000
niraparibbenzenes;
indazoles;
piperidines;
primary carboxamide
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
00low000000
niraparib2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamideantineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent
00low000000
navitoclaxaryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
00low000000
lucitanibaromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines
antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist
00low000000
chondramide cchondramide;
indoles;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideaminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound
anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
cetrorelixoligopeptideantineoplastic agent;
GnRH antagonist
00low000000
histrelinoligopeptideantineoplastic agent;
gonadotropin releasing hormone agonist
00low000000
cabozantinibaromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
salvileucalin bbridged compound;
diterpenoid;
furans;
gamma-lactone
antineoplastic agent;
metabolite
00low000000
incb-018424nitrile;
pyrazoles;
pyrrolopyrimidine
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
poziotinibacrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline
antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist
00low000000
asp3026aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone
antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
00low000000
entrectinibbenzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
pexidartinibaminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
TAK-5801,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
00low000000
glasdegibbenzimidazoles;
nitrile;
phenylureas;
piperidines
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
00low000000
gsk 2126458aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
00low000000
ixazomibbenzamides;
boronic acids;
dichlorobenzene;
glycine derivative
antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor
00low000000
cx 5461diazepine;
naphthyridine derivative;
organic heterotetracyclic compound;
pyrazines;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.7.6 (RNA polymerase) inhibitor
00low000000
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanolbenzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
00low000000
plx4032aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
00low000000
GDC-0623hydroxamic acid ester;
imidazopyridine;
monofluorobenzenes;
organoiodine compound;
primary alcohol;
secondary amino compound;
substituted aniline
antineoplastic agent;
apoptosis inducer;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
00low000000
INDYbenzothiazoles;
enone;
organic hydroxy compound
antineoplastic agent;
drug metabolite;
EC 2.7.12.1 (dual-specificity kinase) inhibitor
00low000000
7,8-dihydroxyflavanonedihydroxyflavanoneantineoplastic agent;
metabolite
00low000000
dabrafenib1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
00low000000
cblc137aromatic ketone;
carbazoles;
methyl ketone;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
NF-kappaB inhibitor;
p53 activator
00low000000
2,3-dihydro-3beta-O-sulfate withaferin A27-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
epoxy steroid;
ergostanoid;
primary alcohol;
steroid sulfate;
withanolide
antineoplastic agent;
metabolite;
plant metabolite
00low000000
leachianone a4'-hydroxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone
antimalarial;
antineoplastic agent;
metabolite
00low000000
thiopental sodiumorganochlorine compound;
piperazines;
pyrimidines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
EG00229benzothiadiazole;
dicarboxylic acid monoamide;
L-arginine derivative;
secondary carboxamide;
sulfonamide;
thiophenes
angiogenesis inhibitor;
antineoplastic agent;
neuropilin receptor antagonist
00low000000
jadomycin bglycoside;
jadomycin;
organic heteropentacyclic compound
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor;
bacterial metabolite
00low000000
tak-632(trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor
00low000000
chondramide achondramide;
indoles;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
englerin acinnamate ester;
glycolate ester;
guaiane sesquiterpenoid
antineoplastic agent;
metabolite
00low000000
lrrk2-in1aromatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
jq1 compoundcarboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine
angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer
00low000000
ML-210C-nitro compound;
diarylmethane;
isoxazoles;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
tertiary carboxamide
antineoplastic agent;
EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer;
prodrug
00low000000
eurycomanonecyclic ether;
delta-lactone;
enone;
organic heteropentacyclic compound;
pentol;
quassinoid;
secondary alcohol;
secondary alpha-hydroxy ketone;
tertiary alcohol
antimalarial;
antineoplastic agent;
metabolite
00low000000
gilteritinibaromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
alectinibaromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
ML240aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound
antineoplastic agent00low000000
torin 1N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines
antineoplastic agent;
mTOR inhibitor
00low000000
abt-199aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
00low000000
pracinostatbenzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound
antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
physalin fenone;
epoxy steroid;
lactone;
physalin
antileishmanial agent;
antimalarial;
antineoplastic agent;
apoptosis inducer;
immunosuppressive agent
00low000000
xl765aromatic amine;
aromatic ether;
benzamides;
quinoxaline derivative;
sulfonamide
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
00low000000
DMH1aromatic ether;
pyrazolopyrimidine;
quinolines
antineoplastic agent;
bone morphogenetic protein receptor antagonist;
protein kinase inhibitor
00low000000
torin 2aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline
antineoplastic agent;
mTOR inhibitor
00low000000
oligomycin aantibiotic antifungal agent;
diketone;
oligomycin;
pentol
antineoplastic agent;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
nematicide
00low000000
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylureaaminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas
antineoplastic agent;
fibroblast growth factor receptor antagonist
00low000000
3alpha,12alpha-dihydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid11-oxo steroid;
12alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7-oxo steroid;
monocarboxylic acid;
secondary alpha-hydroxy ketone;
steroid acid
antineoplastic agent;
metabolite
00low000000
3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid11-oxo steroid;
3alpha-hydroxy steroid;
7-oxo steroid;
monocarboxylic acid;
steroid acid
antineoplastic agent;
cholinergic antagonist;
metabolite;
serotonergic antagonist
00low000000
chir 98014aminopyrimidine;
C-nitro compound;
diaminopyridine;
dichlorobenzene;
imidazoles;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
hypoglycemic agent;
tau aggregation inhibitor;
Wnt signalling activator
00low000000
gsk2656157biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
00low000000
n-(2-(5-methoxy-2-oxo-2,3-dihydro-1h-indol-3-yl)ethyl)acetamideacetamides;
hydroxyindoles;
tryptamines
antineoplastic agent;
apoptosis inducer;
plant metabolite
00low000000
coumermycinaromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor
00low000000
lfm a13aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor
00low000000
AZD3463aminopiperidine;
aminopyrimidine;
indoles;
monomethoxybenzene;
organochlorine compound;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
calicheamicin gamma(1)icalicheamicin;
enediyne antibiotic;
organoiodine compound
antineoplastic agent;
metabolite
00low000000
asperfuranone2-benzofurans;
cyclic ketone;
diol;
polyketide;
secondary alcohol;
tertiary alcohol;
tertiary alpha-hydroxy ketone
antineoplastic agent;
fungal metabolite
00low000000
ceritinibaminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
pelabresibmonochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide
antineoplastic agent;
bromodomain-containing protein 4 inhibitor
00low000000
gsk2879552benzenes;
benzoic acids;
cyclopropanes;
monocarboxylic acid;
piperidines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor
00low000000
ssr128129eorganic sodium saltantineoplastic agent;
fibroblast growth factor receptor antagonist
00low000000
aspergillide abridged compound;
cyclic ether;
macrolide;
secondary alcohol
antineoplastic agent;
Aspergillus metabolite
00low000000
capilliposide balpha-L-arabinopyranoside;
bridged compound;
cyclic ether;
diol;
hexacyclic triterpenoid;
hexanoate ester;
lactol;
secondary alcohol;
tetrasaccharide derivative;
triterpenoid saponin
antineoplastic agent;
plant metabolite
00low000000
brasilicardin abenzoate ester;
carbotricyclic compound;
diterpenoid;
N-acetyl-D-glucosaminide;
non-proteinogenic alpha-amino acid;
phenols
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
immunosuppressive agent
00low000000
surfactin Acyclodepsipeptide;
lipopeptide antibiotic;
macrocyclic lactone
antibacterial agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
metabolite;
surfactant
00low000000
acp-196aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
gsk343aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
00low000000
myriaporone 3beta-hydroxy ketone;
epoxide;
lactol;
oxanes;
primary alcohol;
secondary alcohol
antineoplastic agent;
metabolite
00low000000
GSK1059615pyridines;
quinolines;
thiazolidinone
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
osimertinibacrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
00low000000
ivosidenibcyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
00low000000
phleomycin d1bi-1,3-thiazole;
chelate-forming peptide;
disaccharide derivative;
glycopeptide;
guanidines
antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite
00low000000
ly3009120aminotoluene;
aromatic amine;
biaryl;
monofluorobenzenes;
phenylureas;
pyridopyrimidine;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
B-Raf inhibitor;
necroptosis inhibitor
00low000000
pf-06463922aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
as 1842856organofluorine compound;
primary amino compound;
quinolinemonocarboxylic acid;
quinolone;
secondary amino compound;
tertiary amino compound
anti-obesity agent;
antineoplastic agent;
apoptosis inducer;
autophagy inhibitor;
forkhead box protein O1 inhibitor;
hypoglycemic agent
00low000000
physalin d5alpha-hydroxy steroid;
6beta-hydroxy steroid;
cyclic ether;
enone;
lactone;
organic heteroheptacyclic compound;
physalin
antimalarial;
antimycobacterial drug;
antineoplastic agent
00low000000
acarbosechondramide;
indoles;
organochlorine compound;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
sr9243bromobenzenes;
sulfonamide;
sulfone
antineoplastic agent;
apoptosis inducer;
liver X receptor inverse agonist
00low000000
CCT251545azaspiro compound;
chloropyridine;
pyrazoles
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
Wnt signalling inhibitor
00low000000
ldc4297aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
hg-9-91-01aminopyrimidine;
dimethoxybenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas;
secondary amino compound
antineoplastic agent;
salt-inducible kinase 2 inhibitor
00low000000
cigb-300heterodetic cyclic peptide;
polypeptide
angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
chondramide dchondramide;
indoles;
phenols
antineoplastic agent;
bacterial metabolite
00low000000
bassianolidecyclodepsipeptide;
cyclooctadepsipeptide
antineoplastic agent;
fungal metabolite;
insecticide
00low000000
enasidenib1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
00low000000
BDA-366anthraquinone;
epoxide;
secondary alcohol;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
apoptosis inducer
00low000000
ebc-46diester;
diterpenoid;
organic heteropentacyclic compound;
phorbol ester
antineoplastic agent;
plant metabolite;
protein kinase C agonist
00low000000
THZ531aminopyrimidine;
enamide;
indoles;
N-acylpiperidine;
organochlorine compound;
secondary amino compound;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
can 508aromatic amine;
monoazo compound;
phenols;
pyrazoles
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
00low000000
levoleucovorin5-formyltetrahydrofolic acidantineoplastic agent;
metabolite
00low000000
rifampincyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion
angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
00low000000
azaguaninenucleobase analogue;
triazolopyrimidines
antimetabolite;
antineoplastic agent;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor
00low000000
pemetrexedN-acyl-L-glutamic acid;
pyrrolopyrimidine
antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
00low000000
tirapazaminearomatic amine;
benzotriazines;
N-oxide
antibacterial agent;
antineoplastic agent;
apoptosis inducer
00low000000
pyrazofurinC-glycosyl compound;
pyrazoles
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor
00low000000
MMP-9-IN-1aromatic compound;
organic sulfide;
organofluorine compound;
pyrimidone;
secondary carboxamide
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor
00low000000
hydrazinocurcuminaromatic ether;
olefinic compound;
polyphenol;
pyrazoles
angiogenesis modulating agent;
antineoplastic agent;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
9-arabinofuranosylguaninebeta-D-arabinoside;
purine nucleoside
antineoplastic agent;
DNA synthesis inhibitor
00low000000
cerulomycinaldoxime;
aromatic ether;
bipyridines;
pyridine alkaloid
antineoplastic agent;
bacterial metabolite;
marine metabolite
00low000000
undecylprodigiosinalkaloid;
aromatic ether;
tripyrrole
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
biological pigment;
immunosuppressive agent;
radiosensitizing agent
00low000000
ver 52296aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols
angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor
00low000000
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrilehydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor
00low000000
XL413benzofuropyrimidine;
organochlorine compound;
pyrrolidines
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
pp242aromatic amine;
biaryl;
hydroxyindoles;
phenols;
primary amino compound;
pyrazolopyrimidine
antineoplastic agent;
mTOR inhibitor
00low000000
marineosin aazaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles
antineoplastic agent;
metabolite
00low000000
marineosin bazaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles
antineoplastic agent;
metabolite
00low000000
ARS-1620quinazolinesantineoplastic agent;
antiviral agent;
inhibitor
00low000000
sotorasibacrylamides;
methylpyridines;
monofluorobenzenes;
N-acylpiperazine;
phenols;
pyridopyrimidine;
tertiary amino compound;
tertiary carboxamide
antineoplastic agent00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
sb 220025aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines
angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
sb 202190imidazoles;
organofluorine compound;
phenols;
pyridines
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
00low000000
auraptencoumarins;
monoterpenoid
antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
dopaminergic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
gamma-secretase modulator;
gastrointestinal drug;
hepatoprotective agent;
matrix metalloproteinase inhibitor;
neuroprotective agent;
plant metabolite;
PPARalpha agonist;
vulnerary
00low000000
azd 6244benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
trametinibacetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
00low000000
ph 797804aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
sch772984biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide
analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
MK-8353aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
00low000000
fluorouracilnucleobase analogue;
organofluorine compound
antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
00low000000
entinostatbenzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
00low000000
imatinibaromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
00low000000
streptonigrinpyridines;
quinolone
antimicrobial agent;
antineoplastic agent
00low000000
floxuridinenucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent
00low000000
trifluridinenucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor
00low000000
2-fluoroadenineorganofluorine compound;
purines
antineoplastic agent00low000000
doxifluridineorganofluorine compound;
pyrimidine 5'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
prodrug
00low000000
fludarabine phosphatenucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate
antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
00low000000
gemcitabine hydrochloridehydrochloride;
organofluorine compound
anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent
00low000000
gemcitabineorganofluorine compound;
pyrimidine 2'-deoxyribonucleoside
antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
00low000000
capecitabinecarbamate ester;
cytidines;
organofluorine compound
antimetabolite;
antineoplastic agent;
prodrug
00low000000
enrofloxacincyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone
antibacterial agent;
antimicrobial agent;
antineoplastic agent
00low000000
4-methylumbelliferyl glucuronidebeta-D-glucosiduronic acid;
coumarins;
monosaccharide derivative
antineoplastic agent;
chromogenic compound;
hyaluronan synthesis inhibitor
00low000000
fulvestrant17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide
antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist
00low000000
sc 58125organofluorine compound;
pyrazoles;
sulfone
antineoplastic agent;
cyclooxygenase 2 inhibitor
00low000000
clofarabineadenosines;
organofluorine compound
antimetabolite;
antineoplastic agent
00low000000
abiraterone3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines
antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
00low000000
vatalanibmonochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
canertinibmonochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
lapatinibfurans;
organochlorine compound;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
diflomotecanepsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
00low000000
gant 61aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor
00low000000
8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine6-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound
antineoplastic agent;
Hsp90 inhibitor
00low000000
prinomastataromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor
00low000000
s 1033(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
sulindacmonocarboxylic acid;
organofluorine compound;
sulfoxide
analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent
00low000000
mcb-613cyclic ketone;
enone;
pyridines
antineoplastic agent;
steroid receptor coactivator stimulator
00low000000
zd 6474aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
sc 560aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles
angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug
00low000000
sulindac sulfidearyl sulfide;
monocarboxylic acid;
organofluorine compound
antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug
00low000000
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-oneenone;
pyridines
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor
00low000000
axitinibaryl sulfide;
benzamides;
indazoles;
pyridines
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
00low000000
ru 5866817beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone
anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist
00low000000
abiraterone acetatepyridines;
sterol ester
antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug
00low000000
mocetinostataminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
00low000000
rucaparibazepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound
antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
00low000000
NNC 55-0396 (free base)benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker
00low000000
osu 03012antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
00low000000
masitinib1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines
antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
00low000000
azd2858aromatic amine;
N-methylpiperazine;
pyrazines;
pyridines;
secondary carboxamide;
sulfonamide
antineoplastic agent;
bone density conservation agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator
00low000000
bibw 2992aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
rx-3117organofluorine compound;
primary allylic alcohol;
triol
antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug
00low000000
3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineaminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate
antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
idelalisibaromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
zstk474benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
GDC-0879indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines
antineoplastic agent;
B-Raf inhibitor
00low000000
bgt226aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
00low000000
buparlisibaminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
cnf 20242-aminopurines;
aromatic ether;
organochlorine compound;
pyridines
antineoplastic agent;
Hsp90 inhibitor
00low000000
lde225aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
00low000000
gdc 0449benzamides;
monochlorobenzenes;
pyridines;
sulfone
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
00low000000
bms 754807pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
navitoclaxaryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
00low000000
cabozantinibaromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
00low000000
pexidartinibaminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
00low000000
TAK-5801,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
00low000000
gsk 2126458aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
00low000000
dabrafenib1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
00low000000
torin 1N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines
antineoplastic agent;
mTOR inhibitor
00low000000
torin 2aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline
antineoplastic agent;
mTOR inhibitor
00low000000
gsk2656157biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
00low000000
coumermycinaromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor
00low000000
acp-196aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
00low000000
GSK1059615pyridines;
quinolines;
thiazolidinone
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
00low000000
ivosidenibcyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
00low000000
as 1842856organofluorine compound;
primary amino compound;
quinolinemonocarboxylic acid;
quinolone;
secondary amino compound;
tertiary amino compound
anti-obesity agent;
antineoplastic agent;
apoptosis inducer;
autophagy inhibitor;
forkhead box protein O1 inhibitor;
hypoglycemic agent
00low000000
enasidenib1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol
antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor
00low000000
MMP-9-IN-1aromatic compound;
organic sulfide;
organofluorine compound;
pyrimidone;
secondary carboxamide
antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor
00low000000
2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrilehydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor
00low000000
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
fasudilisoquinolines;
N-sulfonyldiazepane
antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent
201720177.0low000010
miltefosinephosphocholines;
phospholipid
anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor
202220222.0low000001
4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline201720177.0low000010
nsc 664704indolobenzazepine;
lactam;
organobromine compound
cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector
202220222.0low000001
imatinibaromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
201720224.5low000011
triciribine phosphate201720177.0low000010
picropodophyllinfuronaphthodioxole;
lignan;
organic heterotetracyclic compound
antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor
201720177.0low000010
gefitinibaromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
201720177.0low000010
lestaurtinibindolocarbazole201720177.0low000010
perifosineammonium betaine;
phospholipid
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720177.0low000010
lonafarnib4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
202220222.0low000001
vatalanibmonochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
ruboxistaurin201720177.0low000010
canertinibmonochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
cyc 2022,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
sb 203580imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
202220222.0low000001
enzastaurinindoles;
maleimides
201720177.0low000010
erlotinibaromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound
antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor
201720177.0low000010
lapatinibfurans;
organochlorine compound;
organofluorine compound;
quinazolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
sorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide
angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
201720224.5low000011
wortmanninacetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound
anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
202220222.0low000001
ginsenoside rf12beta-hydroxy steroid;
20-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid
antineoplastic agent;
apoptosis inducer;
plant metabolite
202220222.0low000001
s 1033(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
xl147aromatic amine;
benzothiadiazole;
quinoxaline derivative;
sulfonamide
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201720177.0low000010
bms 3870321,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
sf 2370bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound
antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist
201720177.0low000010
tandutinibaromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
dasatinib1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound
anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
201720224.5low000011
ha 1100201720177.0low000010
7-epi-hydroxystaurosporine201720177.0medium000010
zd 6474aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
alsterpaulloneC-nitro compound;
caprolactams;
organic heterotetracyclic compound
anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor
202220222.0low000001
imd 0354benzamides201720177.0low000010
sirolimusantibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol
antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
201720224.5low000011
alvocidibdihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
bosutinibaminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
orantinib201720177.0low000010
su 11248monocarboxylic acid amide;
pyrroles
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
palbociclibaminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
vx680N-arylpiperazine201720177.0low000010
22,23-dihydroavermectin b(1)amacrocyclic lactone;
spiroketal
202220222.0low000001
cyc 116201720177.0low000010
everolimuscyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol
anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
201720224.5low000011
ekb 569aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile
protein kinase inhibitor201720177.0low000010
axitinibaryl sulfide;
benzamides;
indazoles;
pyridines
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
temsirolimusmacrolide lactam201720177.0low000010
on 01910N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycineantineoplastic agent;
apoptosis inducer;
EC 2.7.11.21 (polo kinase) inhibitor;
microtubule-destabilising agent
201720177.0low000010
av 412201720177.0low000010
telatinib201720177.0low000010
y-39983pyrrolopyridine201720177.0low000010
cp 547632201720177.0low000010
lenvatinibaromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
pd 0325901difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound
antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
201520206.7low000030
midostaurinbenzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
201720177.0low000010
px-866acetate ester;
delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720177.0low000010
ripasudilisoquinolines201720177.0medium000010
osi 930aromatic amide201720177.0low000010
scio-469aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
cp 7247142-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamideantineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent
201720177.0low000010
hmn-214201720177.0medium000010
tivozanibaromatic ether201720177.0low000010
hki 272nitrile;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
tofacitinibN-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound
antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720224.5low000011
cediranibaromatic ether201720177.0low000010
masitinib1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines
antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor
201720177.0low000010
ly-2157299aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines
antineoplastic agent;
TGFbeta receptor antagonist
201720177.0low000010
pazopanibaminopyrimidine;
indazoles;
sulfonamide
angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
azd 6244benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
su 14813201720177.0low000010
apilimod202220222.0low000001
bibw 2992aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
binimetinibbenzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
sotrastaurinindoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines
anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent
201720177.0low000010
aee 7886-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amineangiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug
201720177.0low000010
saracatinibaromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound
anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent
201720224.5low000011
vx 702phenylpyridine201720177.0low000010
crenolanibaminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
tg100-115pteridines201720177.0low000010
cc 401pyrazoles;
ring assembly
201720177.0low000010
bms 599626201720177.0low000010
exel-7647201720177.0low000010
volasertib201720177.0low000010
azd 7762aromatic amide;
thiophenes
201720177.0low000010
regorafenib(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide
antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor
201720177.0low000010
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-onemethoxybenzenes;
substituted aniline
201720177.0low000010
brivanibaromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol
angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist
201720177.0low000010
mp470N-arylpiperazine201720177.0low000010
rgb 286638201720177.0medium000010
np 031112benzenes;
naphthalenes;
thiadiazolidine
anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
201720224.5low000011
at 7519dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
201720177.0low000010
bms-690514201720177.0low000010
bi 2536201720177.0low000010
inno-406biaryl201720177.0low000010
kw 2449201720177.0low000010
danusertibpiperazines201720177.0low000010
abt 869aromatic amine;
indazoles;
phenylureas
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
azd 8931aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
201720177.0low000010
arq 197indoles201720177.0low000010
azd 1152anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor;
prodrug
201720177.0low000010
pf 00299804enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
201720177.0low000010
ridaforolimusmacrolide lactam201720177.0low000010
ch 4987655201720177.0high000010
6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamidephenylpyridine201720177.0medium000010
cc-930201720177.0medium000010
tak 285201720177.0low000010
idelalisibaromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201720177.0low000010
crizotinib3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
osi 906cyclobutanes;
quinolines
201720177.0low000010
zstk474benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201520159.0low000010
chir-265aromatic ether201720177.0low000010
motesanibpyridinecarboxamide201720177.0low000010
fostamatinib201720177.0low000010
trametinibacetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
201720205.5low000020
mln8054benzazepine201720177.0low000010
pf-562,271indoles201720177.0low000010
jnj-26483327201720177.0high000010
ly2603618ureas201720177.0low000010
tg100801201720177.0medium000010
dactolisibimidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
201720177.0low000010
bgt226aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
201720177.0low000010
gsk 461364(trifluoromethyl)benzenes201720177.0low000010
azd 1152-hqpaanilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound
antineoplastic agent;
Aurora kinase inhibitor
201720177.0low000010
enmd 2076201720177.0low000010
e 7050aromatic ether201720177.0low000010
2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinonepyrazolopyridine201720177.0medium000010
tak-901201720177.0low000010
gdc-0973aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
buparlisibaminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201720177.0low000010
azd 1480201720177.0low000010
azd8330pyridinecarboxamide201720177.0low000010
pha 848125201720177.0low000010
fedratinibsulfonamide201720177.0low000010
gsk6906931,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
201720177.0low000010
14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene201720177.0low000010
azd5438sulfonamide201720177.0low000010
pf 04217903quinolines201720177.0low000010
gdc 0941indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720224.5low000011
icotinib201720177.0low000010
ph 797804aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
201720177.0low000010
kx-01201720177.0low000010
mk 5108aromatic ether201720177.0low000010
cx 4945201720224.5low000011
cudc 101201720177.0low000010
arry-614201720177.0medium000010
tak 593201720177.0medium000010
mln 8237benzazepine201720177.0low000010
sgx 523aryl sulfide;
biaryl;
pyrazoles;
quinolines;
triazolopyridazine
c-Met tyrosine kinase inhibitor;
nephrotoxic agent
201720177.0low000010
bms 754807pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
bms 777607aromatic amide201720177.0low000010
sgi 1776imidazoles201720177.0low000010
pci 32765acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720177.0low000010
ponatinib(trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
amg 900201720177.0low000010
mk-1775piperazines201720177.0low000010
AMG-208aromatic ether;
quinolines;
triazolopyridazine
antineoplastic agent;
c-Met tyrosine kinase inhibitor
201720177.0low000010
quizartinibbenzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
201720177.0low000010
at13148201720177.0low000010
tak 733201720177.0low000010
mk 2206organic heterotricyclic compoundEC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor201720177.0low000010
sns 314ureas201720177.0low000010
lucitanibaromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines
antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist
201720177.0low000010
pf-04691502201720177.0low000010
n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamideaminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound
anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720177.0low000010
dcc-2036organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines
tyrosine kinase inhibitor201720177.0low000010
cabozantinibaromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines
antineoplastic agent;
tyrosine kinase inhibitor
201720177.0low000010
defactinib201720177.0low000010
ly2584702201720177.0low000010
incb-018424nitrile;
pyrazoles;
pyrrolopyrimidine
antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
201720177.0low000010
poziotinibacrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline
antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist
201720177.0low000010
asp3026aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone
antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor
201720177.0low000010
entrectinibbenzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
pexidartinibaminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
TAK-5801,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor
201720177.0low000010
gsk 2126458aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent
201720224.5low000011
emd1214063201720177.0low000010
pf 3758309organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
201720177.0low000010
gdc 0980201720177.0medium000010
azd2014201720177.0low000010
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanolbenzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound
antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
201720177.0low000010
plx4032aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
201720177.0low000010
gsk 1363089aromatic ether201720177.0low000010
arry-334543201720177.0low000010
kin-193pyridopyrimidine201720177.0low000010
mk 2461201720177.0low000010
bay 869766201720177.0low000010
as 703026pyridinecarboxamide201720177.0low000010
baricitinibazetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide
anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent
201720224.5low000011
dabrafenib1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide
anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor
201720177.0low000010
pki 587201720177.0low000010
n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide201720177.0low000010
ribociclib201720177.0low000010
mk-8033201720177.0low000010
pha 793887piperidinecarboxamide201720177.0low000010
sb 1518201720177.0low000010
abemaciclib201720224.5low000011
mk-8776201720177.0medium000010
afuresertibamphetamines201720177.0low000010
arry-371797202220222.0medium000001
gsk 1070916pyrazoles;
ring assembly
201720177.0low000010
jnj38877605quinolines201720177.0low000010
dinaciclibpyrazolopyrimidine201720224.5low000011
gilteritinibaromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720224.5low000011
alectinibaromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
glpg0634201720177.0low000010
encorafenib201720177.0low000010
bms-911543201720177.0low000010
gsk2141795201720177.0low000010
azd8186201720177.0low000010
byl719proline derivative201720177.0low000010
cep-32496201720177.0low000010
rociletinib201720177.0low000010
ceritinibaminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201720177.0low000010
azd1208201720177.0low000010
vx-509201720177.0low000010
debio 1347201720177.0low000010
volitinib201720177.0medium000010
osimertinibacrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound
antineoplastic agent;
epidermal growth factor receptor antagonist
201720224.5low000011
at 9283201720177.0low000010
otssp167201720177.0low000010
chir 258201720177.0low000010
osi 027201720177.0low000010
nintedanib201720177.0low000010
bay 80-6946201720177.0low000010
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
pyrazinesdiazine;
pyrazines
Daphnia magna metabolite201820186.0low000010
diphenylaminearomatic amine;
bridged diphenyl fungicide;
secondary amino compound
antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger
2014201410.0low000010
triazoles1,2,3-triazole201820205.0low000020
fluorodeoxyglucose f182-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
2012201212.0low000010
lupeolpentacyclic triterpenoid;
secondary alcohol
anti-inflammatory drug;
plant metabolite
201720177.0low000010
ganglioside, gd2202120213.0low000001
pd 0325901difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound
antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
2014201410.0low000010
er-086526cyclic ketal;
cyclic ketone;
macrocycle;
polycyclic ether;
polyether;
primary amino compound
antineoplastic agent;
microtubule-destabilising agent
202120213.0low000001
crizotinib3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amineantineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
201820186.0low000010
zstk474benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
201520159.0low000010
trametinibacetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
201420216.8low000031
plx 4720aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
201820186.0low000010
plx4032aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide
antineoplastic agent;
B-Raf inhibitor
2014201410.0low000010
warfarinbenzenes;
hydroxycoumarin;
methyl ketone
201220216.9low2000153
pyrimidinones201420216.8low000031
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
2019 Novel Coronavirus Disease0202220222.0low000001
Acute Myelogenous Leukemia0201720177.0low000010
Adverse Drug Event0202020204.0low100010
Alloxan Diabetes0201620168.0low000010
Benign Neoplasms0201220228.8low100031
Body Weight0201620168.0low000010
Cancer of Lung0201720177.0low000010
Cancer of the Thyroid0201820186.0low000010
Carcinoma, Ovarian Epithelial0202020204.0low000010
Diabetes Mellitus, Adult-Onset0201620168.0low000010
Diabetes Mellitus, Type 20201620168.0low000010
Disease Models, Animal0201620187.0low000020
Drug-Related Side Effects and Adverse Reactions0202020204.0low100010
Epithelial Ovarian Cancer0202020204.0low000010
ER-Negative PR-Negative HER2-Negative Breast Cancer0202120213.0low000001
Insulin Resistance0201620168.0low000010
Insulin Sensitivity0201620168.0low000010
Kahler Disease0202020213.5low100011
Leukemia, Myeloid, Acute0201720177.0low000010
Local Neoplasm Recurrence0201620215.7low000021
Lung Neoplasms0201720177.0low000010
Malignant Melanoma02014201410.0low000010
Melanoma02014201410.0low000010
Multiple Myeloma0202020213.5low100011
Neoplasms0201220228.8low100031
Neuroblastoma0201620215.7low000021
Rhabdomyosarcoma0201920195.0low000010
Thyroid Cancer, Anaplastic0201820186.0low000010
Thyroid Carcinoma, Anaplastic0201820186.0low000010
Thyroid Neoplasms0201820186.0low000010
Triple Negative Breast Neoplasms0202120213.0low000001

Pharmacokinetics (1)

ArticleYear
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
Cancer chemotherapy and pharmacology, , Volume: 72, Issue:3
2013

Dosage (3)

ArticleYear
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
The Lancet. Oncology, , Volume: 21, Issue:11
2020
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
Cancer chemotherapy and pharmacology, , Volume: 72, Issue:3
2013
Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 53, Issue:12
2012